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General introduction and outline of the thesis 
The immune system
For the protection against infections, the immune system must recognize and respond to 
different types of pathogens, such as bacteria, viruses and parasites. Immune recognition 
is exceptional by the capacity to distinguish foreign- from self-components. In general, 
two systems of immunity can be distinguished, innate and adaptive immunity. The innate 
immune response acts as a first line defense to recognize foreign components, but is not 
able to distinguish small molecular differences and lacks a memory for earlier encountered 
antigens. In contrast, the adaptive immune system is able to recognize, to respond and 
to provide increased protection (memory) against subsequent reinfection with the same 
pathogen. Both T and B cells are important players in the adaptive immune response. 
Depending on the type of T cell, different routes of activation are generated that ultimately 
lead to elimination of the pathogen (Figure 1). The CD4+ T helper cells respond to antigen 
by the production of cytokines and the expression of co-stimulatory molecules on their cell 
surface, which enables them to activate B cells and other immune cells. CD8+ cytotoxic 
T cells respond to antigen by secreting cytokines and cytotoxins such as granzymes and 
perforins. After penetration of the target cell, these cytotoxins trigger a caspase cascade 
that eventually leads to apoptosis of the target cell(1). T cells express a wide variety of T 
cell receptors (TCR) on their cell membrane by which they specifically recognize foreign 
antigens presented by human leukocyte antigen (HLA) molecules. These HLA molecules 
are polymorphic glycoproteins expressed on the cell membrane(2). Two major types of HLA 
molecules can be distinguished: HLA class I and HLA class II. The HLA class I molecules (HLA-A, 
HLA-B) are expressed by all nucleated cells and present peptides that are endogenously 
derived. Peptides presented by HLA class I molecules are predominantly recognized by 
CD8+ T cells, whereas HLA class II molecules (HLA-DR, HLA-DQ) are recognized by CD4+ 
T cells. These HLA class II molecules are restrictedly expressed by antigen-presenting cells 
(APCs), such as dendritic cells (DCs), macrophages and B cells. These APCs are able to take 
up, digest and load exogenous peptides on their cell membrane. Overall, TCR recognition 
of the cognate antigen, together with a co-stimulatory signal and cytokine secretion by the 
APC, results in the activation, proliferation and differentiation of CD4+ and CD8+ T cells(3).
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Figure 1. Activation pathways of CD4+ and CD8+ T cells. 
Foreign antigen is digested by an antigen-presenting cell (APC) and presented by human leucocyte antigen 
(HLA) molecules. Molecules presented by HLA class I are predominantly recognized by the T cell receptor (TCR) 
of CD8+ T cells, followed by co-stimulation via CD28 binding to CD80/86 and cytokine stimulation leading to 
activation of the CD8+ T cell. Via a cytotoxic response the CD8+ T cell mediates killing of the altered self-cells. HLA 
class II molecules specifically present molecules that are recognized by CD4+ T cells. After TCR recognition, co-
stimulation, and cytokine stimulation the CD4+ T cell is activated and starts secreting cytokines by which B cells 
and other immune cells are activated.
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As described above, the immune system is highly capable of protecting us against foreign 
agents. However, in the setting of solid organ transplantation, the immune system also 
recognizes the donor organ as a foreign agent, which will lead to rejection of the transplanted 
cells or organ if not genetically identical to its own. With the discovery of immunosuppressive 
medication the process of donor-specific immune activation can now be often adequately 
suppressed(4). However, the immunosuppressive approaches to maintain survival of the 
allograft are not without complications. Rejection of the transplanted organ still occurs and 
life-long treatment with immunosuppressive drugs is associated side effects.
Kidney transplantation and rejection
Kidney transplantation is the treatment of choice for patients with end-stage renal disease 
(ESRD). The quality of life of ESRD patients improves after kidney transplantation and the 
mortality risk reduces in this group of patients (5). In addition, kidney transplantation is 
a cost-effective alternative to dialysis (6). Since the first kidney transplantation in 1954, 
allograft and patient survival significantly improved. This improvement relies on the 
careful HLA-matching between the donor and recipient, the development of potent 
immunosuppressive drugs and improved diagnostics (4, 7). Despite the promising short 
and long-term results after kidney transplantation, there is still room for improvement to 
better control the process of allograft rejection (8, 9).
Rejection of a kidney transplant is the consequence of genetic differences in the HLA system 
between the recipient and donor. Therefore, HLA matching is important in the organ-
allocation process and matching is associated with fewer rejection episodes and increased 
graft survival rates (7, 10). Foreign HLA antigens expressed and presented by either recipient 
or donor-derived APCs initiate the activation of recipient T and B cells. Rejection of the 
allograft manifests as T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR) 
or a mixed rejection involving the histological features of both rejection types (11). These 
forms of rejection may occur in an acute or chronic fashion. Within TCMR, primed effector 
T cells are taking center stage. After activation of these T cells, clonal expansion occurs and 
these effector T cells migrate towards the allograft and cross the epithelial border to enter 
the allograft. Tubulo-interstitial inflammation is induced within the graft by the effector 
T cells via the production of pro-inflammatory cytokines (11-13). The process of ABMR is 
characterized by the presence of circulating donor-specific antibodies (DSA). These DSA 
interact with the vascular endothelium of the graft causing injury of the tissue (11, 12, 14).
14
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Immunosuppressive medication
After transplantation, immunosuppressive reagents suppress the immune system of the 
transplant patient including the function of immune cells that are involved in the process 
of organ transplant rejection. The current standard combination of immunosuppressive 
reagents after kidney transplantation consists of mycophenolate mofetil (MMF), 
glucocorticoids, and calcineurin inhibitors (CNIs)(15). After intake, MMF is converted to 
the active metabolite mycophenolic acid (MPA) which eventually inhibits the synthesis 
of guanosine monophosphate nucleotides, necessary for the synthesis of DNA and thus 
leading to the prevention of T and B cell proliferation (4). Glucocorticoids are able to bind 
the glucocorticoid receptor present in T cells, but also in a variety of other immune cells. 
Afterwards, translocation of the glucocorticoids to the nucleus occurs where the complex 
interferes with the activity of pro-inflammatory transcription factors such as activator 
protein 1 and nuclear factor-κB (4, 16). Tacrolimus is currently the primary described CNI that 
inhibits T cell activation via blocking the calcineurin dependent dephosphorylation of NFAT, 
which among others results in diminished production of the pro-inflammatory cytokine 
IL-2 (4). As described above, current maintenance immunosuppressive reagents are rather 
general and have a wide biological effect on T cell activation, cell division, and suppressing 
inflammation (17). One consequence of this treatment combination is that the production 
of DSA is not completely inhibited, enhancing the process of ABMR followed by graft failure 
(18-20). Besides, treatment with tacrolimus is associated with different side effects such as 
nephrotoxicity and an increased risk for infections and malignancies (21-24).
Undoubtedly, we need to better understand the mode of action of currently prescribed 
immunosuppressive agents on cells of the immune system. That said, there is also a clear 
rationale for more specific drugs targeting dominant molecules or pathways involved in the 
anti-donor response. This will diminish the occurrence of drug-related side effects as well as 
reduce the incidence of rejection. In order to achieve this, the role of specific lymphocyte 
subsets on the alloimmune response needs to be studied in more detail. Two new subsets 
of T cells have been discovered in the last decade: T follicular helper (Tfh) cells and tissue-
resident memory T (T
RM
) cells. From experimental models we now know that both effector 
memory T cell populations play crucial roles in the interaction with effector B cells and 
cytotoxic T cells, and can accumulate in tissues during infection and in the allograft after 
transplantation. However, whether these newly identified T cell populations contribute in 
immune responses leading to allograft rejection and are targeted by immunosuppressive 
drugs is largely unknown. In this thesis we investigated the role of these two T cell subsets in 
the rejection process of immunosuppressed patients after kidney transplantation. Improved 
knowledge on the contribution of Tfh and T
RM
 cells in alloreactivity will be useful to develop 
new therapeutic strategies for the prevention and treatment of this severe complication.
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The development and function of T follicular helper cells
Tfh cells are a subset of CD4+ T cells that provide help to B cells (25, 26). For this, the cytokine 
milieu is essential for T cell differentiation in a certain direction. Early differentiation towards 
the Tfh cell lineage is mediated by IL-12, IL-6 and TGF-β (27-29). Afterwards, maintenance 
of the Tfh cell phenotype is primarily dependent on the interplay between IL-6 and IL-21 
(Figure 2)(30). Expression of CC-chemokine receptor 7 (CCR7) promotes migration of the T 
cell towards the secondary lymphoid organs (SLO). Within the SLO, CCR7 is downregulated, 
followed by upregulation of CXC-chemokine receptor 5 (CXCR5)(31). The expression of 
CXCR5 is crucial for localization of the Tfh cell at the border of CXCL13+ B-cell follicles (32, 
33). Interaction of the Tfh cell with cognate antigen presenting DCs or B cells is required 
to fully activate the Tfh cell followed by migration inside the B-cell follicles, where Tfh 
cells orchestrate the formation, expansion and selection of high-affinity B cells within the 
germinal center (GC)(34). These activated Tfh cells are also characterized by the expression 
of inducible T-cell co-stimulatory molecule (ICOS) and programmed death 1 (PD-1)(26, 35). 
Expression of a master transcription factor is crucial in defining a T cell subset, in case of Tfh 
cells the expression of B cell lymphoma 6 (BCL6)(36). Circulating Tfh cells are known for their 
expression of CXCR5 and low expression of PD-1 and ICOS, but these cells lack expression of 
BCL6 (37-40). Findings in HIV patients indicate that circulating memory Tfh cells have strong 
transcriptional similarities to activated GC Tfh cells(39). These findings encourage the use 
of circulating Tfh cells for studying the function of these cells in patients as a biomarker for 
disease (37, 39, 41).
Tfh cell
IL-12, IL-6, 
TGF-β
BCL6
APC Naive CD4+ 
T cell
IL-21
CCR7 CXCR5
Figure 2. Differentiation of T follicular helper (Tfh) cells. 
Naïve CD4+ T cells are activated by an antigen-presenting cell (APC) via their T cell receptor and a co-stimulatory 
signal. Subsequently, cytokines IL-12, IL-6, TGF-β and IL-21 are essential in the differentiation and maintenance 
towards the Tfh cell phenotype. Expression of CC-chemokine receptor 7 (CCR7) promotes migration towards 
the lymphoid organs followed by upregulation of CXC-chemokine receptor 5 (CXCR5) and the Tfh cell master 
transcription factor B cell lymphoma 6 (BCL6).
The role of Tfh cells in transplantation has been studied in several animal models. These 
models prove that the activation of allo-specific B cells is dependent on IL-21 producing 
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Tfh cells (42-44). The extent to which Tfh cells are able to communicate with B cells 
is dependent on the TCR interaction with cognate antigens presented by HLA class II 
molecules in combination with co-stimulatory molecules such as CD40 ligand (26, 32) 
(Figure 3). Thereafter, antigen-activated B cells differentiate into long-lived memory B cells 
or immunoglobulin producing plasma cells (45). In transplantation, it is suggestive that the 
formation of DSA relies on the interaction between Tfh and B cells (35). After transplantation, 
DSA can be formed and Tfh-B cell clusters can be detected in renal rejection biopsies (46). 
At present, B cell-depleting therapies such as alemtuzumab, anti-thymocyte globulin (ATG) 
and rituximab are used in patients diagnosed with ABMR, which according to the Banff 
2017 rejection criteria depends on the presence of DSA (11, 47). However, these therapies 
are not optimal due to lack of efficacy. For instance, rituximab depletes CD20+ B cells but 
lacks the capacity to target the immunoglobulin producing CD20- plasma cells (47). Clearly, 
there is room for new strategies especially early in the activation cascade aiming to prevent 
the Tfh-dependent activation of alloantigen-stimulated B cells that leads to the formation 
of DSA. Of particular interest is the intervention of Tfh-B cell interaction via blockade of 
the IL-21/IL-21R signaling pathway. This strategy has been shown to be successful in B cell-
mediated autoimmune diseases (48, 49).
Tfh cell B cell
IgM,
IgG, IgE
(DSA)
CXCR5
ICOS ICOSL
PD-1 PD-L1
CD40L CD40
TCR HLA-II
IL-21
Plasma-
cell
BCR
Long-lived
memory B cell
Figure 3. T follicular helper (Tfh) cell-dependent B cell differentiation. 
B cell differentiation is initiated after cognate interaction of the T cell receptor (TCR) with the antigen presenting 
human leucocyte antigen (HLA) class II molecule followed by co-stimulation via for instance CD40L – CD40 
interaction and interleukin-21 (IL-21) production by the Tfh cell. Binding between inducible T-cell co-stimulatory 
molecule (ICOS) and programmed death 1 (PD-1) and their respective ligands ICOSL and PD-L1 on the B cell 
strengthens the Tfh-B cell interaction. Ultimately, B cell differentiation towards either long-lived memory B cells or 
immunoglobulin producing plasma cells occurs.
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Intervention of interleukin-21 signaling pathway: a new strategy to 
suppress alloimmune responses?
Because current maintenance therapies are less effective against the protection of humoral 
immune responses towards the allograft it is of interest to study early intervention of Tfh-B 
cell interaction. In this respect, selective blockade of Tfh cell help signals might prevent 
the activation of allo-activated B cells. A candidate of interest to target is the pleiotropic 
cytokine interleukin-21 (IL-21). This cytokine is produced by Tfh cells, Th17 cells and natural 
killer (NK) T cells(50). The IL-21 receptor (IL-21R) is among others expressed by CD4+ and 
CD8+ T cells, B cells and NK cells and consists of a common receptor γ-chain and a specific 
IL-21R part that activates downstream JAK1 and JAK3 signaling pathways, which allows the 
recruitment and phosphorylation of predominantly STAT3, but also the phosphorylation 
of STAT1 and STAT5(51, 52). IL-21 is a cytokine that influences the function of CD8+ T cells, 
Th17 cells and B cells(53-56). In the past decade, several studies presented the essential role 
of IL-21R signaling in autoimmune disorders, antiviral and antitumor responses and other 
inflammatory disorders (50, 57-59).
In transplantation, limited studies on the role of IL-21 in the human transplant setting have 
been performed (60, 61). Moreover, de Graav et al. presented that peripheral Tfh cell numbers 
remain stable after kidney transplantation. These Tfh cells still have the capacity to produce 
IL-21 (46). In the presence of the co-stimulatory inhibitor Belatacept the proportions of IL-
21+ activated Tfh cells were only partially decreased in an allogeneic co-culture model (62). 
A study performed on cardiac allograft biopsies revealed that high IL-21 expression levels 
were present during acute rejection (63). However, the exact role of IL-21 in the immune 
activation after allogeneic stimulation is not fully understood. Thus, studies on the efficiency 
of targeting IL-21R pathway in an allogeneic setting are of high interest.
Lymphocytes present in the renal allograft
Effector T and B cells primed for alloantigen are able to migrate from the lymphoid organs 
to the allograft, where they locally contribute to the process of allograft rejection. Moreover, 
these intra-graft lymphocytes are able to form highly organized clusters that represent 
GC-like structures, normally present in the SLO. These lymphoid structures have also been 
detected in tissues affected by infection, autoimmunity and cancer and are referred to as 
ectopic lymphoid structures (ELSs) or tertiary lymphoid organs (TLOs)(64). ELSs are able 
to trigger a local antigen-specific response (64). In organ transplantation, ELSs are mainly 
associated with chronic rejection, but they are also detected in acutely rejected renal 
allografts (46, 65-67). Remarkably, in renal biopsies of acute TCMR the presence of intra-
graft B cells is recognized (65, 68-70). Today, the exact composition and organization of 
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lymphocytes infiltrating the allograft is of interest, since these cells are directly located 
at the site of the alloantigen. The functional characteristics of ELSs are still debated, since 
these structures may have both protective and destructive capacities (67).  In terms of 
influencing the T-cell dependent activation of B cells to prevent rejection of the allograft, 
it is of importance to study whether this T-B cell interaction locally occurs within the renal 
allograft and contributes to the process of rejection.
A recently discovered cell type residing within the non-lymphoid tissue are the tissue-
resident memory T (T
RM
) cells. These cells were first described by Masopust et.al. in 2001 
(71). T
RM
 cells are a non-circulating subset of T cells that survey most non-lymphoid tissues 
and have the ability to respond rapidly to local antigens (72, 73). Several phenotypic and 
molecular markers define the T
RM
 cell subset, such as presentation of specific surface 
markers and up- or downregulation of genes involved in adhesion and migration (Figure 4) 
(74-76). The surface markers responsible for retention of the T
RM
 cells are CD69 and CD103. 
CD69 is able to bind and down-regulate the G-protein-coupled receptor sphingosine-1 
phosphate (S1PR1), a receptor involved in stimulating the migration of the T cells from 
blood into the tissue (77). Another recognized T
RM
 cell marker, the αE integrin CD103, is 
able to bind E-cadherin, which is expressed on epithelial cells (78). After encounter with 
a cognate antigen, T
RM
 cells start to release cytokines including IFNγ and TNFα (79). The 
release of these pro-inflammatory factors results in the attraction of other immune cells 
including B cells and NK cells. Furthermore, T
RM
 cells exert effector function via the release of 
cytotoxic molecules such as granzyme B and perforin (80, 81).
So far, little is known about the presence and function of T
RM
 cells in transplanted organs, 
including the renal allograft (73). Different aspects of the T
RM
 cell are of interest to study from 
the perspective of transplantation, such as the potential of T
RM
 cells to protect the donor 
organ by controlling viral reactivation, while the T
RM
 cells may on the other hand contribute 
to the process of allograft rejection. Another phenomenon of interest is the origin of the T
RM
 
cells within the allograft, since both donor- and recipient-derived T
RM
 cells may be present 
in the donor organ. Overall, the possible protective and destructive roles of T
RM
 cells within 
the renal allograft are of high significance and need further attention.
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Figure 4. Schematic presentation of tissue-resident memory T (TRM) cell characteristics. 
General features of T
RM
 cells are presented. These include the presentation of retention markers CD69 and CD103, 
memory T cell marker CD45RO, and homing marker CXCR6. CD69 promotes residency within the tissue via 
interfering with the G-protein-coupled sphingosine-1 phosphate receptor (S1PR1). S1PR1 mediates migration 
of the T cells from the circulation into the tissues and vice versa. Furthermore, the αE integrin CD103 promotes 
TRM cell retention by binding to E-cadherin expressed by the epithelial tissue. T
RM
 cells are known for their rapid 
response after specific-antigen encounter, for instance via the production of interferon γ (IFNγ) and tumor necrosis 
factor α (TNFα) and via the secretion of cytotoxic molecules such as granzyme B and perforin.
Aim and outline of the thesis
Different T cell subsets are involved in the process of allograft rejection. Communication of 
these T cells with other lymphocyte populations is crucial in the development of a rejection 
response. For instance, studies in kidney transplantation plea for a key role for T cells in the 
process leading to chronic humoral allograft failure, traditionally thought to be orchestrated 
by B cells (82, 83). Current immunosuppressive treatments suppresses the immune system 
in a non-specific manner and outline the need for investigation of new strategies that only 
target specific parts of the well-defined alloimmune response, with which also some of the 
observed side effects can be prevented.
The overarching aim of this thesis is to better understand the role of Tfh and T
RM
 cells in 
alloreactivity by the characterization of the mechanisms by which both effector memory 
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T cell populations modulate anti-donor responses after kidney transplantation. This 
knowledge may help us to understand the contribution of these recently identified T cell 
populations to immune processes occurring after organ transplantation and will help us 
to design less toxic and more efficient immunosuppressive treatment strategies. For this, 
two relevant compartments were investigated: peripheral blood of the recipients and tissue 
biopsies of the transplanted kidney.
In the first part of this thesis the Tfh cell and its role in the alloimmune response takes 
center stage. In Chapter 2 we provide an overview of the current knowledge on the 
effects of immunosuppressive medication on Tfh cell development and function and we 
describe new possible approaches to influence the function of Tfh cells. In addition, the 
potential role of the Tfh cell as pharmacodynamic biomarker to improve alloimmune-risk 
stratification is discussed. In the alloimmune response, the precise role of IL-21-producing 
Tfh cells on B cell differentiation is unknown. Therefore, Chapter 3 focuses on whether Tfh 
cell-mediated differentiation of B cells is dependent on IL-21R signaling. This was performed 
in an allogeneic in vitro model in which we stimulated Tfh cells and memory B cells from 
patients pre-transplantation with their corresponding donor antigen. In Chapter 4, a 
humanized skin transplant mouse model with human T and B cell reconstitution is used to 
study the role of IL-21R signaling blockade in an in vivo transplant setting. 
In the second part of this thesis, we focus on the characterization of lymphocytes within 
the renal allograft. The presence and activation status of T and B cells in organized ectopic 
lymphoid structures (ELSs) in different types of acute renal allograft rejection biopsies is 
studied in Chapter 5. We studied the presence of T and B cells with respect to GC features in 
acute/active antibody-mediated rejection (a/aABMR), acute T-cell mediated rejection grade 
I (aTCMRI) and acute T-cell mediated rejection grade II (aTCMRII). In Chapter 6 we report 
about tissue-resident memory T (T
RM
) cells in transplant nephrectomy specimens, a unique 
source of tissue to study the biology of this T cell population in the renal allograft. We are 
the first to study the presence, origin (donor or recipient) and functional properties of these 
CD8+ T
RM
 cells in the kidney allograft.
In chapter 7 and 8 the results obtained in this thesis are summarized and discussed.
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Abstract 
Over the past decade antibody-mediated (humoral) rejection has been recognized as 
a common cause of graft dysfunction after organ transplantation and an important 
determinant for graft loss. In humoral alloimmunity, T follicular helper (Tfh) cells play 
a crucial role, because they help naïve B cells to differentiate into memory B cells and 
alloantibody-producing plasma cells within germinal centers. In this way, they contribute to 
the induction of donor-specific antibodies, which are responsible for the humoral immune 
response to the allograft. In this article we provide an overview of the current knowledge 
on the effects of immunosuppressive therapies on Tfh cell development and function, and 
discuss possible new approaches to influence the activity of Tfh cells. In addition, we discuss 
the potential use of Tfh cells as a pharmacodynamic biomarker to improve alloimmune 
risk stratification and tailoring of immunosuppression in order to individualize therapy after 
transplantation.
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Introduction
Organ transplantation is the treatment of choice for end-stage organ failure. Although 
current immunosuppressive regimens are effective in the short-term, long-term allograft 
survival rates are still suboptimal with rejection being the leading cause of graft loss (1). 
Allograft rejection can develop from either cellular or humoral immune responses against 
the allograft, or from ‘mixed rejection’ involving both types of responses (2). In particular, 
humoral anti-donor reactivity via the formation of donor specific antibodies (DSA) is 
associated with poor allograft outcomes (3-5). Formation of DSA relies on antigen-activated 
T follicular helper (Tfh) cells, which are located in the germinal centers (GC) where they 
provide help to antigen-activated B cells, which in turn respond by differentiating into 
immunoglobulin-producing plasma cells and high affinity memory B cells (6, 7).
B cell depleting therapies have been used to control the formation of DSA in transplant 
recipients (8) but are not generally used as maintenance treatment because of the risk of 
side effects. Based on their pivotal role in regulating humoral immunity it can be postulated 
that Tfh cells, rather than B cells, could be targeted to inhibit the development of antibody-
mediated anti-donor reactivity. Currently, no Tfh-specific agents have been evaluated in 
phase II or III trials. Several animal studies and a small number of clinical studies in organ 
transplant recipients have demonstrated the importance of Tfh cells in the process of 
alloantibody production (9). The specific effects of immunosuppressive therapies on Tfh cell 
activity, however, are less established and now subject to many ongoing research efforts. In 
this article we summarize current knowledge on the interplay between immunosuppressive 
drugs and the generation and function of Tfh cells, and consider new biological targets that 
might influence the proliferation, differentiation and activity of Tfh cells.
Biology of T follicular helper cells
Differentiation of Tfh cells
Differentiation of a human naïve CD4+ T cell into a Tfh cell is a complex and dynamic 
process involving multiple stages (10). A combination of signals determines whether the 
naïve T cell differentiates toward a Th1, Th2, Th17 or Tfh subset including the expression 
of specific transcription factors, signal transducer and activator of transcription (STAT) 
proteins, cytokines and chemokine receptors that allow the T cell to migrate to the 
site of inflammation. When a naïve T cell expresses C-C chemokine receptor 7 (CCR7), 
migration is promoted to T-cell rich zones in secondary lymphoid organs (SLO) and tertiary 
lymphoid structures present in chronically inflamed organs. Protein activin A (a member 
of the transforming growth factor-β (TGF-ß) superfamily) is present locally after the T cell 
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encounters an antigen-presenting dendritic cell (DC) and mediates downregulation of 
CCR7, followed by upregulation of CXC chemokine receptor 5 (CXCR5) (11). Expression of 
CXCR5 is essential for localization of the Tfh cells at the T-B border of B-cell rich follicles, where 
Tfh cells interact with B cells that recognize antigen via their B cell receptor (BCR) (Figure 1). 
Sequential antigen presentation by DCs and B cells is required for optimal differentiation 
of Tfh cells and the subsequent GC reaction (12). After cognate antigen recognition, 
Tfh cells migrate inside the B cell follicles and develop into activated GC Tfh cells which 
orchestrate the development of high affinity GC B cells. In addition to CXCR5, activated 
Tfh cells express the co-inhibitory protein programmed death 1 (PD-1) and inducible T cell 
costimulatory molecule (ICOS) (7, 9). Recently, it has been demonstrated in a conditional 
knock out mouse model that Tfh cells express the transcription factors Lymphoid Enhancer 
Binding Factor 1 (LEF-1) and T cell factor 1 (TCF-1), both of which are involved in regulation 
of the Tfh transcriptional repressor B cell lymphoma 6 (Bcl-6) (13). These transcription factors 
promote early Tfh cell differentiation by sustaining the expression of IL-6Rα and gp130, 
and by promoting upregulation of ICOS and expression of Bcl-6 which is also known as 
the master transcription factor for Tfh cells and represses transcription of among others 
B lymphocyte-induced maturation protein-1 (Blimp-1), T-box transcription factor (T-bet) (Th1 
development) and RAR-related orphan receptor γt (RORγt) (Th17 development) (14, 15). Apart 
from being present in SLOs, CXCR5+CD4+ Tfh cells are also present in blood, representing 
approximately 10% of human circulating memory CD4+ T cells (16, 17). Memory Tfh cells 
form a heterogeneous population based on the expression of the chemokine receptors 
CXCR3 and CCR6: CXCR3-CCR6- represent Tfh2 cells, CXCR3+CCR6- represent Tfh1 cells and 
CXCR3-CCR6+ represent Tfh17 cells (16). These subsets have distinct capacities to help B 
cells, the CXCR3- Tfh2 and Tfh17 cells promote B cell differentiation toward immunoglobulin 
producing cells via secretion of IL-21, while CXCR3+ Tfh1 cells lack this function (18, 19). In 
addition, the Tfh2 cells promote particularly IgG and IgE secretion, while Tfh17 cells are more 
efficient in promoting IgG and IgA secretion (16). Overall, an appropriate microenvironment 
is essential for coordination of Tfh cell lineage differentiation.
Cytokines involved in Tfh cell differentiation, activation and function
Coordinated activity by cytokines triggers specific transcription programs that stimulate 
the expression of molecules responsible for the effector function of Tfh cells (7). The 
differentiation of naïve human CD4+ T cells in the SLOs toward a Tfh cell phenotype is 
primarily mediated by IL-12, IL-6 and TGF-β signaling. Activin A, in combination with IL-12, 
mediates an early shift toward the Tfh phenotype, including skewing toward expression of 
IL-21 (11, 20). IL-12 production is profoundly increased by activated DCs in the T-cell rich 
zone (21). TGF-β is another cytokine involved in human Tfh cell differentiation that after 
binding to its receptor, phosphorylates the transcription factors STAT3 and STAT4, key steps 
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in the Tfh cell differentiation process (22). As well as IL-12 and TGF-ß, IL-6 contributes to 
differentiation into Tfh cells. One clinical study, for example, showed that secretion of IL-6 by 
plasmablasts resulted in Tfh cell differentiation (23). Of note, interplay between IL-6 and IL-
21 is required to achieve optimal Tfh-cell differentiation and function, although an absence 
of either IL-6 or IL-21 in a mouse model does not fully abolish Tfh cell formation (24, 25). In 
contrast, GC formation and the differentiation of B cells into immunoglobulin-producing 
plasmablasts are dependent on IL-21 producing Tfh cells (25, 26). 
Inhibition of Tfh cells
Tfh cell function depends on the balance between pro-inflammatory and anti-inflammatory 
signals. Several factors have been reported to control Tfh cell activation. Recently it became 
evident that a subset of regulatory T cells – the follicular regulatory T (Tfr) cells – express 
Foxp3, Bcl-6 and CXCR5 and have the capacity to regulate the Tfh-driven GC reaction 
(27-29). However, the immunoregulatory mechanisms by which Tfr cell functions are 
controlled are largely unknown. Animal studies have shown that the co-inhibitory receptor 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) which is highly expressed by Tfr 
cells and moderately expressed on Tfh cells is involved in the suppressive effects of these 
cells. Tfr cells lacking the co-inhibitory molecule CTLA-4 have an impaired ability to inhibit 
B cell antibody production (30, 31). Conversely, mice deficient for PD-1 on Tfr cells have 
increased suppressive activity, since PD-1 controls the activation of Tfr cells (32). In kidney 
transplant patients who received anti-CD20 rituximab induction therapy, both Tfh and Tfr 
cells remained in the lymph nodes despite disruption of the GC and elimination of B cells 
(33), underlining their independent mechanism of action. The role of Tfr cells in preventing 
rejection of the allograft is largely unknown. Recently, Chen et al. showed that the ratio of 
Tfr cells in peripheral blood and renal graft biopsies from patients with antibody-mediated 
rejection (AMR) was significantly lower than in non-AMR patients, while Tfh2 and Tfh17 
ratios increased, suggesting that increased Tfh activation levels contribute to AMR (34).
Anti-inflammatory cytokines secreted by Tfr cells also influence Tfr cell function. The 
pleiotropic cytokine IL-10 inhibits antibody production via regulation of the quantity and 
quality of Tfh cells in mice immunized with sheep red blood cells (35). In contrast, lymphocytic 
choriomeningitis virus (LCMV)-infected mice deficient for IL-10 had lower frequencies of 
virus-specific Tfh cells but no decrease in GC B cells or LCMV-specific antibodies (36). IL-2 is a 
critical factor for the regulation of Tfh-B cell interaction in vivo. Although originally recognized 
as an essential T cell growth factor, IL-2 suppresses Tfh cell differentiation via activation of 
Blimp-1 resulting in a hampered formation of antigen-specific B cells and IgG responses in 
mice infected with the influenza virus (37, 38). Ray et al. recently demonstrated that IL-2-
mediated activation of Akt kinase and mTORc1 was necessary to shift differentiation to Th1, 
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with less differentiation to Tfh cells (39). In contrast, IL-21 inhibits the expression of CD25 
(part of the IL-2 receptor) in a Bcl-6 dependent manner (40).
Tfh-B cell crosstalk
Cytokines and co-stimulatory molecules secreted by B cells are able to encourage activation 
of Tfh cells within the GC (Figure 1). Moreover, apart from their role as an antigen presenting 
cell (APC), B cells contribute to the activation and regulation of the Tfh cells via secretion of 
cytokines like IL-6 and IL-10 (41, 42). Meanwhile, Tfh cells are involved in the GC reaction to 
promote B-cell activation. The GC consists of a polarized structure with two compartments 
that are designed for proliferation and affinity selection. Within the dark zone (DZ), B cells 
undergo several rounds of proliferation and somatic hypermutation (SHM) in the V-region 
of their BCR (43). The point mutations that are created during SHM allow affinity maturation 
and lead to antibody diversity. Afterwards, the DZ B cells migrates to the light zone (LZ), 
where they capture antigen presented by follicular dendritic cell networks and present it 
on MHC class II molecules to cognate Tfh cells (44). The amount of antigen captured by 
the B cell and presented to Tfh cells in the LZ directly corresponds to the amount of B-cell 
division and hypermutation in the DZ (45). Thus, T cell help and not direct competition for 
antigen is the limiting factor in GC selection (46). High affinity B cells present antigen to 
cognate Tfh cells, triggering a signaling pathway which allows (i) B-cell differentiation into 
long-living plasma cells, (ii) differentiation of long-lived memory B cells, or (iii) recirculation 
of B cells to the DZ for a new round of division and SHM (47). Activated Tfh cells produce 
IL-21 and IL-4, two cytokines which support B cell differentiation. Within the GC, Tfh cell 
function changes from IL-21+ Tfh cells, responsible for the selection of high-affinity B cell 
clones, toward IL-4+ Tfh cells that have high expression of CD40L and which direct B cell 
class switch recombination and differentiation toward antibody-producing plasma cells (48, 
49). PD-1hi Tfh cells are involved in this GC reaction while PD-1lo Tfh cells represent precursor 
memory T cells with a Tfh-like phenotype (50). In a previous study, we found co-localization 
of T and B cells in cellular infiltrates of renal rejection biopsies, supporting a role for T-B cell 
interaction within the kidney allograft (51).
Genetic defects influencing human Tfh cell differentiation 
Several heritable monogenic defects are known to affect the function and differentiation of 
Tfh cells. PBMCs of patients with primary immunodeficiencies (PID) have been characterized 
in various studies (52-57). In these studies, loss-of function (LOF) mutations in the genes 
encoding STAT3, ICOS, Bruton’s tyrosine kinase (BTK), CD40L, NF-κB essential modulator 
(NEMO) and IL10R reduced the numbers of Tfh cells (52, 55, 56). LOF mutations in the genes 
encoding STAT3, IL21-R and gain-of function (GOF) mutation in the gene encoding STAT1 
resulted in a phenotype with elevated levels of IFNγ and PD-1, both of which control Tfh-
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Figure 2. Possible effect of tacrolimus and basiliximab on Tfh cell differentiation and activation. 
(A.) An activated T cell is depicted in the upper panel. (B.) After addition of tacrolimus (Tac), calcineurin (CaN) is 
blocked and dephosphorylation of cytoplasmic NFAT is inhibited resulting in lower levels of IL-2 transcription. IL-2 
promotes transcription of Blimp-1, a co-repressor of Bcl-6. In the absence of IL-2, lower transcription of Blimp-1 
leads to increased expression of BCL6 and thus may enhance Tfh cell numbers. Basiliximab may promote the same 
effect of enhancing Tfh cell numbers via blocking the IL-2R.
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mediated B cell differentiation. In contrast, LOF mutations in IFNGR1/2, STAT1 and IL12RB1 
genes caused impaired function of IFNγ and thus promoted Tfh-B-cell interaction (52). 
Another study by Ma et al. reported that mutations in the genes encoding STAT3, IL-21R, 
CD40L, IFNGR1 LOF or STAT1 GOF inhibit the differentiation of Tfh cells via impairing the 
generation of IL-21 (53). Lower frequencies of Tfh cells were observed in patients with two 
transmembrane activator and CAML interactor (TACI) mutations compared to patients with 
a single mutation or without mutations (57). A study by Alroqi et al. described the presence 
of Tfh cells in patients with LPS-responsive beige-like anchor (LRBA) deficiencies. LRBA 
promotes the intracellular transport of CTLA4 toward the cell membrane, mostly expressed 
on regulatory T (Treg) cells and Th17 cells (58). In all patients studied increased frequencies 
of Tfh cells were measured associated with low CTLA4 expression levels on the Treg cells 
(54). When these patients were treated with CTLA4-Ig therapy the frequencies of Tfh levels 
significantly decreased (54). To this end, Tfh cell frequencies may be a useful readout in 
patients with LRBA and CTLA4 deficiencies to monitor the effect of CTLA4-Ig therapy. Taken 
together, the defects in differentiation of Tfh cells found in various PID patients provide 
strong evidence that the genes mutated in these diseases are essential for Tfh differentiation. 
Moreover, the finding of reduced Tfh cells in X-linked agammaglobulinemia patients with 
mutations in BTK shows that Tfh development is B cell dependent (52).
The effects of conventional immunosuppression on Tfh cells
Maintenance immunosuppression after solid organ transplantation typically consists 
of a calcineurin inhibitor (CNI), either tacrolimus or cyclosporin A, the T cell proliferation 
inhibitor mycophenolate mofetil (MMF) and steroids. An in vitro study analyzing the effect 
of methylprednisolone and CNI agents on T cells showed that these immunosuppressants 
could inhibit differentiation of human naïve CD4+ T cells into Tfh cells (59). In vivo, we found 
that Tfh-like cells are present in the circulation of kidney transplant recipients receiving 
tacrolimus-based immunosuppression. These circulating Tfh-like cells have the capacity to 
induce B cell differentiation into immunoglobulin-producing plasmablasts (51). A recent 
study from our group demonstrated that tacrolimus had a small inhibitory effect on Tfh-cell 
generation in vitro and could partially prevent Tfh-cell activation. The production of IL-21 
was incompletely inhibited by high concentrations of tacrolimus, which may be why the 
remaining activated Tfh cells retained the potential capacity to assist B cells (60). In another 
study, methylprednisolone treatment of patients with systemic lupus erythematosus was 
found to reduce the number of peripheral CD4+CXCR5+PD-1+ T cells, but without any 
evidence of altered Tfh function (61). Based on the available data, it can be concluded that 
conventional immunosuppressive therapies do not block Tfh cell activity completely and 
Tfh cell activity could usefully be examined in patients with allograft rejection or rapidly 
declining graft function.
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This limited basis of evidence highlights that there is no clear understanding about the 
mechanisms by which immunosuppressants affect the development of Tfh cells. CNIs 
suppress IL-2 production through inhibiting the dephosphorylation of nuclear factor 
in activated T cells (NFAT), which is the key transcription factor for IL-2 and its receptor 
(Figure 2) (62). In a mouse model with acute viral infection, Ray et al. (39) demonstrated 
that IL-2 is able to enhance the expression of the transcriptional repressor Blimp-1 through 
the STAT5 and PI3K-Akt signaling pathway and promotes inhibition of Bcl-6 expression in 
activated T cells. It ultimately shifts the immune reaction during T cell differentiation away 
from a humoral response (Figure 2A). In theory, calcineurin inhibitors may influences Tfh 
differentiation through the control of IL-2 expression (Figure 2B). Basiliximab may also 
control Tfh differentiation in the same manner via blockade of the IL-2 receptor (Figure 2B). 
However, as proved in a mouse model, NFAT activity, which is suppressed by tacrolimus, is 
also a functional requirement for Tfh differentiation and may induce secretion of IL-21 by 
Tfh cells (63, 64). Since calcineurin inhibitors suppress NFAT activity and the corresponding 
expression of IL-2 and most likely also of IL-21, this class of agents may influence the generation 
of Tfh cells through regulating the balance of IL-2 and IL-21. However, further studies are 
needed to determine the mode of action of immunosuppressive agents on Tfh cells.
Tfh-targeted immunotherapy
Co-inhibitory pathways
As summarized in Figure 3, different strategies can be employed to target Tfh activation 
and/or function. CTLA4 could control B cell responses by modulating Tfh cell activity (30). 
Abatacept and belatacept are first and second generations of the fusion protein CTLA4-Ig. A 
study based on a mouse skin graft model by Kim et al. showed that abatacept reduced the 
number of activated CD4+PD-1+CXCR5+ Tfh cells in the spleen, which was associated with 
suppression of antibodies directed against the skin transplant (65). CTLA4-Ig also inhibited 
the increase in circulating Tfh cells and B cell-mediated antibody production in a mouse 
heart transplant model (66). In primary Sjögren’s syndrome patients, abatacept treatment 
attenuated circulating Tfh-cell numbers and Tfh-cell dependent B cell hyperactivity (67). In 
kidney transplant patients, we found that belatacept partially inhibited Tfh cell activation; 
the remaining activated Tfh cells were able to provide B cell help. Belatacept is less potent 
in vitro than tacrolimus in inhibiting Tfh cell-dependent plasmablast formation (60). Based 
on these preliminary data it seems that human circulating Tfh cells after transplantation 
are less susceptible to co-stimulation blockade than mouse Tfh cells. However, proof that 
lower susceptibility in humans leads to more extensive antibody-mediated anti-donor 
responses has not been established. New immune monitoring trials are needed to confirm 
the immunosuppressive effects of belatacept on human Tfh cells.
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Co-stimulatory pathways
Tfh cells control the quality of long-lived humoral immunity through the ICOS/ICOSL 
signaling pathway (68). ICOS is able to directly promote Tfh cell recruitment toward the GC 
and acts as a linker between T and B cells, supporting positive selection for high-affinity 
bone-marrow plasma cells (68, 69). Based on these studies, targeting the ICOS/ICOSL 
signaling pathway might offer new opportunities to prevent production of DSA and to 
treat transplant patients with de novo DSA. A glyco-engineered antibody which depletes 
ICOS resulted in a significant reduction in anti-nucleosomal autoantibodies in a SLE lupus-
prone mouse model (70). Sato et. al. demonstrated that ICOS expression was up-regulated 
on T cells in a canine hematopoietic cell transplantation model of graft rejection or chronic 
graft-versus-host disease. In this study, immunosuppressive effects were observed in mixed 
leukocyte reactions where anti-ICOS was combined with suboptimal concentrations of 
CLTA4-Ig or cyclosporine (71). Recently, another study showed that anti-ICOSL antibody did 
not impact the early Tfh differentiation in a mouse model with Plasmodium chabaudiAS 
infection, but ICOS is necessary for maintenance of a sustained high-affinity, protective Ab 
response (72). Targeting the ICOS pathway with biologicals is a promising new direction 
to control the function of Tfh cells and subsequently B cells. However, it is clear that 
more knowledge is warranted to better understand the reported discrepancies in above 
described in vitro and in vivo models. Therefore, the clinical use of anti-ICOS therapy is still in 
development. 
The CD40L/CD40 signaling pathway is also important in the interaction between Tfh and 
B cells. There are several known anti-CD40 agents. One of these, 2C10R4, is currently being 
investigated in clinical trials. Kim et al. demonstrated in a rhesus macaques kidney transplant 
model that 2C10R4 prevented antibody-mediated rejection via affecting Tfh cells and IL-21 
production in germinal centers and reducing production of early de novo DSA (73). In this 
study, belatacept was as effective as 2C10R4 in regulating Tfh cells and preventing acute 
rejection. More proof that blockade of the CD40-CD40L pathway is effective in inhibiting 
antibody production comes from studies analyzing the effect of CFZ533, a Fc-silencing and 
non-B cell depleting anti-CD40 monoclonal antibody. Non-human primates treated with this 
agent had prolonged kidney allograft survival rates and better kidney function parameters 
than the untreated control group. Treatment with CFZ533 prevented the production of 
alloantibodies in these animals (74). Hence, next to CTLA4-Ig, anti-CD40 agents represent a 
promising option for co-stimulatory blockade to inhibit both Tfh and B cells. An alternative 
strategy is the combined use of tacrolimus and new co-stimulatory blockers to inhibit 
allograft humoral immunity (73). However, the risk of over-immunosuppression should be 
considered.
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The tumor necrosis factor receptor OX40, activated by its cognate ligand OX40L, functions 
as a T cell costimulatory molecule. OX40L is expressed on DCs and myeloid APCs, but 
not on B cells. CD8α- DCs, known for their MHC class II presentation, are localized at the 
inter-follicular zone and play a pivotal role in the induction of antigen-specific Tfh cells 
by upregulating the expression of ICOSL and OX40L (75). The frequency of circulating 
OX40L-expressing myeloid APCs shows a positive correlation with disease activity and 
the frequency of ICOS+ blood Tfh cells in SLE. This may result from the capacity of OX40 
signals to stimulate naïve and memory CD4+ T cells to express multiple Tfh cell molecules. 
Therefore, OX40 signals are adequate to induce these T cells to become functional B cell 
helpers (76). Blocking the OX40/OX40L pathway resulted in prolonged allograft survival in 
cardiac and skin transplantation mouse models (77, 78). However, the optimal timing for 
OX40 blockade is unclear and there are still potential problems with use of OX40/OX40L 
therapy for post-transplant autoimmunity (79). In addition, OX40L expression on myeloid 
APCs can be induced by immune complexes containing RNA via toll-like receptor 7 (TLR7) 
activation (76). Toll-like receptor 9 (TLR9) signaling in DCs led to higher numbers of Tfh and 
GC B cells, and accelerated production of broad-affinity anti-hapten IgG (80). Hence, TLR7/
TLR9 might also offer a potential route to prevent antigen presentation of APC to Tfh cells.
Cytokine-dependent pathway
IL-21 acts as the dominate cytokine within the GC, and is a promising target to inhibit Tfh 
function. Treatment of SLE lupus-prone mice with an anti-IL-21 blocking antibody reduced 
titers of autoantibodies, delayed progression of glomerulonephritis and diminished renal-
infiltrating Tfh and Th1 cells, whilst improving overall survival (81). In an allogeneic setting, 
we recently demonstrated through ex vivo experimentation that IL-21 produced by donor 
antigen-activated Tfh cells could simulate humoral immunity, while an IL-21 receptor 
antagonist (αIL-21R) could inhibit B cell differentiation and decrease the proportion of 
plasmablasts and production of IgM and IgG2 (26). Moreover, IL-21 has been shown capable 
of overcoming Tfr cell-mediated suppression and inhibiting Tfr cells, thus skewing the ratio 
of Tfh to Tfr cells (40, 82). Since IL-21 is more specific to the interaction of GC-Tfh cells than 
other cytokines and molecules, there is an urgent need to identify the efficiency and safety 
of IL-21 inhibition or IL-21R blockade in the suppression of humoral immunity. Both IL-21 
receptor antagonists and IL-21 blocking antibodies have the potential to modulate the Tfh-
mediated immune response.
IL-6 is a cytokine which offers another attractive option for targeting humoral immunity 
(23). Specific targeting of IL-6 receptor by Tocilizumab in patients with rheumatoid 
arthritis led to a significant reduction in the number of circulating Tfh cells and in IL-21 
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production by CD4+ T cells (23). In transplantation, anti-IL-6 receptor treatment decreased 
the number of IL21+CD4+ and CD4+CXCR5+ Tfh cells in the spleens of allosensitized mice, 
as well as suppressing antibody recall responses and DSA levels (83, 84). A first study in 
kidney transplant patients proved that targeting the IL-6/IL-6R in highly sensitized patients 
could be a safe and new alternative in addition to currently used plasmapheresis with low-
dose intravenous immunoglobulin (85). Given the interplay between IL-6 and IL-21, the 
combined blockade IL-6 and IL-21 might be a better option to inhibit the differentiation, 
expansion and function of Tfh cells at all stages. 
TGF-ß appears to have multiple roles in transplantation. It promotes Tfh cells differentiation 
(22), while prevents Tfh cell accumulation, self-reactive B cell activation and autoantibody 
production in GCs (86). TGF-ß is also a vital fibrosis cytokine (87). A clear understanding 
of the effect of TGF-ß blockade on the entire humoral response and allograft fibrosis is 
required, however, before any therapeutic application.
Tfh migration-dependent pathways 
Targeting chemokine receptors or ligands to prevent Tfh migration offers another possible 
route for intervention. C-X-C chemokine ligand 13 (CXCL13) is produced in abundance by 
follicular stromal cells within B cell follicles. Expression of CXCL13, the receptor for CXCR5, on 
B and Tfh cells is necessary for their migration to the center of follicles to establish GCs (88). 
In addition, circulating Tfh cells respond to CXCL13 and can move back to the secondary 
lymphoid organ GC (9). Although CXCL13 acts locally, it can also be detected in plasma 
and its level is associated with the extent of immune activity (89). Patients with active 
chronic graft versus host disease have a lower frequency of circulating Tfh cells but higher 
CXCL13 plasma levels, suggesting increased homing of Tfh cells to secondary lymphoid 
organs (90). Circulating Tfh cells are also able to migrate into allografts via other chemokines 
such as CXCL10, and take part in the formation of tertiary lymphoid organs (9), which have 
been found in kidney biopsies after rejection (51). Anti-CXCL10 has been used to treat 
rheumatoid arthritis and ulcerative colitis in phase II clinical trials (91, 92). Depletion of B 
cells by rituximab has no effect on tertiary lymphoid organs in chronic allograft dysfunction 
(93). Therefore targeting CXCL13 or CXCL10 to inhibit the homing and trafficking of Tfh cells 
might be a more efficient strategy than B cell depletion to prevent the accumulation of Tfh 
in secondary lymphoid organs and formation of tertiary lymphoid organs in the allograft.
Immune enhancing pathways 
PD-1, which is highly expressed on activated GC-Tfh cells, plays an important role in Tfh 
cell differentiation and formation of GCs (50). In theory, anti-PD-1 could control Tfh-cell 
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activation. However, contradicting results are presented. In a PD-1-deficient mouse model, 
Kawamoto et al. found increased production of Tfh cells with altered phenotypes and 
dysregulation of GCs, eventually resulting in reduced antigen affinity of IgA (94). Good-
Jacobson et al., demonstrated that there were less plasma cells, GCs and Tfh cells in the 
absence of PD-1, however the remaining plasma cells were of a higher affinity (95). Others 
have also observed expansion of Tfh cells and enhanced humoral responses by blocking 
the PD-1 pathway (96, 97). In general, and thus also in organ transplantation patients, 
blockade of the PD-1 pathway boosts the immune response. These agents are approved 
for the treatment of solid tumors (98). A recent case report showed that a kidney transplant 
recipient given anti-PD-1 treatment for metastatic cutaneous squamous cell carcinoma had 
an acute cell-mediated allograft rejection two months after starting anti-PD-1, indirectly 
suggesting a role for PD-1 in regulation of transplant-related immune responses (99). There 
is no direct evidence that PD-1 agonists or antagonists would benefit transplant patients. 
The current observations might make PD-1 an unrealistic and ineffective target for achieving 
allograft humoral immunity.
Tfh cells as a biomarker in pharmacodynamics
Tfh cells may have a role in pharmacodynamic monitoring of immunosuppression, as a 
marker for the extent to which the antibody response is inhibited. Circulating Tfh cells could 
be the counterpart of GC-Tfh cells as they share functional properties with Tfh cells residing 
in SLOs (16). However, whether these circulating Tfh cells are formed in the circulation, or 
have left the GC after exposure to an antigen and reside as memory Tfh cells in the blood 
is unknown. He et al. demonstrated that the circulating CCR7loPD-1hi Tfh subset correlated 
with clinical indices in autoimmune diseases and suggested it might serve as a biomarker 
for pathogenic antibody responses in that setting (100). Bentebibel et al. found that the 
presence of ICOS+CXCR3+CXCR5+CD4+ T cells correlated with influenza vaccination antibody 
responses (101). Several papers have demonstrated that production of the neutralizing 
HIV antibody is dependent on Tfh cells, which could be a predictive biomarker for vaccine 
response (19, 102-104). Chenouard et al. suggested that a lack of Tfh cells, as seen in kidney 
transplant patients with operational tolerance, may induce a pro-tolerogenic environment 
with reduced risk of developing de novo DSA (105).
Individualized therapy after transplantation based on pharmacodynamic monitoring 
is the direction of immunosuppressant development. DSA, the traditional biomarker for 
humoral immunity, may not be the most sensitive indicator of the immune response 
after transplantation. As the launching cells for plasmablasts and memory B cells, the 
frequency of donor specific Tfh cells might also be a sensitive tool to identify patients 
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at risk for developing a DSA mediated immune response. These donor specific Tfh cells 
can be quantified by donor specific IL-21 Enzyme-Linked ImmunoSpot (ELISPOT) assay. 
Perhaps serum IL-21 measured by Enzyme Linked Immunosorbent Assay (ELISA) could also 
be a good alternative for pharmacodynamic monitoring. Of note, CXCL13 has also been 
suggested as a plasma biomarker for GC activity (106). Dose adjustments and switching 
immunosuppressive therapies based on monitoring of donor-specific IL-21+ Tfh numbers in 
combination with serum CXCL13 might be of benefit in alloimmune-risk stratification and 
for individualized therapy in transplantation.
Perspective and future directions 
Graft failure in immunosuppressed patients is often a combination of mixed cellular and 
antibody-mediated rejection. Current immunosuppression seems to have limited capacity 
to control the allograft loss in recipients with high risk of rejection. Targeting the Tfh cell 
during maintenance therapy has the potential to prevent mixed clinical rejection early in 
the activation cascade, due to its pivotal role in conjugating the interaction of T and B cells. 
Suppression of both GC-Tfh cell formation and Tfh cell migration via two different agents 
– for example by blocking IL-21 and CXCL13 –probably provides more robust control of 
humoral immunity. In addition, treatment strategies for patients undergoing solid organ 
transplantation should be defined according to the individual’s immune activity (e.g., 
number of circulating donor-specific IL-21+ T cells) and risk of rejection. Monitoring donor-
specific Tfh and memory B cells to guide the implementation of immunosuppression 
would help to tailor therapy appropriately. It would be of high interest to develop tools 
to easily investigate the specificity of these Tfh cells. In addition, immunosuppressive 
agents such as mTOR inhibitors with known Treg generating effects might also beneficially 
contribute to the generation of antigen specific Tfr cells in transplant patients (107). This 
recently described T cell population controlling B cell immune responses is of high interest 
to intervene in the humoral alloimmune response leading to improved graft survival in 
patients after organ transplantation (27).
Although many agents can influence Tfh cell development and function, only a few 
are likely to be suitable for clinical investigation. Successful immunosuppressive drug 
development has a lifecycle that includes the discovery of a target molecule, research into 
the mechanisms involved, animal experimentation, and validation in clinical trials. Clinical 
assessment requires comparison of the new drug versus current therapies and monitoring 
of adverse effects. Comparing the effects of new Tfh-targeting therapeutics against the 
conventional immunosuppressants used in transplantation, particularly in terms of Tfh 
dependent humoral immune activity, would be of considerable interest.
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Abstract
Interaction between T follicular helper (Tfh) cells and B cells is complex and involves various 
pathways, including the production of IL-21 by the Tfh cells. Secretion of IL-21 results in B 
cell differentiation toward immunoglobulin producing plasmablasts. In patients after kidney 
transplantation, the formation of alloantibodies produced by donor antigen activated B cells 
are a major cause of organ failure. In this allogeneic response, the role of IL-21 producing Tfh 
cells that regulate B cell differentiation is unknown. Here, we tested in an alloantigen driven 
setting whether Tfh cell help signals control B cell differentiation with its dependency 
on IL-21. Pre transplantation patient PBMCs were FACS sorted into pure CD4posCXCR5pos 
Tfh cells and CD19posCD27pos memory B cells and stimulated with donor antigen in the 
presence or absence of an IL-21R antagonist (αIL-21R). Donor antigen stimulation initiated 
expression of the activation markers inducible co-stimulator (ICOS) and programmed death 
1 (PD-1) on Tfh cells, and a shift toward a mixed Tfh2 and Tfh17 phenotype. The memory 
B cells underwent class switch recombination (CSR) and differentiated toward IgM and 
IgG producing plasmablasts. In the presence of αIL-21R, a dose dependent inhibition of 
STAT3 phosphorylation was measured in both T and B cells. Blockade of the IL-21R did not 
have an effect on PD-1 and ICOS expression on Tfh cells but significantly inhibited  B cell 
differentiation. The proportion of plasmablasts decreased by 78% in the presence of αIL-21R. 
Moreover, secreted IgM and IgG2 levels were significantly lower in the presence of αIL-21R. 
In conclusion, our results demonstrate that IL-21 produced by alloantigen activated Tfh cells 
controls B cell differentiation toward antibody producing plasmablasts. The IL-21R might 
therefore be a useful target in organ transplantation to prevent antigen driven immune 
responses leading to graft failure. 
51
Role of IL-21 in Tfh-B cell alloimmunity
3
Introduction
After kidney transplantation the immunological barrier between organ donor and recipient 
still limits graft survival (1). In this setting, a large proportion of allograft recipients develop 
a donor-specific antibody response associated with an increased risk for chronic rejection 
(2-5). This complication accounts for more than 50% of chronic transplant failures leading 
to death, dialysis or re-transplantation of patients (3). Current immunosuppressive agents 
mainly aimed at T-cell-mediated alloimmunity, whereas agents that effectively target 
humoral effectors are still insufficient (6). Therefore, there is a need to develop new agents 
that specifically prevent the activation of B cell mediated immune responses.
Within humoral immunity, T cell-mediated help to B cells is required for the generation 
of antigen-specific antibody responses. This process is mainly driven via IL-21 secreting T 
follicular helper (Tfh) cells. Tfh cells are well known for their expression of CXC chemokine 
receptor 5 (CXCR5) (7). Sustained expression of CXCR5 helps Tfh cells localize to B cell 
follicles, where they interact with germinal-center (GC) B cells and produce IL-21 (8). 
Through autocrine and paracrine mechanisms, IL-21 amplifies and stabilizes Tfh cell-
mediated responses, B cell proliferation, immunoglobulin class switch recombination (CSR), 
and B cell differentiation toward plasmablasts and long-living memory B cells (9, 10). In this 
respect, IL-21 directly effects B cell responses via IL-21R expressed on the B cells (11, 12). IL-
21 signals through a receptor complex consisting of IL-21 receptor (IL-21R) and a common 
cytokine receptor γ-chain that activates downstream JAK/STAT pathways, predominantly by 
the phosphorylation of STAT3 (13, 14). Transcriptional repressor B-cell lymphoma 6 (Bcl-6) 
orchestrates the differentiation program of Tfh cells, while suppressing other T helper subset 
transcription factors (8, 15). The capacity of Tfh cells to interact with B cells is dependent 
on T-cell receptor interaction with antigens presented by MHC class II molecules and co-
stimulatory molecules CD40ligand, inducible co-stimulator (ICOS) and programmed death 1 
(PD-1) (7, 8). The circulating counterparts of the “GC-Tfh cells” in humans express CXCR5, low 
expression levels of PD-1 and ICOS and lack expression of transcription repressor Bcl-6 (16-18).
In transplantation, studies on peripheral Tfh cells and their role in IL-21 driven B cell 
differentiation are limited (19, 20). An increased frequency of circulating Tfh cells was found in 
patients with chronic antibody mediated allograft rejection after kidney transplantation (21). 
Furthermore, in patients with pre-existing donor-specific antibodies (DSA) an association 
was detected between pre-existing DSA’s and the numbers of Tfh cells after transplantation 
(22). Co-stimulation blockade in a nonhuman primate kidney transplant model resulted in 
reduced IL-21 production in GCs and an attenuated antibody response (23). In addition, 
selective blockade of CD28 solely resulted in lower levels of IL-21 compared to CD80/86 co-
stimulatory blocking therapy (24) For the development of immunosuppressive agents that 
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specifically target B cell mediated immune responses directed toward donor antigen early 
in the activation cascade a better understanding of Tfh biology is needed.
Kidney disease patients suffer from defective immune responses caused by decreased T 
and B cell activity (25, 26). Therefore, we have used patient materials to set up an in vitro 
system in which we studied whether Tfh cells instruct donor antigen-driven memory B cells 
to differentiate into immunoglobulin producing plasmablasts. Subsequently, we assessed 
whether this Tfh cell mediated differentiation and plasmablast formation is dependent 
on IL-21 by blocking the IL-21R with an antagonist (αIL-21R). Overall, our data define the 
role of IL-21/IL-21R signaling pathway in alloantigen driven and Tfh cell mediated B cell 
differentiation toward Ig producing plasmablasts.
Material and methods
Study population
For the in vitro assays, PBMCs of 17 kidney transplant recipients obtained one day pre-
transplantation were analyzed and stimulated with the corresponding kidney donor PBMCs. 
Patient demographics are summarized in Table 1. The Medical Ethical Committee of our 
center approved this study (MEC-2010-022). All patients and donors gave written informed 
consent. B cell parameters were measured in all samples and T cell assays were performed 
when enough material was available for analysis. (Table 1)
Co-culture experiments of peripheral Tfh cells and memory B cells
Co-culture experiments with Tfh cells and memory B cells were conducted as schematically 
represented in supp. figure 1 to determine the functional interactions after donor 
antigen stimulation. PBMCs were thawed and CD3posCD4posCXCR5pos T cells (Tfh cells) and 
CD19posCD27pos (memory) B cells were FACS sorted by BD-FACSAria II SORPTM (purities ≥ 
96%). Isolated Tfh cells (2.104 cells/ well) were co-cultured with memory B cells (2.104 cells/
well) in a 96-wells plate for 8 days in the presence of irradiated (40 Gy) donor PBMCs (5.104/ 
well). At day 0 and after 8 days of culture, the Tfh cell phenotype, the B cell phenotype, and B 
cell differentiation toward Ig producing plasmablasts were measured with flow cytometry. 
The following MoAbs were used for the Tfh cell phenotype stainings: CD3 Brilliant Violet 
510 (BV510, Biolegend, San Diego, CA), CD4 Brilliant Violet 421 (BV421, Biolegend), CXCR5 
Alexa Fluor 647 (AF647, BD Biosciences, San José, CA), ICOS phycoerythrin-Cyanine7 (PE-
Cy7, Biolegend), CCR6 PE (eBioscience, San Diego, CA), CXCR3 peridinin chlorophyll (PerCP, 
Biolegend) and PD-1 Allophycocyanin-Cy7 (APC-Cy7, Biolegend). MoAbs used for the B cell 
stainings: CD19 BV510 (Biolegend), CD38 BV421 (BD Biosciences), IgG APC (BD Biosciences), 
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CD27 Pe-Cy7 (eBioscience), IgM PE (BD Biosciences) and IgD APC-Cy7 (Biolegend). 
7-aminoactinomycin (7-AAD) PerCP was included to measure cell viability. To define the role 
of IL-21/IL-21R signaling in alloantigen activated Tfh and memory B cells, the co-cultures 
were pre incubated for 30 minutes with humanized anti-IL-21R antibody ATR-107 (10µg/
ml, kindly provided by Pfizer, New York, NY) or isotype-matched control (10 µg/ml, IgG1-Fc, 
R&D systems, Minneapolis, MN) at 37°C. Hereafter, the irradiated donor cells were added to 
the co-cultures and further incubated at 37°C for 8 days. Total IgM, IgG and IgG2 production 
was measured in the culture supernatants with a sandwich ELISA (eBioscience). All flow 
cytometry analyzes were performed with Kaluza Analysis 1.3 (Beckman Coulter, Fullerton, CA).
Table 1. 
Study group (n=17)
Patients age in years (median, range) 57 (33-74)
Recipient gender (% male) 76.5%
HLA-A mismatches (mean ± s.d.) 1.1 (± 0.7)
HLA-B mismatches (mean ± s.d.) 1.7 (± 0.5)
HLA-DR mismatches (mean ± s.d.) 1.5 (± 0.5)
Panel reactive antigen (median, range)
• Current 0.0% (0.0-71%)
• Peak 4.0% (0.0-99%)
Previous kidney-transplantation 11.8% (2)
• Second kidney transplantation 5.9% (1)
• Third kidney transplantation 5.9% (1)
Renal replacement therapy before transplantation 88.3% (15)
• Haemodialysis 76.5% (13)
• Peritoneal dialysis 11.8% (2)
Cause of end-stage renal disease
• Hypertensive nephropathy 35.3% (6)
• Diabetic nephropathy 41.2% (7)
• Focal segmental glomerulosclerosis 5.9% (1)
• IgA nephropathy 5.9% (1)
• Polyarteritis nodosa 5.9% (1)
• Unknown 5.9% (1)
Numbers between brackets represent patient number unless otherwise specified.
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Phospho-specific flow cytometry
Phosphorylation of STAT3 by CD4+ T cells and CD19+ B cells was determined by phospho-
specific flow cytometry. In brief, PBMCs were stained with CD3 BV510 (Biolegend) and CD19 
Pe-Cy7 (Biolegend) for 30 minutes at RT in the dark. Next, the cells were incubated for 30 
minutes at 37°C with various concentrations of the humanized anti-IL-21R antibody ATR-
107 (Pfizer) or isotype-matched control (IgG1-Fc, R&D systems) followed by stimulation with 
recombinant human IL-21 (100 ng/ml, eBioscience) or recombinant human IL-6 (100 ng/ml, 
PeproTech, Rocky Hill, NJ) for 15 minutes at 37°C. Cells were fixed for 10 minutes with Cytofix 
buffer (BD Biosciences) at 37°C and permeabilized 30 minutes in 1ml methanol 90% at -20°C. 
Next, samples were stained with CD4 BV421 (Biolegend) and pSTAT3 PE (BD Biosciences). 
STAT3 phosphorylation was calculated as the median fluorescence intensity (MFI).
B cell stimulation assay 
B cell stimulation with a minor cocktail of stimuli was performed to study the effect of IL-21, 
co-stimulation and BCR activation on plasmablast formation. CD19+ B cells were isolated 
via CD43 negative selection with CD43 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) (purities ≥ 85%). B cells were incubated with anti-IL-21R antibody ATR-107 (10 
μg/ml, Pfizer) or isotype-matched control (10 μg/ml IgG1-Fc, R&D systems). Next, cells were 
stimulated with 5 μg/ml soluble anti-CD40 (Bioceros, Utrecht, The Netherlands), 10 μg/ml 
goat-anti-human IgM (Jackson Immunoresearch, West Grove, PA) and human recombinant 
IL-21 (100 ng/ml, eBioscience). Subsequently, the presence of plasmablasts on day 0 and 
the differentiation of memory B cells into plasmablasts on day 8 were determined with 
flow cytometry. Plasmablasts were defined as CD19posCD27highCD38high cells (16). The 
following monoclonal antibodies (MoAbs) were used: CD19 BV510 (Biolegend), CD27 Pe-
Cy7 (eBioscience), IgD APC-Cy7 (Biolegend) and CD38 BV421 (BD Biosciences). In addition, 
viability staining with 7-AAD PerCP was performed (BD Biosciences).
Statistics
Statistical analyses were performed using Wilcoxon signed-rank test and Spearman’s 
rank correlation test using GraphPad Prism 5 software (GraphPhad Software, San Diego, 
CA, http://www.graphpad.com). A two-tailed p-value <0.05 was considered statistically 
significant. 
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Results
Tfh cells are activated upon stimulation with alloantigen
We set up an in vitro system to study the functional interaction of CD4posCXCR5pos Tfh cells 
and CD19posCD27pos memory B cells upon alloantigen stimulation and the role of IL-21 in 
this response. Purified Tfh cells and memory B cells were co-cultured and stimulated with 
donor alloantigen. As a negative control, donor alloantigen was omitted (Supp. figure 2). For 
gating strategies see Figure 1A. Proportions of activation markers PD-1 and ICOS on the Tfh 
cells significantly increased after co-culture (Figure 1B, p=0.02 and p=0.008, respectively). 
A heterogeneous Tfh cell population was observed at day 8 based on expression of chemokine 
receptors CCR6 and CXCR3. Three Tfh subsets can be distinguished: CXCR3posCCR6neg Tfh1 
cells, CXCR3negCCR6neg Tfh2 cells and CXCR3negCCR6pos Tfh17 cells. Especially the Tfh2 and 
Tfh17 subsets (CXCR3neg) are able to induce B cell differentiation and Ig CSR via IL-21 while 
the CXCR3pos Tfh1 cells lack this capacity (16, 27). The mean proportion of Tfh2 and Tfh17 
cells at day 8 after co-culture was 71% (range: 38-80%), forming the majority of the different 
subsets (Figure 1C).
Tfh mediated B cell differentiation occurs upon stimulation with alloantigen
Over the 8 days of co-culture, the composition of surface immunoglobulins on the memory 
B cells changed. After co-culture CSR toward IgG occurred in part of the samples, with mean 
proportion surface IgG of 30% (range: 18-56%) before co-culture toward 35% (range: 12-89%) 
after co-culture (Figure 2A, p=0.04) while IgD proportions decreased from mean proportion 
of 18% (range: 4-26%) to 7% (range: 0.0-21%) after co-culture (Figure 2A, p=0.0009). The 
proportion of B cells expressing IgM did not significantly change after the co-culture (Figure 
2A, p=0.09). A significant increase in plasmablast numbers was observed after co-culture, 
proving the robust capacity of alloantigen and Tfh cells in stimulating memory B cell 
differentiation (Maximum 28%, Figure 2B, p=0.003). This increase in plasmablast numbers was 
not observed in co-cultures without donor alloantigen stimulation (Supp. figure 2). Based on 
the median proportion (10%) at day 8, we observed a group of cultures with high plasmablast 
proportions (>10%, n=9) and a group with low plasmablast proportions after culture (<5%, 
n=8). No significant differences were found between the two groups based on baseline 
characteristics (Supp. Table 1). The immunoglobulin producing capacity of the generated 
plasmablasts was proven by the correlation between the proportion of plasmablasts and 
the concentration of IgM or IgG in the supernatants of all cultures (Figure 2C, p<0.0001 
and p=0.0006, respectively). Overall, we showed that kidney transplant patient derived 
circulating Tfh cells before transplantation can be activated and are capable to stimulate 
memory B cell CSR and differentiation toward plasmablasts in the presence of alloantigen.
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Figure 1. Tfh cells are activated upon stimulation with alloantigen.
Tfh cells and memory B cells from patients, pre kidney transplantation, were stimulated with alloantigen and co-
cultured for 8 days. (A) Typical example of fluorescence activated cell sorting (FACS) gating strategy to obtain 
CD4posCXCR5pos Tfh cells and CD19posCD27pos memory B-cells. Cells were gated from viable (7-AAD negative) 
lymphocytes, defined by forward- and side-scatter. (B) Histogram overlays and quantified data of proportions PD-1 
and ICOS within CD4posCXCR5pos Tfh cells at baseline (day 0) and day 8 after co-culture (PD-1 n=7; ICOS n=8). (C) 
Gating strategy and distribution of proportions CCR6negCXCR3pos Tfh1, CCR6negCXCR3neg Tfh2 and CCR6posCXCR3neg 
Tfh17 cells of the total Tfh population on day 0 and 8 after co-culture. N.B.: Box whiskers represent minimal and 
maximal values. The upper and lower border of the box represent the 25% and 75% percentile with the middle line 
representing the median  (n=8).
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Figure 2. Tfh mediated B cell differentiation occurs upon stimulation with alloantigen
Tfh and memory B cells were stimulated with alloantigen and co-cultured for 8 days. (A) Gating strategy of 
surface immunoglobulins IgM, IgD and IgG within the memory B cell population before and after co-culture 
and corresponding quantified data (n=17). (B) Gating strategy of CD27highCD38high plasmablasts and remaining 
memory B cells at baseline (day 0) and after 8 days co-culture is depicted on the left. Quantified data of plasmablast 
proportions at day 0 and after 8 days co-culture are depicted on the right. Dashed line distinguishes between 
cultures with a high plasmablast proportion (>10%) compared to a low plasmablast proportion (<5%) at day 8 
(n=17). (C) Correlation between percentage plasmablasts and IgM or IgG (ng/ml) in the culture supernatant after 
8 days co-culture (n=16). *p<0.05, **p<0.003, ***p<0.0009. Pb = plasmablast.
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Phosphorylation of STAT3 is inhibited in the presence of Anti IL-21R antibodies
To determine the functionality of the IL-21R antibody (αIL-21R) in blocking IL-21R induced 
signaling events in T and B cells, we performed phosphor-specific flow cytometry. 
Phosphorylation of STAT3 was measured after stimulation with IL-21 or IL-6 (positive control). 
The specificity of αIL-21R was demonstrated by a 3.5 fold reduction in the phosphorylation 
of STAT3 on CD4+ T cells in the presence of 2 μg/ml αIL-21R onwards when comparing the 
IL-21 stimulated cells with the IL-6 stimulated cells (Figure 3A). Complete inhibition of STAT3 
phosphorylation in the presence of αIL-21R was seen on both T and B cells (Figure 3B and 3C, 
p=0.002 and p=0.0005, respectively). In the presence of an isotype-matched control of αIL-
21R the STAT3p levels were similar to the condition with only IL-21 stimulation. From these 
findings we conclude that αIL-21R efficiently blocks IL-21R induced signaling in T and B cells.
Figure 3. Phosphorylation of STAT3 is inhibited in the presence of αIL-21R antibodies
(A-C) PBMCs were stimulated with 100 ng/ml IL-21 or 100 ng/ml IL-6 for 15 minutes in the absence or presence of 
10 ug/ml αIL-21R or 10 ug/ml IgG1 isotype. MFI values of phosphorylated STAT3 were measured directly afterwards. 
(A) Dose-response curve of STAT3p in CD4pos T cells stimulated with 100 ng/ml IL-21 and different concentrations 
of αIL-21R. Stimulation with 100 ng/ml IL-6 was used as a positive control. (B-C) Histogram overlays and quantified 
data of phosphorylated STAT3 MFI values in CD4pos T-cells (C) and CD19pos B-cells (D) (n=7). *p<0.05, **p<0.005, 
***p<0.0005. Upper line of the boxes represent mean with SEM represented by the whiskers.
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Anti IL-21R inhibits memory B cell differentiation upon alloantigen stimulation
To explore the importance of the IL-21/IL-21R signaling pathway in an allogeneic system, 
αIL-21R was added to the co-cultures containing Tfh cells and memory B cells stimulated 
with alloantigen. Both cell populations expressed IL-21R  (Supp. Figure 3). Prior to the co-
cultures, we tested the capacity of αIL-21R to block the formation of plasmablasts in a culture 
system described by Ettinger and colleagues, where B cells were stimulated with anti-CD40, 
anti-IgM and IL-21 resulting in robust plasmablast proportions (28). Significant inhibition of 
plasmablast formation was found in the presence of αIL-21R in this setting (Supp. figure 4).
Next, we tested the efficacy of αIL-21R to block in our alloantigen Tfh-B cell co-culture 
system. To determine the inhibitory capacity of αIL-21R on B cell function we focused on 
the cultures with the highest proportion of plasmablasts. Cultures with low plasmablast 
proportions (<5%) were excluded. In these samples, after the culture period of 8 days, no 
differences were found regarding the phenotype of the Tfh cells. Moreover, proportions 
of PD-1, ICOS, and the distribution of CCR6 and CXCR3 expressed were comparable in the 
presence and absence of αIL-21R (Supp. figure 5). Thus, activated Tfh cells, and their Tfh1, Tfh2 
or Tfh17 phenotype are not altered in terms of their phenotype when cultured with αIL-21R.
In the presence of αIL-21R, formation of plasmablasts was inhibited by 78% (p=0.004, 
Figure 4A). In parallel, IgM production was inhibited from mean production of 169 ng/ml 
(range: 20-226 ng/ml) to 38 ng/ml (range: 2-50 ng/ml) in the presence of αIL-21R   (p=0.004, 
Figure 4B). Since αIL-21R is a fully humanized IgG1 compound we measured IgG2 levels 
in the culture supernatant. Although IgG2 is a noncomplement-fixing antibody, the IgG2 
subclass of antibodies is the second most common Ig subclass present after immunization 
(29). Production of IgG2 decreased from mean production of 975 ng/ml (range: 116-6763 
ng/ml) to 87 ng/ml (range: 22-540 ng/ml) in the presence of αIL-21R (p=0.004, Figure 4B). 
Taken together, these data show that the αIL-21R antibody has the capacity to inhibit B cell 
differentiation and subsequent immunoglobulin production.
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Discussion
We studied the activation of Tfh and memory B cells upon stimulation with alloantigen and 
the role of IL-21 within this process. The present study demonstrates that stimulation of Tfh 
and memory B cells with donor alloantigen results in an activated Tfh2 and Tfh17 phenotype, 
CSR of memory B cells and differentiation of antigen driven memory B cells toward IgM and 
IgG producing plasmablasts. In the presence of αIL-21R, formation of plasmablasts and IgM 
and IgG2 production were significantly inhibited. Our in vitro system is of high value to test 
other interventions that might alter Tfh-B cell interaction after alloantigen response.
While αIL-21R nicely inhibited IL-21 dependent STAT3p, the Tfh cell phenotype was not 
changed (Sup. figure 5). This suggests that the autocrine effect of IL-21 on the Tfh cell 
and the presence of antigen is not essential for upregulation of activation markers PD-
1, ICOS and chemokine receptors CCR6 and CXCR3. Our data are in line with in vivo and 
in vitro studies where the absence of either IL-21 or IL-6 did not affect Tfh differentiation, 
whereas combined absence of IL-21 and IL-6 led to a decreased Tfh frequency and Bcl6 
gene expression (15, 30, 31). Thus, in our co-culture system the effect of IL-21 on the Tfh cell 
phenotype is redundant.
In our patient cohort, a high inter-individual variation in plasmablast numbers was observed 
after 8 days stimulation of Tfh and memory B cells with donor antigen (Figure 2B) reflecting 
the natural variation among patients. Response toward alloantigen apparently varied among 
the different co-cultures, even though no significant differences in baseline characteristics 
were found between the co-cultures with and without plasmablast formation (Supp. 
Table 1). Immunological variation, e.g. distinct expression rates of co-stimulation surface 
markers or distinct IL-21 production by the Tfh cells among the different co-cultures might 
contribute to this variation. Finally, effect of vaccination or viral infection might support the 
formation of alloantibody producing plasmablasts via cross-reactivity. This cross-reactivity 
results in heterologous immunity within the patient population, this may contribute to the 
variation in plasmablast numbers in our co-cultures (32).
In transplantation, the formation of complement fixing DSA and anti-HLA antibodies is 
associated with graft loss (2-5). In the presence of currently prescribed immunosuppressive 
drugs, de novo DSA and anti-HLA antibodies can be formed which contribute to the process 
of allograft rejection leading to graft loss (4, 33). A first hint that IL-21 producing Tfh cells are 
involved in processes leading to the production of alloantibodies comes from our study 
reporting that the absolute numbers of Tfh cells after transplantation are the highest in 
patients with pre-existing DSA (22). In addition, this study reports a decrease in plasmablast 
numbers when stimulating Tfh and memory B cells with staphylococcal enterotoxin B (SEB), 
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a strong polyclonal superantigen (22). In the present study, we determined the mechanisms 
involved by analyzing the IL-21+ Tfh and B cell activation pathway during activation by 
donor antigen solely. This study demonstrates that alloantigen and IL-21 are key factors in 
this response. Translating the outcome of our in vitro study by using patient materials, we 
speculate that also in vivo B cell differentiation might be mediated by IL-21 producing Tfh 
cells and that interaction with donor antigen stimulated B cells results in the formation 
of DSA. Future experiments, e.g. in vivo experimental transplantation studies, should reveal 
whether indeed IL-21 drives antibody mediated allogeneic immune responses.
In a phase I trial in healthy volunteers, 76% of the participants who received αIL-21R developed 
anti-drug antibodies (ADA) due to increased activity of the antigen presentation machinery 
(34, 35). Thus, identification of an IL-21R blocker with lower immunogenicity or a switch to 
an IL-21 cytokine antagonist may be an alternative. In addition, in sensitized patients αIL-21R 
may not work sufficiently since these patients have high levels of circulating DSA due to 
previous transplants or pregnancy. In these patients, the destructive effects of the existing 
plasma cells need to be neutralized, for instance via protease inhibitors, inhibition of IL-6 or 
inhibition of BAFF and APRIL (6). To date, B-cell depletion is achieved via treatment with the 
anti-CD52 antibody alemtuzumab, anti-thymocyte globulin (ATG) and anti-CD20 antibody 
rituximab. Compared to these treatments, IL-21R blocking therapy is of interest since it is 
a biological that mainly interferes the Tfh-B cell crosstalk, saving the presence of T and B 
cells with a resting or regulatory phenotype. The use of anti-IL6R treatment to decrease 
the formation of anti-HLA antibodies has also been widely studied. The first study in kidney 
transplant patients and experimental transplant models showed that anti-IL6R treatment 
affected the proportion Tfh cells and reduced B cell differentiation toward IgG producing 
plasmablasts (36-38). In these studies no data were reported on anti-IL21R agents and a 
next step would be to compare the functionality of these biologicals. We speculate that 
inhibition of both pathways i.e., IL-6 and IL-21 may be of interest to test.
In this study, we focused on the interplay between peripheral Tfh cells and B cells. Low 
numbers of IL-21 producing T cells are present in the circulation, compared to high numbers 
found in inflamed tissues (39). In transplantation, the presence of Tfh cells that co-localized 
with B cells in follicular-like structures was confirmed in kidney biopsies taken during acute 
cellular rejection, suggesting IL-21 mediated Tfh-B cell interaction in local tertiary lymphoid 
structures in the kidney allograft (22, 23). In depth analysis of these graft infiltrating Tfh and 
B cells, e.g. via next generation sequencing or other single cell analysis, would be of great 
importance to improve our knowledge about molecular pathways involved in the anti-
donor response.
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Identifying the mode of action of Tfh-mediated activation of B cells upon alloantigen 
stimulation is important to further understand immunological processes that occur in 
transplant patients. In our allogeneic co-culture system IL-21 plays a non-redundant role in 
promoting B cell differentiation, as blockade of the IL-21/IL-21R signaling pathway resulted 
in almost complete inhibition of plasmablast formation as well as antibody production. In 
conclusion, our results demonstrate that IL-21 produced by alloantigen activated Tfh cells 
controls B cell differentiation toward antibody producing plasmablasts. The IL-21R might 
therefore be a useful target in organ transplantation to prevent rejection.
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Supplemental figures
Start co-culture:
+ Patient Tfh cells
+ Patient Memory B cell
+/- αIL-21R
Flow cytometry analysis:
Tfh cell markers
B cell markers
ELISA:
IgM, IgG2
Day 0
30 min.
Day 8
+ Irradiated donor PBMCs
Flow cytometry analysis:
Tfh cell markers
B cell markers
FACS sort for:
Tfh cells
Memory B cells
Patient PBMCs
Supplemental Figure 1.
Schematic representation of the co-culture model and analytical approaches used in this study.
65
Role of IL-21 in Tfh-B cell alloimmunity
3
CX
CR
5+
CD
27
+
U
ns
tim
CX
CR
5+
CD
27
+
D
on
or
 a
.g
.
SSC
FS
C
SSC
FS
C
Viaprobe
CD
19
Viaprobe
CD
19
CD27
CD
38
CD27
CD
38 7.
2%0.
0%
A
.
B.
Su
pp
le
m
en
ta
l F
ig
ur
e 
2.
C
D
4p
os
C
XC
R5
po
s 
Tf
h 
ce
lls
 a
nd
 C
D
19
po
sC
D
27
po
s 
m
em
or
y 
B-
ce
lls
 w
er
e 
FA
C
S 
so
rt
ed
 a
nd
 c
ul
tu
re
d 
fo
r 8
 d
ay
s 
in
 t
he
 a
bs
en
ce
 (A
) o
r p
re
se
nc
e 
(B
) o
f d
on
or
 a
nt
ig
en
. C
el
ls
 
w
er
e 
ga
te
d 
by
 fo
rw
ar
d-
 a
nd
 s
id
e-
sc
at
te
r a
nd
 v
ia
bi
lit
y 
w
as
 d
et
er
m
in
ed
 b
y 
7-
A
A
D
 n
eg
at
iv
e 
ce
lls
 (v
ia
pr
ob
e)
. P
la
sm
ab
la
st
s 
(C
D
27
hi
gh
C
D
38
hi
gh
) w
er
e 
ga
te
d 
fro
m
 th
e 
to
ta
l 
B 
ce
ll 
po
pu
la
tio
n 
(C
D
19
po
s)
.
66
Chapter 3
IL-21R
IL-21R
FMO
Memory B cells
IL-21R
IL-21R
FMO
Tfh cells
Supplemental Figure 3.
Histogram overlays of IL-21R MFI values (black) or FMO (grey) on Tfh cells and memory B-cells. MFI: mean 
fluorescence intensity, FMO: fluorescence minus one.
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0
20
40
60
80
PD-1 ICOS Tfh1 Tfh2 Tfh17
NS
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NS
%
Tfh cells (day 8 after co-culture)
αIL-21R
Supplemental Figure 5.
Tfh and memory B-cells were co-cultured for 8 days in the presence (+) or absence (-) of 10ug/ml αIL-21R. (A) 
Percentages of PD-1pos, ICOSpos, CCR6negCXCR3pos Tfh1, CCR6negCXCR3neg Tfh2 and CCR6posCXCR3neg 
Tfh17 cells within the Tfh population after 8 days co-culture. Upper line of the boxes represent mean with SEM 
represented by the whiskers. n=8, NS=not significant.
Supplemental Table 1.
Plasmablast formation
No 
(n=8)
Yes 
(n=9)
p value 
(two-sided)
Patients age in years (median, range) 50 (33-68) 62 (39-74) 0.89
Recipient gender (% male) 87.5% 66.7% 0.58
HLA-A mismatches (mean ± s.d.) 1,1 (±0.6) 1.0 (±0.9) 0.83
HLA-B mismatches (mean ± s.d.) 1.6 (±0.5) 1.7 (±0.5) 0.33
HLA-DR mismatches (mean ± s.d.) 1.5 (±0.5) 1.6 (±0.5) 0.35
Panel reactive antigen (median, range)
•  Current 8.9% (0.0-71%) 1.1% (0.0-5%) 0.80
•  Peak 14,9% (0.0-99%) 1.7% (0.0-4%) 0.23
Previous kidney-transplantation 0% (0) 22.2% (2)
•  Second kidney transplantation - 11.1% (1)
•  Third kidney transplantation - 11.1% (1)
Renal replacement therapy before transplantation
•  None 0% (0) 22.2% (2) 0.36
•  Haemodialysis 87.5% (7) 66.7% (6)
•  Peritoneal dialysis 12.5% (1) 11.1% (1)
Numbers between brackets represent patient number unless otherwise specified
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Abstract
Background
Interleukin 21 (IL-21) is involved in regulating the expansion and effector function of a broad 
range of leukocytes, including T cells and B cells. In transplantation, the exact role of IL-21 
in the process of allograft rejection is unknown. To further explore this, the aim of this study 
is to test the effect of an IL-21 receptor (IL-21R) blocking antibody on the early phase of 
allograft rejection in a humanized skin transplantation model in mice reconstituted with 
human T and B cells.
Methods
Immunodeficient Balb/c IL2rγ-/-Rag2-/- mice were transplanted with human skin followed 
by adoptive transfer of human allogeneic splenocytes. Control animals were treated with 
a PBS vehicle while the other group was treated with a humanized anti-IL-21R antibody 
(αIL-21R).
Results
In PBS treated animals, human skin allografts were infiltrated with lymphocytes and 
developed a thickened epidermis with increased expression of the inflammatory markers 
Keratin 17 (Ker17) and Ki67. In mice treated with αIL-21R, these signs of allograft reactivity 
were significantly reduced. Concordantly, STAT3 phosphorylation was inhibited in this 
group. Of note, treatment with αIL-21R attenuated the process of T and B cell reconstitution 
after adoptive cellular transfer.
Conclusion
These findings demonstrate that blockade of IL-21 signaling can delay allograft rejection in 
a humanized skin transplantation model.
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Introduction
In transplantation, both short- and long-term allograft survival rates remain suboptimal, 
illustrating the need for new immunosuppressive agents(1). In general, two types of renal 
allograft rejection are recognized: T cell-mediated rejection (TCMR) and antibody-mediated 
rejection (ABMR). However, over the last years it has become clear that these two types of 
rejection responses are not as distinct as thought before. For example, in renal allograft 
biopsies, overlapping histological features of TCMR and ABMR are often detected(2). These 
rejections are characterized by allograft infiltration with both T and B cells as well as typical 
features of ABMR, for instance the presence of de novo donor-specific antibodies (DSA)(2, 
3). Unsurprisingly, these cases are not responsive to treatment strategies that target either 
TCMR or ABMR alone(4).
Adaptive alloimmune responses are established via three essential signals: 1) donor antigen 
presentation, 2) co-stimulation, and 3) upregulation of cytokine receptors and cytokine 
production, resulting in T and B cell activation. Current immunosuppressive treatments 
include calcineurin inhibitors (CNIs) that mainly target the T cell activation cascade. CNIs 
are unable to prevent B-cell driven ABMR, which is normally addressed with B cell depleting 
therapies (e.g. rituximab and intravenous immunoglobulins). Therapies that target B cells 
are generally not used as maintenance therapy due to the side effect profile and their 
ineffectiveness in the prevention of TCMR(5). There is therefore a need for the development 
of immunosuppressive drugs with mechanisms of action that concurrently target T and B 
cells.
Interleukin-21 (IL-21) is a cytokine with a broad pattern of actions that affect the differentiation 
and function of several lymphoid cells(6). IL-21 binds to the IL-21 receptor (IL-21R), which 
forms a heterodimer with the common gamma chain (γc)(7). Upon IL-21/IL-21R signaling, 
downstream JAK/STAT pathways are activated, of which signal transducer and activator of 
transcription 3 (STAT3) is most predominant(6). IL-21 is produced by T follicular helper (Tfh) 
cells, Th17 cells, and natural killer T (NKT) cells and is important in the differentiation of 
functional Th17 and Tfh cells(6, 8-10). For the CD8+ T cell compartment, IL-21 is a potent 
regulator of expansion and effector function and prolongs CD8+ T cell effector function 
in chronically infected hosts(11-13). IL-21 is also crucial for naïve B cell differentiation to 
immunoglobulin-producing plasma cells after antigen recognition(14, 15).
In solid organ transplantation, IL-21 is expressed during the process of rejection(16-18). 
Upon alloantigen stimulation, IL-21-secreting Tfh cells are present in the circulation at 
three months after renal transplantation and provide help to B cells for their differentiation 
towards plasmablasts(19). In addition, IL-21-expressing cells have been detected in renal 
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rejection biopsies in acute TCMR, suggesting a local effect of IL-21 on cytotoxic CD8+ 
T cells in this type of rejection(20). We have previously demonstrated that IL-21 is a key 
factor in the Tfh-cell dependent differentiation of alloantigen-stimulated B cells towards 
immunoglobulin producing plasmablasts(21). Anti-human IL-21 mAb treatment has also 
been shown to suppress graft-versus-host (GVH)-associated disease in a humanized murine 
model(22). Therefore, IL-21R blockade may affect the process of allograft rejection. In the 
present study, we investigated whether blockade of the IL-21/IL-21R pathway can inhibit 
the process of allograft rejection in the early phase.
To investigate the effect of human IL-21 signaling blockade on allograft rejection, we used 
a humanized skin transplant model in which immunodeficient Balb/c IL2rγ-/- Rag2-/- mice 
are transplanted with human skin followed by adoptive transfer of human allogeneic 
splenocytes(23). When setting up a humanized transplantation model in mice, a skin 
transplant model is the first choice, since it is relatively easy to obtain human skin and with one 
piece of human skin several experiments can be performed, which improves reproducibility. 
The process of rejection of skin and a solid organ occurs via similar mechanism, making skin 
transplantation useful as a model for studying organ transplantation. Also, the use of the 
humanized skin transplant mouse model has proven successful in previous studies, in which 
the effect of several immune modulating therapies on skin inflammation was tested(23-26). 
In general, many of these compounds were shown to reduce the number of infiltrating T 
cells in the human skin(23-25). Using this model, we provide evidence for efficacy of IL-21 
blockade in the control of the start of alloimmunity.
Material and methods
Mice
Balb/c IL2rγ-/- Rag2-/- mice were bred and housed under specific pathogen free (SPF) 
conditions at the Erasmus Medical Center Experimental Animal Facility. The animals were 
housed in individually ventilated cages with ad libitum access to water and food and a 12 
hour light-dark cycle. Mice were aged between 8 and 14 weeks at the time of the first 
experimental procedure. All experiments were approved by the Central Committee Animal 
Experiments Ethical Committee (license number AVD101002016635) and complied with 
the 1986 directive 86/609/EC of the Council of Europe.
Human skin
Waste material from human abdominal skin surgeries performed for deep inferior epigastric 
artery perforator (DIEP) flap reconstruction was anonymously obtained as approved by the 
Medical Ethical Committee of our center (MEC-2014-347). The humanized skin allograft 
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transplant model is based on the model described by Issa et al. (23). Human skin grafts were 
harvested from discarded abdominal skin using an electric dermatome (Zimmer, Utrecht, 
the Netherlands) in strips with a thickness of 200 μm. From these strips, punch biopsies 
were taken with a diameter of 1cm and kept in ice-cold PBS. The human skin grafts were all 
transplanted within 16 hours.
Human skin transplantation
Animals were subcutaneously injected with 0.05 mg/kg buprenorphine 0.5 hours prior and 
12 hours after the surgery as analgesic. During the surgical procedure mice were kept under 
complete anesthesia via isoflurane inhalation (5% isoflurane initially followed by 2% to 2.5% 
with 1:1 air/oxygen mixture for maintenance) and the animals were kept warm on 37°C 
heating pads. The left dorsal flank of the mice was shaved and a circular piece of skin with a 
diameter of 1 cm was removed. A human skin graft was placed in the circular incision and 
stitched on the mouse with absorbable 5/0 suture (Safil®, B. Braun, Melsungen, Germany). 
The skin grafts were covered with a povidone-iodine non-adherent mesh (Johnson & 
Johnson, Amersfoort, the Netherlands) and pressure dressing wound and fixed with 
surgical tape. Ten days after the transplant procedure, the tape was removed under general 
anesthesia. Engraftment of the human skin graft was achieved 35 days after transplantation.
Preparation and adoptive transfer of human splenocytes
Human splenocytes were adoptively transferred 35 days after skin transplantation. Human 
splenocytes were obtained from a segment of the spleen from deceased kidney donors. 
Splenocytes were anonymously used for research purposes as described in article 13 of The 
Netherlands law of organ donation (Wet op Orgaandonatie, WOD). The spleen segments 
were disrupted and filtered through a 70μm cell strainer (Greiner Bio-one, Alphen a/d Rijn, 
The Netherlands) to obtain a single-cell suspension. Ficoll-paque (Amersham Pharmacia 
Biotech, Uppsala, Sweden) density gradient was used to collect mononuclear cells. An 
aliquot of splenocytes was used to isolate quiescent B cells via negative selection with 
CD43 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) (purities ≥ 90%). 25x106 
splenocytes were mixed with 12.5x106 enriched B cells and suspended in 1mL of PBS. 
35 days post skin transplantation 5x106 splenocytes and 2.5x106 enriched B cells were 
administered in 200μl PBS via intraperitoneal (IP) injection. The composition of T and B cells 
within the total infusion is depicted in Supplemental Figure 1.
αIL-21R therapy
Humanized anti-IL-21R antibody (αIL-21R; also referred to as ATR-107) was kindly provided 
by Pfizer (New York, NY, USA). αIL-21R was administered via IP injection at a dose of 10mg/kg 
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(recommended by Pfizer) on days 7, 14 and 21 after adoptive transfer of splenocytes(27, 28). 
We started the administration of αIL-21R at day 7 after adoptive transfer in order to allow the 
splenocytes to first engraft and proliferate in order to reflect a healthy functioning immune 
system in the mice. αIL-21R antibody was infused three times to build up a significant level 
of antibody. PBS was used as a vehicle control.
Monitoring of the human skin graft
All mice were sacrificed 30 days after adoptive transfer of splenocytes in order to assess for 
evidence of skin rejection and inflammation at a single time point(23).
Flow cytometry
Human splenocytes were characterized by flow cytometry prior to adoptive transfer and 
from mouse blood and spleens 30 days after adoptive transfer. Cells were stained with 
antibodies specific for CD45 allophycocyanin (APC, BD), CD3 Brilliant Violet 510 (BV510, 
Biolegend, San Diego, CA, USA), CD4 Brilliant Violet 421 (BV421, Biolegend), and CD19 BV510 
(Biolegend) and the viability marker 7-AAD (BD Biosciences).
In order to test whether αIL-21R effectively blocked the IL-21R, phosphorylation of STAT3 
downstream of IL-21R was measured on CD4+ T cells by phospho-specific flow cytometry. 
Briefly, 200μl of blood from treated animals was stained with anti-CD3 BV510 (Biolegend, 
San Diego, CA, USA) and subsequently stimulated with recombinant human IL-21 (100 ng/
ml, eBioscience, San Diego, CA, USA) or recombinant human IL-6 (100 ng/ml, PeproTech, 
Rocky Hill, NJ) for 15 minutes at 37°C. Cells were fixed for 10 minutes with Cytofix buffer 
(BD Biosciences, San José, CA, USA) at 37°C and permeabilized for 30 minutes in 1 ml 90% 
methanol at -20°C. Samples were then stained with anti-CD4 BV421 (Biolegend) and anti-
pSTAT3 phycoerythrin (PE, BD Biosciences). All samples were measured on the FACSCanto 
II (BD Bioscience). Flow data were analyzed with Kaluza Analysis 5.1 software (Beckman 
Coulter, Brea, CA, USA).
Immunohistochemistry
Human skin grafts were removed at day 30 post adoptive cell transfer, formalin fixed and 
paraffin-embedded (FFPE), and processed following a standardized diagnostic protocol. Three 
μm sections were cut and stained with hematoxylin and eosin (H&E). Immunohistochemical 
staining was performed on the Benchmark Ultra Stainer (Ventana, Basel, Switzerland). The 
following human mAbs were used: CD45 (Cell Marque, ref. V0000963, Rocklin, CA, USA), CD4 
(Ventana, ref. 790-4423), CD8 (Ventana, ref. Y04591), CD20 (Ventana, ref. 790-2531), Keratin 
17 (Ker17, Ventana, ref. G03114), Ki67 (Ventana, ref. 790-4286). Antibodies were incubated 
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on the tissue sections for 30 minutes together with anti-rabbit or anti-mouse amplifiers. 
3.3’-diaminobenzidine (DAB) was used as chromogen and sections were counterstained 
with hematoxylin. Analysis of the proportions of positive cells in a representative region of 
interest (including the epidermis and dermis) was performed by setting a fixed threshold 
followed by calculating the positive area with the ImageJ software (NIH, http://imagej.nih.
gov/ij/).
Measurement of the epidermal thickness 
Epidermal thickness was measured at twenty consecutive points in H&E stained skin slides 
from which the mean epidermal thickness was calculated.
Statistical testing
GraphPad Prism 5 software (GraphPad Software Inc, San Diego, CA, USA, http://www.
graphpad.com) was used for statistical analysis. Differences between unpaired groups were 
analyzed with the nonparametric Mann-Whitney test. A two-tailed p-value of <0.05 was 
considered to be statistically significant. 
Results
αIL-21R antibody effectively blocks STAT3 phosphorylation
In order to assess the efficacy of αIL-21R to block IL-21R signaling, phosphorylation of 
STAT3 downstream of the IL-21R was measured on human T cells after adoptive transfer of 
human splenocytes in mice(29). We tested the duration of efficient blockade of the IL-21R 
by measuring STAT3 phosphorylation at multiple time points after cellular infusion (Figure 
1A). Mice were treated with the αIL-21R compound on days 7, 14 and 21 after adoptive 
transfer of human splenocytes and sacrificed at specific time points as depicted in Figure 
1A (n=1 per time point). From day 42 after adoptive cellular transfer onwards the degree 
of human leukocyte chimerism within the blood was sufficient to perform the phospho-
specific flow cytometry protocol to measure STAT3 phosphorylation (STAT3p). Whole blood 
was stimulated with IL-21 or IL-6 to induce STAT3p, followed by measurement of STAT3p. IL-6 
stimulation was used as a positive control to induce STAT3p through bypassing the IL-21R. 
Figure 1B shows a representative flow cytometry plot of STAT3p staining. In this example, 
only 1.4% of CD3+ T cells were positive for STAT3p after IL-21 stimulation in the presence 
of αIL-21R, compared with 65.9% in control animals that did not receive αIL-21R treatment. 
These cells responded to IL-6 stimulation thereby demonstrating that αIL-21R specifically 
targets the IL-21R. Cells from a vehicle treated animal expressed pSTAT3 after both IL-21 and 
IL-6 stimulation (Figure 1B). STAT3p remained suppressed until 49 days after the last infusion 
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of αIL-21R (56 days after adoptive cellular transfer, Figure 1C). These data confirm efficient 
blockade of the IL-21 signaling pathway by αIL-21R treatment. For subsequent assays, we 
selected day 30 after adoptive cellular transfer for analysis to ensure IL-21R blockade.
αIL-21R mAb treatment delays rejection of the human skin
We next assessed the in vivo immunosuppressive effects of αIL-21R using a humanized 
mouse skin transplantation model. Mice were transplanted with a human skin allograft, 
reconstituted with human splenocytes, and subsequently treated with αIL-21R or PBS 
control as described above (Figure 2A). Mice were sacrificed at day 30 after adoptive cellular 
transfer for cross-sectional analysis by measurement of several hallmarks of skin rejection 
(Figure 2A). As expected, there was clear epidermal dyskeratosis in skin allografts from mice 
treated with PBS control. By contrast, mice that received αIL-21R treatment had markedly 
reduced evidence of epidermal damage (Figure 2B). Mean epidermal thickness was 370.9 
μm in animals treated with vehicle control (n=7) compared with 90.6 μm in the αIL-21R-
treated animals (n=8; p<0.05, Figures 2B and D). Infiltrates of mononuclear cells were 
detected in the human dermis of vehicle-treated animals. These infiltrates were absent in 
the human dermis of αIL-21R-treated animals (Figure 2C). Overall, these results show that 
the epidermal changes indicative of severe rejection that occur in vehicle-treated animals 
are delayed upon infusion of αIL-21R.
IL-21R blockade reduces lymphocyte infiltration in skin grafts
Human skin graft sections were stained by immunohistochemistry in order to phenotype 
the infiltrating mononuclear cells. The mean area of CD45 cell positivity in the dermis was 
10.2% in the vehicle-treated animals compared to 2.2% in the αIL-21R-treated animals 
(p<0.001, Figure 3A). CD3 cell positivity correlated with the staining patterns for CD45, 
with 9.0% in the control group compared to 1.4% in the αIL-21R group (p<0.05, Figure 3B). 
CD4 cell positivity was 6.2% in the control group compared to 1.2% in the αIL-21R group 
(p<0.05, Figure 3C). CD8+ T cell numbers in the dermis and epidermis were low in both the 
control group and αIL-21R group (Figure 3D; p<0.05). Some CD8+ T cells resided within the 
epidermis in the control group animals while the CD4+ cells in these animals were mainly 
detected within the dermis (Figures 3C and D). CD20+ B cells were low within the control 
animals and barely detectable within the skin of αIL-21R-treated animals (p=0.07; Figure 3E).
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Figure 1. STAT3 phosphorylation is effectively blocked by Anti IL-21R
(A) Schematic representation of the treatment strategy to measure blockade of IL-21R dependent STAT3 
phosphorylation (STAT3p). Mice were adoptively transferred with 5x106 splenocytes plus 2.5x106 enriched 
quiescent B cells. αIL-21R was administered via intraperitoneal injection at a concentration of 10mg/kg at day 7, 
14 and 21 after adoptive transfer of splenocytes. PBS was used as a vehicle control. Blood was sampled on days 28, 
35, 42, 49, 56, and 62 after adoptive cellular transfer (n=1 per time point). (B) Typical example dot plots of STAT3p 
analysis of a vehicle-treated animal and a αIL-21R-treated animal. 42 days after adoptive cellular transfer blood 
was sampled and stimulated for 15 minutes with 100 ng/ml recombinant human IL-21, 100 ng/ml recombinant 
human IL-6 as a positive control, or not stimulated (unstim.). Subsequently, cells were stained for CD3, CD4 and 
STAT3p. Numbers within the dot plots indicate proportions of the STAT3p positive population. (C) Proportions of 
STAT3p of CD4+ T cells after stimulation with IL-21, IL-6, or control at different time points after adoptive cellular 
transfer and αIL-21R treatment. Before day 42, the human lymphocyte numbers in the blood were not sufficient 
for STAT3p measurements.
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Figure 2. αIL-21R mAb treatment delays rejection of human skin grafts
(A) Treatment strategy used to explore the effect of αIL-21R on rejection of human skin grafts. A circular piece 
of human skin with a diameter of 1 cm was stitched on the mouse (day -35). After 35 days the human skin was 
engrafted and mice then received 5x106 splenocytes with 2.5x106 enriched quiescent B cells (day 0). αIL-21R was 
administered at a concentration of 10mg/kg on days 7, 14 and 21 after adoptive cellular transfer (n=8 mice). PBS 
was used as a vehicle control (n=7 mice). 30 days after adoptive cellular transfer mice were sacrificed for cross-
sectional analysis. (B) Hematoxylin and eosin (H&E) staining of the complete human skin graft of a vehicle-treated 
animal and an αIL-21R-treated animal. (C) 10x magnification of the H&E staining of the human skin graft of a vehicle 
and αIL-21R-treated animal. In the vehicle-treated animal (upper panel) thickening of the epidermis and dermal 
infiltrate was detected in contrast to the αIL-21R-treated animal (lower panel). (D) Quantified data of epidermal 
thickness. Epidermal thickness is presented in μm as a mean of twenty consecutive measurements with the 
standard error of the mean (SEM). Vehicle group n=7, αIL-21R group n=8. (* p<0.05).
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Figure 3. IL-21R blockade reduces lymphocyte infiltration in skin grafts
Typical examples of immunohistochemical stainings of human skin grafts for (A) human CD45, (B) human CD3, 
(C) human CD4, (D) human CD8, and (E) human CD20. Increased infiltration of human lymphocytes was detected 
in skin of vehicle-treated animals compared to αIL-21R-treated animals. Quantified data are presented as mean 
proportions of the positive area with SEM or as mean positive cells counted within the total dermis and epidermis 
with SEM. Magnification: 10x. Vehicle group n=7, αIL-21R group n=8. (* p<0.05, *** p<0.001).
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IL-21R blockade reduces human skin inflammation markers
A consequence of the infiltration of mononuclear cells is the induction of local inflammation 
measured among others by increased cell proliferation (epidermal hyperplasia) and 
the activation of several keratines. In order to further assess this, we stained human skin 
graft sections with two epidermal proliferation markers. Upon injury, de novo production 
of Keratin 17 (Ker17) is associated with epidermal formation after skin injury(30). Indeed, 
significantly higher levels of Ker17 were found in the vehicle-treated animals (mean positive 
area: 30.5%) compared to the αIL-21R-treated animals (mean positive area: 7.6%, p<0.05, 
Figure 4A). Proliferation of the epidermal cells was assessed by staining with the proliferation 
marker Ki67. The mean area of dividing epidermal cells of the vehicle-treated animals was 
4.6% compared to 1.9% in the αIL-21R-treated animals (p<0.05, Figure 4B). Ki67 positive cells 
were mainly detected in the basal layers of the epidermis, suggesting active hyperplastic 
activity in vehicle-treated animals. These findings suggest that IL-21R signaling contributes 
to the generation of a pro-inflammatory climate in the transplanted skin.
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Figure 4. IL21R blockade reduces human skin inflammation markers
(A) Immunohistochemistry for skin inflammation marker keratin 17 (Ker17). Typical example of the human skin 
graft of a vehicle-treated animal and an αIL-21R-treated animal are depicted combined with the quantified data. 
(B) Immunohistochemistry for proliferation marker Ki67. A typical example of the human skin graft of a vehicle-
treated animal and an αIL-21R-treated animal are depicted combined with the quantified data. Quantified data 
are presented as mean proportions of the positive area with SEM. Magnification: 10x. Vehicle group n=7, αIL-21R 
group n=8. (* p<0.05).
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Figure 5. αIL-21R mAb treatment affects human leukocyte engraftment
(A) Spleen weight in mg of mice treated following the schedule depicted in Figure 1A Mice were sacrificed on 
days 28, 35, 42, 49, 56, and 63 post adoptive cellular transfer. Two vehicle-treated animals were sacrificed on days 
28 and 42 post adoptive cellular transfer. n=1 per time point. (B) Absolute numbers of CD45+ lymphocytes of 
mice treated following the schedule depicted in Figure 1A. Mice were sacrificed on days 28, 35, 42, 49, 56, and 63 
post adoptive cellular transfer. One vehicle-treated animal was sacrificed on day 42 post adoptive cellular transfer. 
n=1 per time point. (C) Spleen weight in mg and proportions of CD45+ human lymphocytes of the total viable 
leukocytes in the spleen. Measurements were performed 30 days post adoptive cellular transfer (D) Proportions of 
human CD45+ lymphocytes within the total viable leukocytes within blood of the vehicle-treated animals versus 
the αIL-21R-treated animals 30 days after adoptive cellular transfer. A typical example of a dot plot from a vehicle-
treated animal and an αIL-21R-treated animals is depicted on the right-hand side. (E) Proportions of CD3+ T cells 
and CD19+ B cells within human CD45+ lymphocytes in the blood. Vehicle-treated animals were compared to the 
αIL-21R-treated animals 30 days after adoptive cellular transfer. Vehicle group n=7, αIL-21R group n=8. (N.S. = not 
significant, * p<0.05, ** p<0.01, *** p<0.001).
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αIL-21R mAb treatment reduced human leukocyte engraftment
In order to investigate the mechanisms underlying decreased infiltration of lymphocytes 
and reduced inflammation of human skin grafts in αIL-21R-treated animals, we measured 
the numbers of lymphocytes in blood and spleen at different time points after adoptive 
transfer of human splenocytes in animals without a skin graft. The mean spleen weight (as 
a measure of cell engraftment) of two vehicle-treated animals was 319 mg at day 28 and 
42 post splenocyte infusion (Figure 5A). Spleen weights of the αIL-21R-treated animals (at 
day 7, 14 and 21; protocol Figure 1A) were 38 mg at day 28 and increased to 169 mg at day 
63 after cell infusion (Figure 5A). Absolute numbers of human CD45+ cells in the spleen of 
αIL-21R-treated animals also increased over time (Figure 5B).
In animals that received a skin graft, similar effects of αIL-21R mAb on human splenocyte 
engraftment were observed. The average spleen weight was 192 mg in the vehicle-treated 
animals compared to 42 mg in the αIL-21R-treated animals at day 30 after administration of 
splenocytes (p<0.001, Figure 5C) and the proportions of human CD45+ within total viable 
lymphocytes were 22% in the vehicle group versus 0.8% in the αIL-21R group (p<0.01, 
Figure 5C). In the blood we detected the same trend with a significant difference in human 
CD45+ lymphocyte chimerism levels when comparing the vehicle group and the αIL-21R 
group (mean: 3.6% versus 38% of total viable cells within the lymphocyte gate, respectively, 
p<0.001, Figure 5D). The majority of the human CD45+ lymphocytes measured within the 
blood consisted of CD3+ T cells, with only minor amounts of CD19+ B cells (Figure 5E). 
This was observed for both the vehicle-treated group and the αIL-21R-treated group and 
correlated with the low level of infiltrating human B cells in the human skin (Figure 3D). 
Overall, blockade of IL-21R signaling hampers engraftment of human lymphocytes in Balb/c 
IL2rγ-/- Rag2-/- mice, suggesting an effect of IL-21R blockade on human leukocyte survival 
and proliferation.
Discussion
Evidence from previous studies presents a role for the pleiotropic cytokine IL-21 in the 
process of allograft rejection(16, 17). Therefore, we hypothesized that blockade of the IL-
21R in a humanized skin transplant model affects the early phase of rejection of the human 
skin. In the present study we demonstrate that rejection of a human skin graft occurs after 
adoptive transfer of human splenocytes in Balb/c IL2rγ-/- Rag2-/- mice. In the presence of 
αIL-21R mAb, phosphorylation of STAT3 downstream the IL-21R is effectively blocked. 
Blockade of IL-21R signaling led to a significant inhibition of epidermal thickening, reduced 
infiltration of lymphocytes and decreased expression of inflammation markers Ker17 and 
Ki67 in human skin allografts.
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The inhibition of human skin rejection through IL-21R blockade was accompanied 
by impaired engraftment of human lymphocytes. Blockade of IL-21R influenced the 
homeostatic proliferation of the infused cells and therefore their engraftment within the 
host. Indeed, previous studies present a role for IL-21 in lymphocyte homeostasis(31-33). 
This impaired homeostatic proliferation may be a result of impaired cross talk between 
different lymphocyte subsets upon IL-21R blockade. For instance, IL-21R signaling is involved 
in the generation of Tfh cells and mediates Tfh cell help to activate B cell differentiation 
towards immunoglobulin producing plasma cells(21, 34, 35). Moreover, IL-21 is involved 
in sustaining CD8+ T cell responses, which is in line with the low levels of CD8+ T cells in 
the human skin that we detected in the presence of αIL-21R(36, 37). Furthermore, there 
is evidence that activation of Th17 cells is impaired by αIL-21R(10), which may contribute 
to the reduced allograft rejection upon IL-21R blockade. Despite the low engraftment of 
human lymphocytes following IL-21R inhibition, we succeeded to reach a level of human 
lymphocyte chimerism that is acknowledged in the literature as a reconstituted human 
lymphocyte system(38, 39). To allow some degree of immune cell engraftment to occur, 
we decided to delay blockade of IL-21R signaling until day seven after infusion of human 
lymphocytes. Further delay of αIL-21R treatment or administration of higher numbers of 
immune cells to enhance engraftment of the human immune system was limited by the 
risk for graft-versus-host disease (GVHD) in this model.
In the present study, B cell engraftment was detected with marginal B cell numbers in the 
peripheral blood and less than expected B cells in the spleens of control mice. In αIL-21R-
treated animals, B cell engraftment was negligible. It is known that the engraftment of B 
cells in humanized mouse models is challenging, as described by others(40). One technical 
obstacle is the long maturation time of B cells after infusion, which can take up to five 
to six months after administration of human hematopoietic stem cells in mice(41). The 
model used in the present study does not allow such long engraftment times as after three 
months the risk for GVHD caused by human T cells that recognize mouse antigens rapidly 
increases(42). In addition, we have seen that infusion of higher splenocyte doses as well 
leads to an increased incidence of GVHD. In our study, infusion of αIL-21R at a later time 
point in order to diminish the effect of the IL-21R blockade on T and B cell repopulation is 
therefore an unsuitable option. An alternative might be to infuse mature B cells instead of 
the CD43- quiescent B cell population in order to accelerate the process of B cell activation 
and reconstitution. 
As described above, T cells are necessary in the process of B cell expansion(41). Thus, a 
decreased T cell homeostastic proliferation caused by αIL-21R might lead to impairment 
of B cell reconstitution as we have seen in our model. Since we found an effect of αIL-
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21R on T and B cell engraftment within the host due to the effects of IL-21R signaling 
on homeostatic proliferation, blockade of this receptor may also impair maintenance of 
both arms of the immune system. The inhibition of allograft rejection through reduced 
engraftment of reconstituted immune cells by IL-21R blockade that we detected in our 
study is in line with a previous study by Oliviera et al.(25). In this study, cyclosporine-A and 
rapamycin were introduced in a similar humanized skin transplant mouse model which 
resulted in lower numbers of peripheral T cells combined with a decrease in T cell infiltration 
and inflammation of the human skin(25). The humanized skin transplant model is also used 
to study the effect of regulatory T (Treg) cells on reducing rejection of human skin (23, 24). 
These studies demonstrated that Treg cells may have an inhibiting effect on the engraftment 
of human lymphocytes. The effect of immune modulating compounds on the engraftment 
of lymphocytes forms the main limitation in this study. For future studies, local infusion of 
the compound into the transplanted skin may be an alternative to overcome the systemic 
effect of the immune modulating therapies on lymphocyte reconstitution (43). In addition, 
the use of a reference drug alongside the αIL-21R compound during future experiments will 
further clarify the effectiveness of blockade of IL-21R signaling.
The humanized mouse model represented in this study forms a valuable preclinical model 
to evaluate human-specific reagents such as humanized monoclonal antibody therapies. 
However, since the infusion of these reagents might also affect the reconstitution of the 
infused human lymphocytes one should take into account that reduced rejection of the 
skin may occur as a result of the impaired engraftment of the human lymphocytes. In 
conclusion, we prove that blockade of IL-21R signaling delays the start of rejection of a 
human skin graft, but also influences T and B cell reconstitution in Balb/c IL2rγ-/-Rag2-/- mice. 
These preclinical data using an in vivo humanized system demonstrate significant promise 
for blockade of IL-21R signaling in transplantation.
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Summary
We hypothesize that T cells such as interleuking (IL)-21+ B cell lymphoma 6 (BCL6)+ T 
follicular helper cells can regulate B cell-mediated immunity within the allograft during 
acute T cell-mediated rejection; this process may feed chronic allograft rejection on long 
term. To investigate this mechanism we determined the presence and activation status of 
organized T and B cells in so-called ectopic lymphoid structures (ELSs) in different types 
of acute renal allograft rejection. Biopsies showing the following primary diagnosis were 
included:  acute/active antibody-mediated rejection, C4d+ (a/aABMR), acute T cell-mediated 
rejection grade I (aTCMRI), and acute T cell-mediated rejection grade II (aTCMRII). Paraffin 
sections were stained for T cells (CD3 and CD4), B cells (CD20), follicular dendritic cells (FDCs, 
CD23), activated B cells (CD79A), immunoglobulin (Ig)D, cell proliferation (Ki67), and double 
immunofluorescent stainings for IL-21 and BCL6 were performed. Infiltrates of T cells were 
detected in all biopsies. In aTCMRI, B cells formed aggregates surrounded by T cells. In these 
aggregates, FDCs, IgD and Ki67 were detected, suggesting the presence of ELSs. In contrast, 
a/aABMR and aTCMRII showed diffuse infiltrates of T and B cells but no FDCs and IgD. IL-
21 was present in all biopsies. However, co-localization with BCL6 was observed mainly in 
aTCMRI biopsies. In conclusion, ELSs with an activated phenotype are found predominantly 
in aTCMRI where T cells co-localize with B cells. These findings suggest a direct pathway of 
B cell alloactivation at the graft site during T cell mediated rejection.
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Introduction 
Current immunosuppressive regimens in renal transplantation are directed primarily against 
T cell-mediated alloimmunity. However, many allograft recipients still develop allograft 
rejection through  both T cell-mediated and/or antibody-mediated alloimmune responses 
(1, 2). Allograft rejection is a consequence of the activation of the recipient’s immune 
system and includes the interaction between T and B cells via antigen presentation, co-
stimulation and cytokine production. The local interaction in the renal allograft between T 
and B cells and its potential contribution to graft damage is still debated (3). Recent studies 
by Loupy et al. and Holloran et al. plea for a key role for T cells in the mechanism leading 
to chronic allograft rejection, traditionally the outcome of B cell mediated immunity (4, 5). 
Thus, studying the presence, organization and functional hallmarks of T and B cells within 
grafts of acute renal allograft rejection is essential for gaining a better understanding of the 
in situ immunological interactions in renal allograft rejection.
The formation of antibodies is a result of the interaction between T follicular helper (Tfh) 
cells and B cells (6). This Tfh-B-cell interaction is complex and involves various activation and 
regulatory pathways, including interleukin (IL)-21 signaling (6, 7). Activated Tfh and B cells 
reside in germinal centers (GCs) and both express transcriptional repressor B-cell lymphoma 
6 (BCL6). Expression of BCL6 is essential for GC maintenance and BCL6 represses transcription 
factors of other lymphocyte subsets (8). The organized structure of the GC -a T-cell zone 
surrounding the active center where B cells and follicular dendritic cells (FDCs) reside- is 
crucial for correct B cell affinity maturation (9). After antigen recognition, Tfh cells initiate 
the differentiation of B cells into antibody-producing plasma cells via secretion of IL-21 (10). 
The maintenance of the GCs as part of secondary lymphoid organs (SLOs) is preserved by 
the presence of FDC networks (11). These FDC networks are involved in antigen priming of 
T cells and stimulation of B-cell affinity selection and maturation. Antigen-dependent Tfh-
B-cell interaction and GC formation primarily takes place in SLOs such as draining lymph 
nodes. However, chronic persistence of antigen leads to the formation of highly organized 
leukocyte aggregates that resemble SLOs. These ectopic lymphoid structures (ELSs) or 
also called tertiary lymphoid organs (TLOs) initiate antigen-specific responses locally, i.e. at 
the site of the antigen (12). The formation of ELSs has been recognized in inflamed tissue 
caused by infection, auto-immunity and cancer (12). In organ transplantation ELSs are 
mainly associated with chronic rejection, though these structures are also recognized in 
acute renal allograft rejection (13-15). In 2003 Sarwal et al. described the presence of CD20+ 
B cell clusters in kidneys of renal transplant patients with acute rejection (13). The potential 
functions of these T and B cells in ELSs in acute renal allograft rejection and in which types 
of acute renal rejection these ELSs are particularly formed is largely unknown.
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To better understand the pathophysiology of rejection after organ transplantation we 
studied the organization of T- and B-cells with respect to GC features (i.e. positive for FDCs, 
IgD (indicating active Ig production), Ki67 (indicating proliferation) and co-localization of 
BCL6 and IL-21)(16) in human renal allografts with acute rejection. To assess whether T 
cells regulate B cell mediated immunity within the grafts of T cell mediated rejection, we 
studied for the first time the presence of these structures in various categories of acute 
rejection: acute T cell-mediated rejection grade I (aTCMRI), acute T cell-mediated rejection 
grade II (aTCMRII) and acute/active antibody-mediated rejection (a/aABMR). Improved 
characterization of the immunological features of the ELSs in the renal allograft may provide 
a deeper understanding of the mechanisms underlying different types of acute rejection.
Materials and methods
Patient population
In this retrospective study we analysed a total of fifteen renal transplant biopsies from 
fifteen different patients with an acute allograft rejection. The patients were selected 
based upon the primary rejection diagnosis based on routine histopathological stainings. 
The primary diagnoses were acute/active antibody-mediated rejection (a/aABMR, n=5), in 
which, according to the Banff, C4d was positive and donor specific antigens (DSA) were 
present; acute T cell-mediated rejection grade I (aTCMRI, n=5), and acute T cell-mediated 
rejection grade II (aTCMRII, n=5). The different pathological features of the renal allograft 
rejections were classified according to the Banff ‘15 classification (17). Patient characteristics 
are summarized in Table 1. The Medical Ethical Committee of the Erasmus MC approved 
this study (MEC-2010-022). Renal biopsy material used was that what was available after 
routine diagnostics and this resides under the Dutch law on medical research and is not 
WMO compliant and is regulated by the Dutch Code of Conduct. 
Immunohistochemical stainings
All renal biopsies were formalin fixed and paraffin-embedded (FFPE). Biopsies were 
processed according to a standardized diagnostic protocol. For histomorphological 
assessment, 3 µm sections were cut and stained with hematoxylin and eosin (H&E), periodic 
acid-schiff (PAS) and Jones’ silver stain. In addition, an immunohistochemical C4d staining 
was performed on a 4 µm paraffin section. Subsequently, immunohistochemical stainings 
were performed on the Benchmark Ultra Stainer (Ventana, Basel, Switzerland). The following 
ready to use mAbs were used: CD3 (Ventana, ref. 290-4341), CD4 (Ventana, ref. 790-4423), 
CD20 (Ventana, ref. 790-2531), CD23 (Ventana, ref. 790-4408), CD79A (Ventana, ref. 790-4432), 
IgD (Ventana, ref. 760-4444) and Ki67 (Ventana, ref. 790-4286). Antibodies were incubated 
on the tissue sections for 30 minutes and anti-rabbit or anti-mouse amplifiers were used. 
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3.3’-diaminobenzidine (DAB) was used as chromogen. Sections were counterstained with 
hematoxylin. The quantification method used for these stainings was based on a numerical 
scale ranging from negative (0) to severe (3). High-power fields (HPF) with 0-25 positive cells 
were scored as mild (1), 26-100 positive cells were scored as moderate (2) and >100 positive 
cells were scored as severe (3). When biopsy material on the slide was insufficient we did 
not score and noted the staining as not applicable (N/A).
Table 1. Patient baseline characteristics
Number of mismatches
Case 
number BANFF Gender
Age 
at KT
L(U)R/
PM
Rejection 
(days 
post Tx)
Previous 
Ktx HLA-A HLA-B HLA-DR
a/aABMR
1 a/aABMR C4d+ M 53 PM 10 1 1 2 1
2 a/aABMR C4d+ F 61 LUR 2 0 0 2 1
3 a/aABMR C4d+ M 38 LUR 7 1 0 1 2
4 a/aABMR C4d+ F 32 LR 34 0 1 1 1
5 a/aABMR C4d+ M 54 LUR 65 1 2 2 1
aTCMR I
1 aTCMR IB M 65 LUR 117 0 2 2 1
2 aTCMR IB M 25 LR 94 0 1 1 1
3 aTCMR IA M 55 LR 63 0 1 2 2
4 aTCMR IA F 25 LR 408 0 1 1 1
5 aTCMR IB M 42 LUR 589 0 1 2 2
aTCMR II
1  aTCMR IIB M 60 LUR 146 0 2 1 1
2  aTCMR IIA M 50 LUR 5 1 1 1 1
3  aTCMR IIB M 59 LR 1268 0 0 0 0
4  aTCMR IIB M 55 PM 11 1 2 1 0
5  aTCMR IIA F 53 LR 4 0 1 0 1
a/aABMR = acute/active antibody-mediated rejection; aTCMR I = acute T cell-mediated rejection grade I; aTCMR II = 
acute T cell-mediated rejection grade II; L(U)R = living (un)related; PM = post mortal; Ktx = kidney transplantation; 
HLA = human leukocyte antigen.
Immunofluorescence
Four µm FFPE sections were deparaffinized up to 100% EtOH. Endogenous peroxidase 
was blocked for 10 minutes in 0.5% H
2
O
2 
in methanol. Afterwards, sections were heated 
in a microwave in a Tris-EDTA buffer to obtain antigen retrieval. In order to bypass non-
specific antibody binding, sections were incubated for 30 minutes with 10% human serum 
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and 10% goat serum in a Tris-EDTA buffer enriched with 0.15M sodiumchloride, 0.25% 
gelatin and 0.05% Tween-20 at 4ºC. Primary antibodies BCL6 (mouse monoclonal; 1:200 
dilution; Novocastra; Newcastle upon Tyne, UK) and IL-21 (rabbit polyclonal; 1:100 dilution; 
LS Bio; Seattle, WA) were incubated at 4ºC overnight. Subsequently, secondary antibodies 
Dyelight®594 (1:200 dilution; Vector laboratories; Burlingame, CA, USA) to visualize BCL6 
expression in red and Dyelight®488 (1:200 dilution; vector laboratories) to visualize IL-21 
expression in green were incubated for 1 hour at room temperature. Finally, sections were 
incubated with DAPI (Sigma-Aldrich, St. Louis, MO) for 30 minutes and enclosed with mowiol 
and a coverslip. As a positive control for IL-21 and BCL6 co-localization, duodenal biopsy 
sections obtained from a patient with celiac disease were used (Supp. figure 1). Images 
were taken and a double blind scoring on the images was performed on the presence of 
single and double positive cells with a ranked scale ranging from negative (0) to severe (3) 
presence of positive cells.
Results
Organized ELSs predominantly present in aTCMRI
All fifteen renal rejection biopsies were stained with H&E to assess cellular infiltrates within 
the renal allograft (a representative example is shown in Figure 1). In total, six out of fifteen 
biopsies (40%) contained dense cellular aggregates. Remarkably, cellular aggregates 
were detected in four out of five aTCMRI biopsies (80%) (black arrows, Figure 1, Table 2). 
In contrast, only one out of five biopsies (20%) in both the aTCMRII and a/aABMR groups 
contained cellular aggregates (Table 2). 
Analyses of the immunohistochemical stainings are depicted in Table 2 and representative 
examples are presented in Figure 2 and 3. In all 15 biopsies, diffuse cellular infiltrates of 
CD3pos T cells were detected in the tubulointerstitial compartment and CD4pos cells were 
present which might be a mixture of CD4+ T cells and monocytes (Figure 2, Table 2)(18, 
19). Within the aTCMRI biopsies, with aggregate formation, the T cells formed clear clusters 
compared to a more diffuse localization of T cells in the biopsies with aTCMRII or a/aABMR 
(Figure 2). As expected, biopsies showing a/aABMR only had moderate to mild infiltration of 
T cells in contrast to extensive T cell infiltration in the biopsies with either aTCMRI or aTCMRII.
CD20pos B cells were detected in a diffuse manner in four out of five a/aABMR biopsies (80%) 
and three out of five aTCMRII biopsies (60%). In contrast, all biopsies with aTCMRI revealed 
a moderate to severe presence of B cells, which on consecutive sections co-localized with 
the T-cell infiltrates (Figure 2), representing a B- and T-cell architecture of an ELS. In addition, 
Five out of six biopsies with aggregates (83%) showed the presence of CD23-positive FDC 
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networks, of which 4 (80%) were biopsies with an aTCMRI. The FDCs formed clear networks 
in the center of the B- and T-cell aggregates, with overlap with the B-cell nodules (Figure 2).
Figure 1. Representative haematoxylin and eosin (H&E) stainings of the different renal allograft 
rejection types. 
Black arrows indicate cellular infiltrates referred to in table 2 as aggregates. Cropped images represent an aggregate 
in the acute T cell-mediated rejection grade I (aTCMRI) and a more diffuse cellular infiltrate in the aTCMRII. a/aABMR 
= acute/active antibody-mediated rejection, aTCMRI = acute T cell-mediated rejection grade I, aTCMRII = acute T 
cell-mediated rejection grade II.
In terms of activation, a subset of the B cells was positive for CD79A in all biopsies with 
aTCMRI, demonstrating an activated B-cell phenotype, up until differentiation to plasma 
cells (Figure 3) (20). The presence of IgD in all aTCMRI biopsies –mainly within the 
aggregates- confirmed local immunoglobulin production supporting a GC reaction (Figure 
3). In all aTCMRI biopsies Ki67+ cells were present pointing towards active structures with 
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proliferating cells. As expected, in the aTCMRII biopsies infiltrating cells stained positive for 
Ki67 due to the high number of infiltrating cells in this type of rejection. In contrast, the 
majority of the a/aABMR stained negative for Ki67. The follow up of renal graft function after 
the rejection episode revealed that the patients with aTCMRI biopsies positive for T cells, B 
cells, FDC networks and IgD did not present differences in graft function at 3 months after 
the rejection biopsy compared to the other patients (Table 3). 
Co-localization of BCL6 and IL-21 in ELSs
Simultaneous staining for BCL6 and IL-21 was performed to determine GC features. IL-21pos 
cells were found in all biopsies. Within the aggregates, the majority of cells were IL-21pos, 
whereas outside the aggregates and in biopsies without aggregates, lower numbers of 
IL-21pos cells were found. Co-localization of IL-21 and BCL6 expression was predominantly 
observed within the B- and T-cell aggregates (Figure 4) in the aTCMRI biopsies (Table 2).
Table 2. Amount of renal biopsy stainings
Case number
Aggregates
(ELSs) CD3 CD4 CD20 CD79A CD23 IgD Ki67 IL-21 IL-21+BCL6
a/aABMR
1 Yes 2 3 1 1 1 1 2 2 1
2 No 2 3 1 1 0 0 0 n.a. n.a.
3 No 1 2 0 n.a. n.a. n.a. n.a. n.a. n.a.
4 No 2 2 1 1 0 0 0 1 0
5 No 1 2 1 1 0 0 0 1 0
aTCMR I
1 No 3 3 3 1 1 1 2 2 1
2 Yes 3 3 2 2 1 1 1 2 1
3 Yes 2 2 1 1 1 3 2 3 1
4 Yes 2 2 1 1 1 1 1 3 1
5 Yes 3 3 3 3 2 3 1 3 2
aTCMR II
1 Yes 3 3 3 0 0 0 1 1 0
2 No 3 3 0 0 1 0 1 1 0
3 No 3 3 2 0 n.a. n.a. n.a. 1 0
4 No 2 2 0 0 0 0 1 n.a. n.a.
5 No 3 3 1 1 0 1 2 1 0
a/aABMR = acute/active antibody-mediated rejection; aTCMR I = acute T cell-mediated rejection grade I; aTCMR 
II = acute T cell-mediated rejection grade II; 3, severe (>100 positive cells/HPF); 2, mild (26-100 positive cells/
HPF); 1, moderate (0-25 positive cells/HPF); 0 = negative; n.a. = not applicable; HPF = high-power field; Ig = 
immunoglobulin; IL = interleukin; BCL6 = B cell lymphoma 6; ELSs = ectopic lymphoid structures.
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Figure 4. Immunofluorescent stainings for transcription factor B cell lymphoma 6 (BCL6) (red) 
and cytokine interleukin (IL)-21 (green) were performed. 
4’,6-diamidino-2-phenylindole (DAPI) (blue) was used to stain the chromatin of the cells. Magnification: x20. aTCMRI 
= acute T cell-mediated rejection grade I.
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Table 3. Follow-up renal allograft function
Rejection therapy
Case 
number
Lowest 
creatinine 
before 
rejection
Creatinine 
rejection
Creatinine 
M3
Methyl 
pred-
nisolon ATG IVIg
Alemtu-
zumab
Rituxi-
mab
Graft loss 
(Months 
after 
biopsy)
a/aABMR
1 556 556 149 Yes No Yes No No No
2 313 313 134 Yes No Yes Yes No No
3 312 312 462 Yes No Yes No Yes No
4 148 254 190 Yes No No No No No
5 191 249 183 Yes No Yes Yes No Yes (29)
aTCMR I
1 142 229 235 Yes No No No No No
2 109 148 112 Yes No No No No No
3 106 155 95 Yes No No No No Yes (37)
4 91 188 185 Yes No No Yes No No
5 135 222 207 Yes Yes No No No No
aTCMR II
1 122 269 431 Yes Yes No No No Yes (3)
2 157 157 142 Yes No No No No No
3 135 327 331 Yes Yes No No No No
4 1083 1083 106 Yes Yes No No No No
5 303 303 200 Yes Yes No No No No
Follow-up renal allograft function with lowest creatinine (μmol/L) between renal transplantation and renal allograft 
rejection, creatinine at time-point rejection and creatinine 3 months (M3) after rejection. a/aABMR = acute/active 
antibody-mediated rejection; aTCMR I = acute T cell-mediated rejection grade I; aTCMR II = acute T cell-mediated 
rejection grade II; ATG = anti-thymocyte globulin; IVIg = intravenous immunoglobulin
Discussion
T and B cell aggregates are formed locally in the renal allograft upon persistent alloantigen 
exposure (3, 7, 13). The role of these aggregates in alloreactivity is still debated. A growing 
body of evidence suggests that these structures are also present in more acute responses 
in which T cells are dominating (21). Here, we characterized lymphoid aggregates present 
in renal allografts and describe for the first time, to our knowledge, differences in the 
composition and formation of ELSs among three types of renal allograft rejection, namely 
aTCMRI, aTCMRII and a/aABMR. We found that organized lymphoid aggregates are mainly 
present in biopsies diagnosed as aTCMRI. We believe these represent active ELSs with FDC 
networks, IgD and BCL6posIL-21pos cells, possibly Tfh cells, that provide B cell help.
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B-cells were found in all biopsies in which aggregates were seen. In accordance with previous 
work by Sarwal et al. and de Graav et al., high numbers of B-cells were found in biopsies 
showing aTCMRI (13, 15). The role of these intragraft B-cell infiltrates is debated. Some studies 
have found that B-cell clusters are associated with poorer graft outcomes (22, 23), whereas 
other studies did not find an association between CD20pos B-cell infiltrates and graft survival 
(24-26). The presence of B cells in combination with FDC networks, IgD and Ki67 suggests 
humoral activity including the production of antibodies. However, all cases of aTCMRI were 
negative for C4d and DSA. Although it is possible that these B-cells produced donor-specific 
non-HLA antibodies we believe this is not the most likely explanation since such antibodies 
are rare. B-cell infiltrates in the setting of aTCMRI more likely have an antibody-independent 
function. B cells are known for their antigen-presenting capacity that may facilitate T cell-
mediated alloreactivity and aTCMRI. From mouse studies we know that antigen presentation 
by B cells does indeed contribute to acute T cell-mediated rejection (27, 28). In addition, 
B cells may also contribute to T-cell activation via the secretion of cytokines like IFNγ, IL-
10, TNF and IL-6 (29). Another hypothesis is that the clustered, intragraft B-cells found in 
aTCMRI have a resting phenotype. However, all aTCMRI biopsies were double positive for 
BCL6 and IL-21, markers associated with an activated state of Tfh cells and B cells. Finally, in 
different mouse models ELSs are also associated with donor-specific tolerance rather than 
rejection (30, 31), suggesting that the B cells may have a regulatory function. The presence 
of transitional CD19+CD24hiCD38hi B cells, also known as regulatory B cells, is associated with 
lower acute rejection rates after renal transplantation (32-34). In addition, in a mouse model 
for multiple sclerosis, maturation of regulatory B cells requires IL-21 and CD40 interaction 
with T cells (35), both present in ELSs in our aTCMRI biopsies. In our  study, analyzing biopsy 
specimens from patients, the function of the aggregates in aTCMRI renal allografts has not 
been determined. Though given that aTCMRI is considered to be less detrimental to the 
graft than the other rejection types it is tempting to speculate that these aggregates might 
have a resting or regulatory function rather than a harmful one. In contrast, on long term 
the T-cell dependent activation of B cells within the allograft may contribute to the process 
of chronic allograft rejection.
All aggregates contained numerous IL-21 single positive cells of which only a few were 
positive for BCL6, the hallmark of GC Tfh cells and B-cells. The presence of BCL6posIL-21pos 
cells in the aggregates in combination with Ki67 positivity points towards GC activity and 
suggests the presence of activated Tfh cells. In addition to B-cell help, the IL-21 positive T 
cells in aTCMRI might also enhance IFNγ production and cytotoxic activity of CD8+ effector 
T cells, as observed in an allogeneic system by Kasaian et al. (36). Another possibility is that 
the IL-21 single positive cells represent Th17 cells that are known to be involved in ELS 
formation (37, 38). In the biopsies with either aTCMRII or a/aABMR a diffuse presence of T 
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and B cells was observed and no FDC networks, IgD and co-localization of BCL6 and IL-21 
was present in the majority of the cases. These findings suggest that the peripheral DSA 
present in the a/aABMR cases were not produced locally but outside the allograft (e.g. in 
draining lymph nodes). The effect of the presence of ELSs on renal allograft outcome is 
debated, with conflicting data that present both harmful and protective function. A recent 
study by Xu et al. found an association between the presence of ELSs and well-functioning 
kidney grafts pointing toward a regulatory role for these ELSs (39). The small number of 
samples in this study does not allow us to draw conclusions about the impact of ELS on 
kidney function and warrant further investigation.
In this study, we focused on T-B cell interaction and their functional activation markers in 
different types of acute renal allograft rejection. We found organized lymphoid structures 
in aTCMRI, implicating an important role for T- and B-cell interactions in this type of renal 
allograft rejection. Apparently, more cells are involved in aTCMRI than meets the eye, with 
presumably more mechanisms occurring than the classical alloreactive CD8+ T cell infiltrates 
such as providing help to allo-activated B cells. In conclusion, various compositions of 
infiltrating lymphocytes are present in the setting of aTCMRI, aTCMRII and a/aABMR with 
ELS formation predominantly in aTCMRI. These findings suggest a direct pathway of B cell 
allo-activation at the graft site during aTCMRI.
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Supplemental Figures
Supplemental Figure 1. 
Positive control for interleukin (IL)-21 (green) and B cell lymphoma 6 (BCL6) (red) immunofluorescent double 
staining of a duodenal biopsy from a patient with celiac disease. 4’,6-diamidino-2-phenylindole (DAPI) (blue) was 
used to stain the chromatin of the cells. Magnification: x20.
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Abstract
Tissue-resident memory T (T
RM
) cells are characterized by their surface expression of 
CD69 and can be subdivided in CD103+ and CD103- T
RM
 cells. The origin and functional 
characteristics of T
RM
 cells in the renal allograft are largely unknown. To determine these 
features we studied T
RM
 cells in transplant nephrectomies. T
RM
 cells with a CD103+ and 
CD103- phenotype were present in all samples (n=13) and were mainly
 
CD8+ T cells. Of 
note, donor-derived T
RM
 cells were only detectable in renal allografts that failed in the first 
month after transplantation. Grafts, which failed later, mainly contained recipient derived 
T
RM
 cells. The gene expression profiles of the recipient derived CD8+ T
RM
 cells were studied 
in more detail and showed a previously described signature of tissue residence within both 
CD103+ and CD103- T
RM
 cells. All CD8+ T
RM
 cells had strong effector abilities through the 
production of IFNγ and TNFα, and harboured high levels of intracellular granzyme B and low 
levels of perforin. In conclusion, our results demonstrate that donor and recipient T
RM
 cells 
reside in the rejected renal allograft. Over time, the donor-derived T
RM
 cells are replaced by 
recipient T
RM
 cells which have features that enables these cells to aggressively respond to 
the allograft.
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Introduction
Over the last two decades, the presence and importance of a non-migrating subset of memory 
T cells surveying immune responses in non-lymphoid tissues has been recognized: the so-
called tissue-resident memory T (T
RM
) cells (1, 2). Their restricted anatomical localization in 
combination with their effector memory phenotype enables T
RM
 cells to rapidly respond to 
local antigens. Today, two distinct subsets of T
RM
 cells have been identified: CD69+CD103+ 
and CD69+CD103- T
RM
 cells (hereafter referred to as CD103+ T
RM
 cells and CD103- T
RM
 
cells, respectively)(3-6). CD69 is a C-type lectin that was originally identified as a marker 
of activated T cells but is also involved in tissue retention of T
RM
 cells (2, 7-9). CD69 binds 
to and down-regulates the G protein-coupled receptor sphingosine 1 phosphate (S1PR1) 
expressed on the T cell membrane, resulting in a decreased ability of T
RM
 cells to sense the 
S1P gradient that promotes migration of memory T cells from the blood into peripheral 
tissue (7-9). A unique T
RM
 cell gene expression profile has recently been identified by Kumar 
et al. with 31 core genes that are differentially up- or downregulated in CD69+ T
RM
 cells 
isolated from human lung and spleen(10). The other recognized T
RM
 marker, CD103, is an αE 
integrin that binds E-cadherin which is expressed on epithelial tissues (11). Today, no clear 
consensus exists about the functional differences between CD103+ and CD103- T
RM
 cells.
Although the presence and antigen specificity of T
RM
 cells is recognized in several non-
lymphoid human tissues (e.g. skin, liver, lungs, intestine and brain), the presence and 
function of T
RM
 cells in the human kidney is currently unknown (4, 5, 12-16). In experimental 
mouse models, it was demonstrated that T
RM
 cells homed to the kidney where they resided, 
and that this migration was promoted by TGF-β (17, 18). Otherwise, little is known about the 
functional properties of these kidney T
RM
 cells (19).
Transplantation of a renal allograft is accompanied by the transfer of donor leucocytes. It is 
probable that these leucocytes also include donor-derived T
RM
 cells. It is, however, unknown 
if these cells persist after transplantation or whether they are replaced by T
RM
 cells of recipient 
origin. It is therefore informative to identify the donor or acceptor origin of these cells and 
thus the degree of chimerism. This will help us to understand if donor T
RM
 cells are present 
in the allograft to control local viral and bacterial responses (20) and whether these T
RM
 cells 
might be enriched for graft-versus-host (GvH) reactive clones, as seen in intestinal transplant 
patients (21-23). The presence of recipient T
RM
 cells will shed light on their potential role in 
alloreactivity and will show if recipient T cells differentiate into T
RM
 cells in the renal allograft.
Here, we postulate that T
RM
 cells are present in the renal allograft and that these cells are 
primarily from recipient origin and are capable of mounting an allo-reactive response. 
To this end, we used the unique tissue resource of transplant nephrectomies from 
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immunosuppressed patients to study the presence, provenance (donor or recipient), and 
the effector phenotype of CD103+ T
RM
 cells (CD69+CD103+), CD103- T
RM
 (CD69+CD103-), 
and recirculating T cells not expressing the tissue retention markers CD69 and CD103 (CD69-
CD103-). We performed similar control experiments with spleen cells of organ donors, a 
lymphoid cell population in which T
RM
 cells are known to be present (3, 10).
Materials and Methods
Study population
Thirteen transplant nephrectomy specimens and two kidneys that were discarded for 
transplantation were studied. The characteristics of the patients from whom the transplant 
nephrectomies were derived are described in Table 1. Of these nephrectomies, the 
pathological features corresponding to the type of renal allograft rejection were classified 
according to the Banff’17 classification(43). In this study, residual material previously used 
for histopathological diagnosis was analysed. Residual materials were used in accordance 
with non-WMO compliant research that is regulated by the Dutch Code of Conduct 
(Federa). Splenocytes were obtained from deceased organ donors and peripheral blood 
mononuclear cells (PBMCs) were from healthy controls. The Medical Ethical Committee 
of the Erasmus MC, University Medical Center, approved this work (MEC-2010-022). All 
experiments were performed in accordance with relevant guidelines and regulations as 
described by our institution. All patients gave written informed consent. No organs were 
procured from (executed) prisoners.
Isolation of lymphocytes
Half of the renal allograft (cortex and medulla) was processed towards a single cell 
suspension, the other half was used for routine diagnostic assessment. The renal allograft 
was thoroughly rinsed with PBS to remove peripheral cells and afterwards dissected into 
small pieces (<0.5 cm3) and incubated for 60 minutes at 37°C with 1.1 mg/ml collagenase 
IV (Serva, Heidelberg, Germany). The collagenase treatment was stopped by the addition 
of heat-inactivated fetal bovine serum with an end concentration of 10%. The tissue 
suspension was filtered through different sieves up to a 100μm sieve (Greiner Bio-One, 
Kremsmünster, Austria) followed by a Ficoll-Paque Plus procedure (GE healthcare, Uppsala, 
Sweden). Isolated cells were stored at -190°C until further use. Afterwards, cells were thawed 
and analysed by flow cytometry and reverse transcription-qPCR (RT-qPCR) to determine 
their phenotype and gene expression profile.
6115
T
RM
 cells in transplant nephrectomies
Human splenocytes were disrupted and filtered through a 70μm cell strainer (Greiner Bio-
one, Alphen a/d Rijn, The Netherlands) to obtain a single-cell suspension. Ficoll-paque 
(Amersham Pharmacia Biotech, Uppsala, Sweden) density gradient was used to collect 
mononuclear cells. Human PBMCs were isolated with the Ficoll-paque density gradient 
method.
Flow cytometric and functional analysis
Renal lymphocytes, splenocytes and PBMCs were stained with the following antibodies 
to characterize the T
RM
 phenotype: CD3 brilliant violet 510 (BV510; Biolegend, San Diego, 
CA, USA), CD8 Allophycocyanin-Cy7 (APC-Cy7; Biolegend), CD4 fluorescein isothiocyanate 
(FITC; BD, Franklin Lakes, New Jersey, USA) CD69 brilliant violet 421 (BV421; BD), CD103 
phycoerythrin-cyanine7 (PE-Cy7; Biolegend). Viability was measured with the live-dead 
marker 7-aminoactinomycin (7-AAD; BD). FACS flow enriched with bovine serum albumin 
was used to wash the cells and block a-specific antibody interactions.
The donor or acceptor origin of the cells was determined with monoclonal antibodies (mAb) 
directed against human leukocyte antigen (HLA) class I antigens of the donor or acceptor. 
mAb used are listed in Supplemental Table 1, and were developed at Leiden University 
Medical Centre. We performed single labelling with either an antigen for which solely the 
donor was positive or solely the acceptor was positive.
The cytotoxic potential of T
RM
 cells was analysed by measuring intracellular granzyme B 
and perforin. Cells were stained as described above for T
RM 
cells. Afterwards, the cells were 
immediately fixed with FACS lysing solution (BD) and permeabilized with PERM II (BD). 
Subsequently, cells were stained intracellularly with granzyme B Allophycocyanin (APC) 
(Biolegend) and perforin phycoerythrin (PE; Biolegend).
The cytokine-producing capacity of the cells was measured after the cells were stimulated for 
four hours with 50 ng/ml phorbol myristate acetate (PMA) and 1 μg/ml ionomycin (Sigma-
Aldrich, St. Louis, MO, USA) at 37°C. Monensin and Brefeldin A (GolgiStop and GolgiPlug, BD 
Biosciences, Franklin Lakes, NJ, USA) were used to promote intracellular accumulation of 
the cytokines. PMA/ionomycin stimulation was stopped by adding Ethylene-diamine-tetra-
acetic acid. Subsequently, cells were stained with the T
RM
 surface staining mixture and fixed 
and permeabilized as described above. The following mAb were used to measure cytokine 
production: interferon-γ (IFNγ) FITC (BD Biosciences), and tumour necrosis factor-α (TNFα) 
PE (Biolegend). Cell samples were measured on the FACSCanto II (BD) and analysed with 
Kaluza Analysis 1.5a software (Beckman Coulter, Brea, CA, USA). 
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Allogeneic reactivity
Mixed lymphocyte reactions (MLR) were performed in order to study T cell-reactivity of 
the renal lymphocytes following stimulation with donor cells, 3rd party cells, or recipient 
PBMCs. Renal lymphocytes were thawed and labelled with carboxyfluorescein succinimidyl 
ester (CFSE; Molecular Probes®, Leiden, The Netherlands). Next, the renal lymphocytes were 
stimulated at 5 x 104 cells per well with irradiated donor cells, 3rd party cells, or recipient 
PBMCs (40 Gray) from which the CD3+ T cells had been depleted with magnetic-activated 
cell sorting (MACS). The cells were cultured at a ratio 1:1 in human culture medium (HCM) 
and after 7 days the CFSE dilution was measured on the FACSCanto II, indicating the amount 
of proliferation. Degranulation was measured by APC-labelled anti-CD107a (BD).
IFNγ ELISPOT
The frequencies of IFNγ producing cells upon stimulation with donor cells, 3rd party cells, 
or recipient PBMCs were measured with an Enzyme-Linked ImmunoSpot (ELISPOT) assay 
(U-CyTech Biosciences, Utrecht, The Netherlands). Briefly, anti IFNγ coated plates (U-CyTech 
Biosciences), were seeded with 100,000 renal lymphocytes and 100,000 irradiated donor 
cells, 3rd party cells or recipient PBMCs. Upon overnight incubation, plates were washed 
and incubated with biotinylated anti-human IFNγ detection antibody and streptavidin-HRP 
conjugate  followed by the addition of AEC substrate (U-CyTech Biosciences). Spots were 
analysed using the ELISPOT reader (Bioreader®-600V, BIO-SYS GmbH, Karben, Germany).
Cell sorting of TRM cells and RT-qPCR analysis 
To determine the expression levels of a set of T
RM
 key genes of the CD103+ and CD103- T
RM
 
cells and CD69-CD103- recirculating T cells, we performed RT-qPCR analysis on FACS-sorted, 
pure (>95%) T cell populations. Renal lymphocytes and splenocytes were sorted with the 
BD-FACSAria II SORPTM. Subsequently, cells were pelleted and snap frozen and stored at 
-190°C until further use.
RNA was isolated with the RNeasy Micro Kit (Qiagen, Hilden, Germany) for the collection of 
high-quality RNA. Total RNA was subsequently reverse transcribed with oligo-dT. We used 
RT-qPCR to quantify the amount of ITGA1, IL10, CXCR6, CX3CR1, KLF2, KLF3, SELL, S1PR1, and 
the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Assay-on-
demand products for the detection and quantification of the different genes were used and 
are listed in Supplemental Table 2 (ThermoFisher, Waltham, MA, USA). The amount of each 
target gene was quantified by measuring the threshold cycle (Ct), which was transformed 
on a TaqMan Real-Time PCR system to the number of cDNA copies (2(40-Ct)). The relative 
concentrations of the analysed genes were normalized to the relative concentration of the 
6117
T
RM
 cells in transplant nephrectomies
housekeeping gene GAPDH present in each sample. Heatmapper software was used to 
cluster the cell-sorted samples based on the expression of the above described genes(44).
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software; 
San Diego, CA, USA). Differences between paired groups were analysed with the Wilcoxon 
signed-rank test. A two-tailed p-value of <0.05 was considered statistically significant.
Results
T cells of donor and recipient origin are present in the renal allograft
Thirteen transplant nephrectomy specimens were studied. Patient demographics are listed 
in Table 1. These kidney allografts failed either acute (n = 4) or chronically (n = 9) as a result of 
humoral, cellular or mixed-type rejection and were removed after a mean time of 6.1 years 
(range: 8 days – 26 years).
After the isolation procedure, CD3+ T cells were detected in all renal allografts with a 
median proportion among the total viable lymphocytes of 72.1% (range: 30.1 – 78.5%; Fig. 
1A). Of the CD3+ T cells, 37.6% (22.9 – 83.2%) were CD8+ and 47.4% (13.1 – 70.0%) were 
CD4+ T cells (Fig. 1A). The CD3+ T cells isolated from nephrectomy number three and four 
(Table 1) were capable of mounting an allogeneic response, since both the proportions of 
proliferating cells and the expression of the degranulation marker CD107a increased in the 
presence of donor antigen, while a negligible response was measured after stimulation 
with irradiated recipient PBMCs (Supp. Fig. 1A, B). In addition, the cells of patient number 
three reacted to a fully HLA mismatched 3rd party and responded to donor antigen by the 
production of IFNγ (Supp. Fig. 1A-C).
Next, the degree of chimerism was studied in the explanted renal allografts. Conjugated 
HLA-mAbs were available to distinguish recipient from donor cells in ten renal lymphocyte 
samples. In the example depicted in Figure 1B (upper panel), the proportions of donor cells 
measured by a mAb against HLA-B7 (donor positive) and a mAb against HLA-B70 (acceptor 
positive) resulted in similar donor proportions of 1.71% and 1.70% respectively, showing 
chimerism in this sample. Three out of the ten renal allografts studied were removed within 
the first month after transplantation (Table 1). In these renal allografts, clear populations 
of CD4+ and CD8+ T cells from donor origin were detected (Fig. 1C). The renal allografts 
removed five months or later after transplantation only contained marginal proportions 
(<0.5%) of donor-derived T cells, and we could not distinguish a clear positive and negative 
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fraction in these samples as depicted in the dot plots of patient number 7 in figure 1B (lower 
panel). Thus, high proportions of donor-derived T cells were only seen in early rejection 
nephrectomies. 
Figure 1.
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Figure 1. CD8+ and CD4+ T cells of donor and recipient origin are present in the renal 
allograft
Lymphocytes were isolated from the rejected renal allografts and subsequently stained and analysed by flow 
cytometry. (A) Gating strategy used to detect CD3+ T cells within the total viable lymphocytes, of which the 
CD8+ and CD4+ T cells were selected. (B) Typical examples of renal lymphocyte samples of patient number three 
and seven stained with mAb against human leukocyte antigen (HLA) class I antigens within the CD4+ T cells. 
Proportions of cells originating from the donor are depicted. (C) Table with numbers referring to the renal allografts 
described in Table 1, the time to explantation in days, and the proportions of donor cells detected within the CD8+ 
and CD4+ T cell compartment. Frequencies of the cells are presented as individual proportions with medians. HLA 
= human leukocyte antigen; N.S. = not significant; N/D = not determined.
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Figure 2. TRM cells are present within CD8+ and CD4+ T cells in the renal allograft
Lymphocytes from rejected renal allografts, spleens of organ donors, and blood from healthy individuals were 
stained with mAb against CD69 and CD103. (A) Representative examples of the gating strategy of CD69 and 
CD103 of lymphocytes originating from the renal allograft, spleen, and blood. Proportions of the gated areas are 
depicted within the dot-plots. (B-C) Quantified data of the recirculating T cells (CD69-CD103-), CD103- T
RM
 cells 
(CD69+CD103-), and CD103+ T
RM
 cells (CD69+CD103+) subsets within the CD8+ T cell compartment (B) and CD4+ 
T cell compartment (C) of the renal allograft, spleen, and blood (blood n = 5, spleen n = 10, renal allograft n = 
13). Frequencies of the cells are presented as individual proportions with medians. Significant differences were 
calculated and presented (* p < 0.05 , ** p < 0.01 , *** p < 0.001). (D) mAb against HLA class I antigens were 
used to discriminate between donor and recipient lymphocytes. Typical example dot plots and quantified data 
of proportions of donor-derived cells within the CD103+ T
RM
 cells, CD103- T
RM
 cells and recirculating T cells are 
depicted of the transplant nephrectomies removed within the first month after transplantation (Table 1, patient 
1 to 3). Frequencies of the positive cells are depicted within the dot plots. Frequencies of positive cells are shown 
as mean with the SEM (n = 3). 
TRM cells are present in the renal allograft
The absence of T
RM
 cells in PBMC fractions and the presence of T
RM
 cells in the spleen was 
recognized in previous studies(3, 10). Subsequently we used PBMCs from healthy controls 
as a negative control and splenocytes of deceased organ donors as a positive control for T
RM
 
cell identification. CD69+ T
RM
 cells were present in all transplant nephrectomy specimens 
with a median proportion of 73.2% in the CD8+ T cell compartment and 62% in the CD4+ T 
cell compartment (Fig. 2A). We subdivided the T
RM
 cells in CD103+ T
RM
 (CD69+CD103+) cells 
and CD103- T
RM
 cells (CD69+CD103-). The median proportion of CD103+ T
RM
 cells within the 
CD8+ T cell compartment was 32.3% (range: 4.5 - 54.4%) compared to 1.4% (0.7 – 8.8%) within 
the CD4+ T cell compartment. In contrast, CD103- T
RM
 cells were more evenly distributed 
among the CD8+ (40.9%, 9.4 – 78.8%) and CD4+ (60.6%, 20.2 – 81.2%) T cell compartments 
(Fig. 2B, C). As expected, minimal proportions of CD103+ T
RM
 cells and CD103- T
RM
 cells were 
found in peripheral blood, while both T
RM
 cell subsets were present in the spleen (Fig. 2). 
Similar proportions of CD4+ and CD8+ T
RM 
cells were detected in two native kidneys that 
were discarded for transplantation (Supp. Fig. 2). No significant differences were detected 
when we subdivided the CD103+ and CD103- T
RM
 cells of the transplant nephrectomies 
based on donor type, Banff 2017 category and time to explantation (Supp. Fig. 3 A-C). 
Of interest might be the observation that in chronic-active antibody-mediated rejection 
(c-aABMR) specimens the proportion of CD103- T
RM
 cells was low (Supp. Fig 3B). However, 
this observation is only based on two c-aABMR cases.
We questioned whether T
RM
 cells of donor or recipient origin were present in the kidneys 
explanted in the first month after transplantation (Fig. 1C). For that we stained the renal 
lymphocytes of the transplant nephrectomies removed within the first month after 
transplantation (patients 1-3, Table 1) again with antibodies recognizing either donor or 
recipient HLA molecules. Remarkably, donor-derived lymphocytes were most prominent 
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within the CD103+ T
RM
 cell population, with lower levels of donor cells in the CD103- T
RM
 
cells and recirculating T cell compartments (Fig. 2D). This was observed for both CD8+ and 
CD4+ donor T cells. These data suggest the increased ability of donor-derived CD103+ T
RM
 
cells to reside in the renal allograft compared to the remaining donor-derived T cells.
Because the proportion of CD103+ T
RM
 cells was very low among the CD4+ T cells, not 
allowing further analysis, we focused on the CD8+ T
RM
 cells for subsequent experiments. 
In addition, the three renal allografts explanted within the first month after transplantation 
were excluded in order to study a pure population of recipient T
RM
 cells that may mediate 
and control the local immune response.
Expression of TRM signature genes
To define the gene expression profile of the T
RM
 cells, we selected 8 genes from a set of 
signature genes described by Kumar et al. that are differentially expressed between CD69- 
and CD69+ CD8+ T cells isolated from the spleen and lung (10). We compared the expression 
of these genes in cells isolated form the renal allograft and in splenocytes in the following 
FACS-sorted CD8+ T cell populations: CD69+CD103+ T
RM
 cells, CD69+CD103- T
RM
 cells, and 
CD69-CD103- (recirculating) T cells. The gating strategy for the FACS sort experiments is 
depicted in Figure 3A.
We used RT-qPCR to quantify the expression of genes that are involved in pathways that 
mainly control T cell migration, adhesion and activation. Separate heat maps were created 
of the gene expression levels of the renal allograft and spleen (Fig. 3B). Overall, two clusters 
were identified in the heat maps of both the renal allograft and spleen: a cluster of genes 
upregulated in the total T
RM
 cells (CD103+ and CD103- T
RM
 cells) and a cluster of genes 
downregulated in the total T
RM
 cells, compared to the recirculating T cells (Fig. 3B). The 
gene expression levels of the adhesion marker ITGA1 (CD49a) were especially high in the 
CD103+ T
RM
 cells, with lower expression levels in the CD103- T
RM
 cells and recirculating T 
cells. Chemokine receptor CXCR6 and cytokine IL-10 were clearly expressed at a higher 
level in the total T
RM
 cell subsets compared to the recirculating T cells. In both the spleen 
and renal allograft samples, the T cell trafficking and homing markers S1PR1, Kruppel-like 
transcription factor 2 (KLF2), SELL (CD62L), KLF3 and CX3CR1 were expressed at a lower level 
in the total T
RM
 cells compared to the expression levels in the recirculating T cells. When 
we clustered the FACS-sorted samples of the renal allograft and spleen, the CD103+ T
RM
 
cells and CD103- T
RM
 cells clearly clustered together as opposed to the recirculating T cells 
(Supp. Fig. 4). In summary, the total population of T
RM
 cells can be clearly distinguished 
from the recirculating T cells based on their gene expression profile. In addition, similar 
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gene expression levels were found in the different T cell subsets when comparing the renal 
allograft and the spleen samples. 
Renal allograft Spleen
ITGA1
IL10
CXCR6
CXC3CR1
KLF2
KLF3
SELL
S1PR1
CD103- 
TRM cells
Recirculating
 T cells
FSC-A
SS
C-
A
FSC-A
7A
A
D
CD3
CD
8
CD69
CD
10
3
Viable cells FACS sorted populations:Renal lymphocytes
Figure 3.
A.
B.
CD103+ 
TRM cells
CD103- 
TRM cells
Recirculating
 T cells
CD103+ 
TRM cells
Figure 3. Expression of TRM signature genes
(A) Typical example of the gating strategy used after fluorescence activated CD8+ cell sorting to obtain recirculating 
T cells (CD69-CD103-), CD103- T
RM
 cells (CD69+CD103-), and CD103+ T
RM
 cells (CD69+CD103+). Cells were gated by 
forward- and side-scatter followed by 7-AAD negative (viable) gating. (B) Heatmaps depicting the normalized gene 
expression of eight core genes known to be upregulated (yellow) or downregulated (blue) in T
RM
 cells of the renal 
allograft and spleen. Spleen n = 5, renal lymphocytes n=4.
124
Chapter 6
TRM cells in the renal allograft have an effector memory phenotype
To demonstrate that the CD8+ T
RM
 cells found in the renal allograft have an effector 
phenotype we stained the cells for the surface molecules CCR7 and CD45RO. With these 
markers naïve (CCR7+CD45RO-), central memory (CM, CCR7+CD45RO+), effector memory 
(EM, CCR7-CD45RO+) and highly-differentiated effector memory (EMRA, CCR7-CD45RO-) 
T cells were discriminated (see Fig. 4A for a typical example). While the recirculating T 
cells in the renal allograft and spleen were more divergent in terms of CCR7 and CD45RO 
expression, the majority of the CD103- T
RM
 cells and CD103+ T
RM
 cells were CCR7-CD45RO+ 
and thus EM T cells (Fig. 4B). This finding is in line with previous studies in non-lymphoid 
tissues where the majority of T
RM
 cells was also of an EM phenotype(3, 10).
TRM cells are capable of producing effector molecules
The capacity of the cells to produce the pro-inflammatory cytokines IFNγ and TNFα was 
measured after polyclonal stimulation. No change in the expression and proportion of 
CD69+ cells before and after three hours of polyclonal T cell stimulation was observed, in 
contrast to an altered expression of CD69 and CD103 on the CD8+ T cells after seven days 
allostimulation (Supp. Fig. 5, 6). Subsequently, we compared the T
RM
 cell subsets and the 
recirculating T cells after stimulation for their cytokine production capacity.
stimulation, all resident and recirculating CD8+ T
 
cell subsets expressed high levels of IFNγ 
(Fig. 5A). A slightly higher expression in the IFNγ production capacity was observed in the 
CD103+ T
RM
 cells in both renal allograft and spleen compared to the recirculating and 
CD103- T
RM
 cell subsets (Fig. 5A). For TNFα, a different profile was found with the highest 
expression levels in the recirculating T cells, lower levels in the CD103- T
RM
 cells and the 
lowest levels in the CD103+ T
RM
 cells (Fig. 5B). Within the spleen, the differences in TNFα 
proportions were significantly different between the different subsets (Fig. 5B). Highly 
effector CD8+ T cells that were concurrently positive for IFNγ and TNFα were present in 
both the renal CD103- and CD103+ T
RM
 cells (Supp. Fig. 7).
To determine the degranulation capacity of the different CD8+ T
RM
 cell subsets, intracellular 
granzyme B and perforin expression were measured (Fig. 5C, D). In the renal allograft, the 
intracellular granzyme B levels did not significantly differ between the recirculating T cells, 
the CD103- T
RM
 cells and CD103+ T
RM
 cells (Fig. 5C). The granzyme B levels within the spleen 
were significantly lower in the CD103+ T
RM
 cells compared to both the recirculating T cells 
and the CD103- T
RM
 cells. With regard to the intracellular levels of perforin, the same trend 
between the different subsets was found in the renal allograft samples compared to the 
spleen samples (Fig. 5D). The perforin levels were significantly lower in the CD103+ T
RM
 cells 
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compared to the recirculating T cells (Fig. 5D). Together, these data show that T
RM
 cells, but 
also the recirculating T cells, are capable of mounting and effector response.
Recirculating T cells
Renal allograft
Spleen
B.
Figure 4.
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84.16.2
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Recirculating T cells
CD103- TRM cells
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CD103+ TRM cells
CD103- TRM cells CD103+ TRM cells
Figure 4. TRM cells in the renal allograft have an effector memory phenotype
(A) Typical examples of dot plots presenting the distribution of naïve T cells (CCR7+CD45RO-), central memory 
T cells (CM; CCR7+CD45RO+), effector memory T cells (EM; CCR7-CD45RO+), and EMRA T cells (CCR7-CD45RO-) 
within the CD8+ recirculating T cells, CD103- T
RM
 cells and CD103+ T
RM
 cells of the renal allograft. Numbers within 
the dot plots indicate proportions of the different cell subsets. (B) Pie charts representing the median proportion 
of naïve, central memory, effector memory, and EMRA T cells within the CD8+ recirculating T cells, CD103- T
RM
 cells 
and CD103+ T
RM
 cells of the renal allograft and spleen (renal lymphocytes n=6, spleen n=8).
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Figure 5. TRM cells are capable of producing effector molecules 
(A-B) Proportions of IFNγ (A) and TNFα (B) producing cells are depicted upon 4 hours PMA/ionomycin stimulation 
in the presence of monensin and brefeldin A. Cytokine proportions were measured in renal lymphocytes and 
splenocytes within the recirculating T cells, CD103- T
RM
 cells, and CD103+ T
RM
 cells of the CD8+ T cell compartment. 
(C-D) Frequencies of granzyme B (C) and perforin (D) levels were measured in the recirculating T cells, CD103- T
RM
, 
and CD103+ T
RM
 cells of the CD8+ T cell compartment. Frequencies of positive cells were shown as mean with 
the SEM (renal lymphocytes n=6, spleen n=10). Significant differences were calculated and depicted (N.S. = not 
significant, * p<0.05, ** p<0.01).
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Discussion
In this study, we demonstrate that 1) T cells with a resident memory phenotype and gene 
expression profile are present in the renal allograft, 2) T
RM
 cells in the renal allograft have 
strong immunostimulatory capacity, and 3) the donor-derived cells present are mainly 
CD103+ T
RM
 cells and are replaced by recipient-derived T cells within five months after 
transplantation. An overview of these findings is depicted in Figure 6.
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CD103- TRM cells and CD103+ TRM cells
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Figure 6. Schematic overview of TRM cell characteristics in the renal allograft
Distribution of donor-derived and recipient-derived tissue-resident memory (T
RM
) cells and the phenotypic 
and functional characteristics of the recipient-derived T
RM
 cells in the explanted renal allograft are depicted in a 
schematic overview. Cluster one and cluster two indicate T
RM 
core genes of which the expression was measured. 
Cluster one consists of genes involved in T cell activation (ITGA1, IL10, and CXCR6) and cluster two consists of genes 
involved in T cell migration (CX3CR1, KLF2, KLF3, SELL, S1PR1).
No major differences were found in gene expression signature and functional profiles 
between the CD103+ T
RM 
and CD103- T
RM
 cells, highlighting that these two T
RM
 cell subtypes 
have comparable characteristics. Previous studies report that CD103+ T
RM
 cells reside more 
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predominantly within the barrier tissues while CD103- T
RM
 cells are more common within 
non-barrier tissues(18). In transplantation, CD8+CD69-CD103+ T cells are involved in the 
effector mechanism of chronic and acute renal allograft rejection(24-27). In addition, in 
urinary samples, the mRNA levels of CD103 predicted acute renal allograft rejection(28). 
However, in the context of kidney transplantation the exact difference in CD103+ and 
CD103- T
RM
 cells is unknown and of interest for further analysis.
The majority of the T
RM
 cells detected in the renal allograft were of an effector memory 
phenotype. Therefore, these cells have been antigen challenged and are able to rapidly exert 
immunological responses. Both the CD103+ and CD103- T
RM 
cell subsets had the capacity 
to produce TNFα, a cytokine involved in, among others, the activation of endothelial cells, 
thereby attracting other T cells to the site of inflammation(29). The capacity of the T
RM
 cells 
to produce IFNγ and the presence of preloaded granzyme B positive granules underlines 
their cytotoxic phenotype. Low levels of perforin were measured in the T
RM 
cells which is in 
line with previous studies(30, 31). In these studies, perforin was rapidly upregulated upon 
antigen stimulation, delineating a dynamic process(30, 32). Here we found that T
RM
 cells 
present in renal allografts are potentially harmful cells that might contribute to the process 
of allograft rejection. However, additional experiments need to clarify the exact roles of the 
T
RM
 cell subsets in the alloimmune response and show causality. For future studies, it would 
be of interest to include the number of cells per gram tissue. The functional profiles of the 
T
RM
 subtypes found in the renal allograft were comparable to those found in the T
RM
 subsets 
residing in the spleen. This supports that we have identified T
RM
 cells in the renal allograft.
Memory T cell signalling is still occurring under immunosuppression because these cells 
are less reliant on co-stimulatory signals(33-36). For this reason, we can hypothesize about 
the long lasting persistence of T
RM
 cells within the renal allograft. Also, the distribution 
of immunosuppressive agents into the tissue may influence the presence of T
RM
 cells. 
For instance, alemtuzumab depletes circulating CM T cells in leukemic cutaneous T cell 
lymphoma patients without completely compromising the immune response to infection, 
since the skin resident memory cells are spared(37). The samples analysed in this study 
are a heterogeneous group with different types of end-stage immunological transplant 
failure. Further study on the differentiation and function of T
RM
 cells upon transplantation, 
would benefit from similar studies on cells harvested from healthy renal tissue or grafts 
undergoing an evolving rejection, which for obvious reasons is not possible in transplant 
recipients. The best alternative for healthy renal tissue would be the use of kidneys discarded 
for transplantation. Our first findings showed the presence of T
RM
 cells in these kidneys 
with comparable frequencies of CD103- and CD103+ T
RM
 cells as found in the transplant 
nephrectomies.
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The results of our study reveal that donor-derived lymphocytes are replaced by their recipient 
counterparts within five months after transplantation and that the recipient-derived T cells 
differentiate locally towards a resident memory phenotype. The rapid presence of recipient 
T
RM
 cells in these specimens sheds light on the important role of this cell type in the process 
of alloreactivity. The repopulation by recipient lymphocytes has also been observed in lung 
and intestinal allografts(38, 39). The prolonged retention of the CD103+ T
RM
 cells compared 
to the other donor-derived T cells supports that this subtype of T
RM
 cells is highly capable to 
bind to epithelial cells of the renal allograft (Fig. 6). The retention of donor-derived T
RM
 cells 
might have a protective role in the renal allograft since irradiation of donor cells in rodent 
models resulted in rejection of liver transplants(40, 41). Also, in visceral transplant patients, 
T cell chimerism is observed in the absence of graft-versus-host disease (GVHD)(21). Donor-
derived cells with graft specific TCR clones are even thought to slow down the constant threat 
of recipient-derived T cells, illustrating that the balance between graft-versus-host (GvH) 
and host-versus-graft (HvG) clones in situ influences lymphocyte turnover and development 
of rejection(22). A rapid clearance of the donor-derived cells may thus contribute to the 
rejection of the renal allograft. The low IFNγ-producing response of the renal lymphocytes 
to recipient PBMCs that we measured might be due to the mixed population of donor 
and recipient cells within the renal lymphocytes. This observation might be a reflection 
of the potential GvH response which may also explain a lower response to the donor 
cells, in line with the findings of Zuber et. al.(22). For future experiments, it is of interest to 
compare the GvH and HvG T cell balance in protocol biopsies at different time points after 
transplantation and compare this balance between patients with and without rejection. 
In addition to the response to the allograft, T
RM
 cells also recognize and clear pathogens. 
Therefore, it is tempting to speculate that the T
RM
 cells are both friends and foes to the renal 
allograft. Virus-specific T
RM
 cells are known to be able to quickly exert their effector function 
within the peripheral tissue, and thus the T
RM
 cells present in the renal allograft may also 
exert this function(20, 42). Therefore, the precise contribution of donor and recipient T
RM
 
cells to alloreactivity is of high interest for future studies.
In conclusion, our results demonstrate that T
RM
 cells are present in the human renal allograft 
and that donor-derived T
RM
 cells are replaced within the first months after transplantation 
by recipient T
RM
 cells, which have the capacity to aggressively respond to the allograft. 
Understanding the potentially destructive or protective roles of the T
RM
 cells in the renal 
allograft is of high interest to enhance renal transplant outcomes. 
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Supplemental figure 1. Renal lymphocytes do have specificity for donor cells
(A) Renal lymphocytes of transplant nephrectomy number three and four (Table 1, Fig. 1C) were labelled with CFSE 
and stimulated with only human culture medium (HCM), donor cells, 3rd party cells, or recipient PBMCs for seven 
days. Afterwards, the proportion of proliferating cells was measured by gating the CFSE negative T cell fraction. 
(B) Degranulation of the renal lymphocytes after seven days of stimulation with HCM, donor cells, 3rd party cells, 
or recipient PBMCs was measured by measuring the CD107a+ T cell fraction. (C) Numbers of IFNγ producing cells 
were measured with the ELISPOT assay after stimulating the renal lymphocytes with HCM, donor cells, 3rd party 
cells, or recipient PBMCs. (D) HLA-typing of the renal allograft recipients, donor and 3rd party cells used for the 
mixed lymphocyte reaction and ELISPOT assay. The number of renal lymphocytes of patient four was not sufficient 
to include a 3rd party control and to perform an ELISPOT assay.
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Supplemental figure 2. TRM cells are present in two kidneys that were discarded for 
transplantation
Lymphocytes from two kidneys that were discarded for transplantation were stained with mAb against CD69 and 
CD103. Frequencies of CD69+ and CD103+ T cells within the CD4+ and CD8+ T cell compartment are depicted 
within the figure.
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Supplemental figure 3. No significant differences in TRM cell frequencies when subdividing on 
donor type, Banff 2017 category, and time to explantation.
We subdivided the CD103- and CD103+ T cells within the CD8+ compartment based of donor type (A), Banff 2017 
category (B), and time to explantation (C). No significant differences in T
RM
 cell frequencies were detected between 
the different subgroups.
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Supplemental gure 4.
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Supplemental figure 4. Clustered expression of TRM signature genes
Heatmaps depicting the normalized gene expression of eight core genes in the renal allograft (A) and spleen (B). 
The genes depicted are known to be upregulated (yellow) or downregulated (blue) in T
RM
 cells. Gene expression 
was measured in recirculating T cells (blue line), CD103- T
RM
 cells (green line), and CD103+ T
RM
 cells (red line) within 
the CD8+ compartment. Spleen n=5, renal lymphocytes n=4. Average linkage method was used to cluster the 
different samples and the Euclidean method was used to calculate the distance between the different samples
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Supplemental figure 5. No difference in CD69 and CD103 expression before and after PMA/
ionomycin stimulation
Renal lymphocytes were stimulated for 4 hours with PMA/ionomycin in order to study cytokine producing 
capacities. Before and after stimulation the expression of CD69 and CD103 was measured with flow cytometry. 
Proportions of gated areas are depicted within the figure. 
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Supplemental figure 6. Decreased expression of CD69 and CD103 on renal CD8+ T cells 
after allostimulation
Renal lymphocytes of patient number three and four (Table 1) were stimulated with the corresponding donor cells 
for seven days. Subsequently, cells were stained for CD8+ T cells. Within the CD8+ T cells, proportions of CD69 and 
CD103 were measured. Numbers in the figure represent the proportions of the gated cells.
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Supplemental figure 7. Proportions of different TRM subsets that produce both IFNγ and TNFα
Proportions of IFNγ and TNFα producing cells are depicted upon 4 hours PMA/ionomycin stimulation in the 
presence of monensin and brefeldin A. Cytokine proportions were measured in renal lymphocytes and splenocytes 
within the recirculating T cells, CD103- T
RM
 cells, and CD103+ T
RM
 cells of the CD8+ T cell compartment. Frequencies 
of positive cells were shown as mean with the SEM (renal lymphocytes n = 6, spleen n = 10). Significant differences 
were calculated and depicted (N.S. = not significant, * p < 0.05, ** p < 0.01 *** p < 0.001).
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Summary
Kidney transplantation has become the treatment of choice for patients with end-stage 
renal disease (ESRD). Currently, the five-year survival time of recipients with a donor kidney 
is over 90%. Unfortunately, acute rejection is still a barrier on the short-term while chronic 
rejection is causing late graft failure (1, 2). At present, the cornerstone immunosuppressant 
after kidney transplantation is calcineurin inhibition by tacrolimus (3). The efficacy and 
safety of this treatment is well recognized. The ultimate goal in transplantation is achieving 
long-term graft and patient survival, both of which are currently negatively influenced 
by side effects of the given immunosuppressive drugs and by uncontrolled anti-donor 
responses in which T cells and B cells of the recipient play a crucial role (1, 4). Acute rejection 
is often dominated by T cell-mediated rejection (TCMR), in which effector helper CD4+ 
and cytotoxic CD8+ T cells infiltrate the transplanted kidney, are activated and express 
pro-inflammatory soluble factors such as interferon-gamma (IFNγ) and granzyme B (5). 
Importantly, alloantigen-challenged T cells provide help to antigen-activated B cells that 
in turn differentiate into immunoglobulin secreting plasma cells and are responsible for 
antibody-mediated rejection (ABMR) in which donor-specific antibodies (DSA) play an 
important role (6). The presence of DSA is associated with poor transplant outcomes. Eight 
to ten percent of the kidney transplant recipients develop de novo DSA within the first 
year, and 15% to 30% within 10 years after transplantation (7, 8). Another challenge is the 
short- and long-term toxicity profile of tacrolimus or other calcineurin inhibitor (CNI)-based 
treatments. Patients on CNI suffer from an increased risk for nephrotoxic, metabolic, and 
cardiovascular side effects (9-11). There is therefore an interest in finding new directions 
to intervene in the allogeneic response in a more safe and specific way. In this respect, 
T cells that support differentiation of alloantigen-activated B cells and the formation of 
DSA secreting plasma cells are of interest. So far, the precise functions of T cells within the 
alloimmune response are unknown. A better understanding about the features and the 
mechanisms by which alloreactive T and B cells mediate the anti-donor response may 
contribute to the development of new immunosuppressive strategies and the discovery 
of new biomarkers.
In this thesis, we aim to better understand the role T follicular helper (Tfh) cells and tissue-
resident memory T (T
RM
) cells in the process leading to and mediating alloimmunity. We 
characterized the mechanisms by which these effector memory T cell subsets modulate the 
alloimmune response in vivo and in vitro by following three complementary approaches. 
First, we determined the helper function of patient Tfh cells to B cells, whereby we focused 
on the actions of the pleiotropic cytokine IL-21. Apart from determining the fate of B cells 
this particular cytokine is also of importance for the function of cytolytic T cell responses. 
Second, we studied the contribution of IL-21 in the rejection process using an experimental 
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humanized mouse skin transplant model and third, we characterized T cell infiltrates in 
kidney biopsies and rejected kidneys. Insights into these immune mechanisms can help to 
fine-tune treatment strategies and design less toxic and more efficient immunosuppressive 
drugs, thereby increasing the quality of life of kidney transplant recipients. In part I of this 
thesis the role of Tfh cells and the cytokine IL-21 is studied in different allogeneic settings. 
Part II of this thesis focuses on the characterization and functional properties of ectopic 
lymphoid structures (ELSs) and T
RM
 cells in the kidney allograft. 
Part I: The role of T follicular helper cells and IL-21 signaling in the alloimmune 
response
Tfh cells play a crucial role in T cell-dependent activation of B cells, in which naïve B cells 
differentiate into memory B cells and antibody producing plasma cells. In this way, Tfh 
cells contribute to the formation of DSA after transplantation, which are involved in the 
process of ABMR. In Chapter 2, we reviewed the current knowledge on the effects of 
immunosuppressive drugs on Tfh cell differentiation and function. With the existing evidence 
described in the literature we discuss new possible approaches to influence the functions 
of Tfh cells, which can yield new therapeutic targets in the transplantation field. Available 
evidence suggests that conventional immunosuppressive therapies, including tacrolimus, 
only partially block Tfh-cell differentiation and activity. We propose a model in which the IL-2 
blocking compounds tacrolimus and basiliximab may influence the generation of Tfh cells 
through disturbing the balance between IL-2 and IL-21. Tfh-cell activity may be altered at 
different stages in the activation, effector and differentiation pathways, such as blocking co-
stimulatory signaling, cytokine-dependent pathways, and migration-dependent pathways. 
Lastly, we speculate about the potential of Tfh cells to act as a pharmacodynamic biomarker 
to improve alloimmune-risk stratification. In this perspective, the measurement of donor-
specific Tfh cell frequencies by donor-specific IL-21 ELISPOT assays might be a sensitive tool 
to identify patients at risk for rejection.
As described above, blockade of cytokine-dependent pathways is of interest to affect 
Tfh-cell activity. In Chapter 3 we tested the role of IL-21R signaling in an allogeneic co-
culture model. Through autocrine and paracrine mechanisms IL-21 is able to support 
Tfh-cell activation and subsequent Tfh-dependent differentiation of B cells. We used pre-
transplantation patient peripheral blood mononuclear cells (PBMCs) and isolated pure Tfh 
cells and memory B cells. Subsequently, the Tfh and memory B cells were stimulated with 
corresponding donor antigen in the absence or presence of an IL-21R antagonistic antibody 
(αIL-21R). Stimulation of the Tfh cells and memory B cells resulted in an activated Tfh cell 
phenotype corresponding to Tfh2 and Tfh17 cells, as well as the induction of antigen-driven 
differentiation and class switch recombination (CSR) of memory B cells resulting in the 
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formation of IgM and IgG-producing plasmablasts. The formation of plasmablasts and IgM 
and IgG synthesis were significantly inhibited in the presence of the αIL-21R compound. 
Because we did not find evidence for effects of IL-21R blockade on the activation of the Tfh 
cells, we concluded that IL-21 produced by alloantigen-stimulated Tfh cells acted on B cells 
to support the formation of antibody-producing plasmablasts. Therefore, the IL-21R might 
be a potent target to prevent the generation of DSA.
To further investigate the role of IL-21 signaling in an in vivo model of alloreactivity 
we performed a study in a humanized skin transplant mouse model (Chapter 4). We 
transplanted immunodeficient Balb/c IL2rγ-/- Rag2-/- mice, which lack B, T and NK cells, 
with human skin and infused them with human allogeneic splenocytes. Control animals 
were treated with PBS, while the treatment group received the αIL-21R compound. In the 
control animals, STAT3 was phosphorylated downstream of the IL-21R and we observed a 
thickened epidermis, infiltration of T and B cells in the graft and increased expression of the 
inflammation marker keratin 17 (Ker17) and proliferation marker Ki67 in the epidermal cells. 
In contrast, in the αIL-21R-treated animals phosphorylation of STAT3 was efficiently blocked 
downstream of IL-21R and this resulted in inhibition of the epidermal thickening, reduced 
infiltration of T and B cells, and decreased expression of inflammation markers Ker17 and 
Ki67. This reduction in histological signs of rejection might be explained by the observed 
reduction in T and B cell reconstitution in the presence of αIL-21R.
Part II: Composition of lymphocytes within the renal allograft 
After renal transplantation, recipient-derived lymphocytes have the capability to infiltrate 
the donor organ. These lymphocytes are directly located at the graft site and are therefore 
a cell population of high interest to study. Due to chronic persistence of the allograft the 
infiltrating lymphocytes may form highly organized ELSs, resembling germinal centers with 
B cells and follicular dendritic cells (FDCs) and surrounded by T cells. The exact function 
of these ELSs in the local tissue is largely obscure. In Chapter 5 we therefore aimed to 
determine the presence and activation status of ELSs in three different types of acute renal 
allograft rejection. For this, paraffin sections of acute/active antibody-mediated rejection 
(a/aABMR), acute T cell-mediated rejection grade I (aTCMRI), and acute T cell-mediated 
rejection grade II (aTCMRII) biopsies were stained for different markers related to GC-
features. Remarkably, in the aTCMRI rejection biopsies we detected B cell aggregates that 
were surrounded by T cells. These aggregates were also positive for FDCs, IgD, Ki67, Bcl6 
and IL-21, which are all features of ELSs. In contrast, in the a/aABMR and aTCMRII biopsies 
we found diffuse infiltration of T and B cells. We speculate that the T cells found in the ELSs 
regulate B cell-mediated immunity during acute T cell-mediated rejection, which on the 
long-term may feed the process of chronic humoral rejection of the allograft.
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Understanding the pathophysiology of rejection after kidney transplantation is of high 
interest. However, studies on T
RM
 cells in the kidney allograft and their local role in the 
process of rejection are currently lacking. In Chapter 6, results are presented on the origin 
and functional characteristics of T
RM
 cells in a set of transplant nephrectomy specimens. T 
cells with a tissue-resident memory phenotype and gene expression profile were detected 
in all transplant nephrectomies, with the highest proportions of T
RM
 cells within the CD8+ 
T cell compartment. Moreover, these CD8+ T
RM
 cells had strong immunostimulatory 
capacity measured by the production of pro-inflammatory cytokines IFNγ and TNFα, as well 
as granzyme B, but harbored low levels of intracellular perforin. Within the first months 
after transplantation, the donor-derived T cells were replaced by recipient-derived T cells. 
Remarkably, prolonged retention of CD103+ T
RM
 cells was detected, when compared with 
other donor-derived T cells. We are the first to describe the presence and effector phenotype 
of this recently discovered T cell population in the renal allograft.
Taken together, in this thesis we explored the functional characteristics of Tfh cells and T
RM
 
cells within the alloimmune response. Our study demonstrates that Tfh cells and T
RM
 cells 
communicate to other immune competent cells to improve alloreactivity via among others 
the formation of DSA, cytotoxins such as granzyme B and perforin, and pro-inflammatory 
cytokines (Table 1). Modeling these cell-to-cell communication networks will help us to 
design less toxic and more efficient immunosuppressive treatment strategies. 
Table 1.
Overall conclusions based on this thesis:
•	 The activation of Tfh cells by alloantigen does not rely on IL-21R signaling
•	 IL-21 is a non-redundant factor in alloantigen-driven B cell differentiation towards immunoglobulin 
producing plasmablasts
•	 Blockade of IL-21R signaling in a humanized mouse skin transplantation model prevents rejection of the 
human skin, but also effects reconstitution of the human T and B cells in this model
•	 Ectopic lymphoid structures that resemble activated germinal-center structures are predominantly 
found in aTCMRI renal allograft biopsies, with more diffuse patterns of infiltrating lymphocytes detected 
in aTCMRII and a/aABMR biopsies
•	 T cells with a tissue-resident memory  cell-surface phenotype and gene expression profile are present in 
transplant nephrectomy specimens
•	 T
RM
 cells of donor-origin are completely replaced by their recipient counterparts within the first five 
months after transplantation
Tfh cell = T follicular helper cell; IL-21R = IL-21 receptor; aTCMRI = acute T-cell mediated rejection grade I; aTCMRII = 
acute T-cell mediated rejection grade II; a/aABMR = acute/active antibody-mediated rejection; T
RM
 = tissue-resident 
memory T cell
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General Discussion
The main challenge after kidney transplantation is to establish long-term graft and patient 
survival without the occurrence of rejection and drug-related side effects. Despite the use of 
conventional immunosuppressive treatments, T-cell alloimmune responses are still a major 
problem after kidney transplantation. Activated CD4+ T cells are thought to feed the process 
of CD8+ T cell-mediated immune responses such as TCMR and B cell-mediated rejection 
leading to ABMR (12, 13). Therefore, it is of importance to understand the immunological 
mechanisms that are responsible for these anti-donor responses. In this thesis, we explored 
the role of two recently discovered T cell subsets; the Tfh cells and T
RM
 cells. We studied their 
role in alloreactivity by the characterization of the mechanisms by which these effector 
memory T cell populations modulate anti-donor responses after transplantation. This will 
help us to design more safe and efficient immunosuppressive treatment strategies.
The role of Tfh cells in the alloimmune response
Formation of DSA requires the interaction between Tfh cells and B cells (14-16). 
Consequently, an intriguing question is how to interfere with this Tfh-B cell interaction in 
order to diminish the formation of de novo DSA. As described in Chapter 2, Tfh cell function 
can be inhibited in different ways via blockade of for instance co-stimulatory signaling, 
cytokine-dependent pathways, or Tfh cell migration-dependent pathways. In this thesis, 
we demonstrate that IL-21 production by activated Tfh cells controls the differentiation of 
alloantigen-activated B cells towards antibody producing plasmablasts (Chapter 3). This 
was not dependent on the autocrine effect of IL-21. Moreover, in the presence of an anti-
IL-21R mAb the expression of Tfh cell activation markers ICOS and PD-1 after alloantigen 
stimulation was upregulated. This is in line with other studies that prove the redundant 
effect of IL-21 on maintenance of the Tfh cell phenotype. These studies report that only 
combined blockade of IL-21 and IL-6 is effective in reducing Tfh cell frequencies (17, 18). This 
combined IL-21 and IL-6 blocking therapy was also proven successful in the suppression 
of disease onset in a collagen-induced arthritis mouse model and might be an interesting 
approach to study in an allogeneic setting (19). One could question whether complete 
blockade of Tfh cell activation is truly necessary, since reduction of the end product, the DSA 
in organ transplantation, is the ultimate goal. To this end, interfering with Tfh cell function 
by blocking IL-21R signaling prevents the formation of de novo DSA. However, pre-formed 
circulating DSA and long-living plasma cells formed during previous sensitization can still 
exert their destructive effects during IL-21R blockade. These cells may be neutralized via 
other interventions, such as the use of the protease inhibitor bortezomib (20).
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When we stimulated patient Tfh and memory B cells with corresponding donor antigen, 
we detected a high inter-individual variation in the proportions of plasmablasts that were 
formed after 8 days of stimulation (Chapter 3). No significant differences in patient baseline 
characteristics were detected between the co-cultures with high and low plasmablast 
numbers. Therefore, it is likely that the observed differences in plasmablast formation 
reflected the natural variation among patients, established for instance via cross-reactivity, 
differences in IL-21 levels, and distinct expression rates of co-stimulatory surface markers. In 
the last decade, a regulatory counterpart of the Tfh cell has been described, the T follicular 
regulatory (Tfr) cell. These Tfr cells have the ability to enter B-cell follicles and temper the 
production of antibodies. Tfr cells are characterized by the expression of Bcl6 alongside 
Foxp3 and other Tfh markers such as CXCR5, PD-1 and ICOS (21-23). In our co-culture model, 
we used total CD4+CXCR5+ Tfh cells. Within this T cell population we did not determine the 
ratio between Tfr and Tfh cells. Fluctuations in Tfr:Tfh ratio might also explain the variable 
numbers of plasmablasts formed after our Tfh-B cell co-cultures. Moreover, during an 
immune response the Tfh and Tfr cells both start to proliferate, but the Tfh cells proliferate 
faster and skew towards a pro-inflammatory response (24). When the antigen is cleared Tfh 
cell numbers start to drop again, while the Tfr cells continue proliferating and thus the Tfr:Tfh 
ratio is increasing and returns to a resting state (25). In tissues with continuous antigen 
exposure the Tfr:Tfh ratio is constantly low. This low Tfr:Tfh ratio is for example detected 
in Peyer patches in which constitutive IgA production occurs, and in the spleen where 
ongoing fast responses towards blood born antigens are needed (26, 27). Interestingly, in 
a pilot experiment in which we quantified the Tfr:Tfh ratios in age and gender-matched 
PBMCs of healthy individuals, PBMCs of patients pre-kidney transplantation, and PBMCs 
of patients six months post kidney transplantation a significantly lower Tfr:Tfh ratio was 
detected in the PBMCs of patients six months post transplantation compared with PBMCs 
of patients prior to transplantation (Figure 1). This might be explained by the constant 
threat of donor antigen that is skewing the Tfr:Tfh balance in favor of helper capacity. 
Overall, future research should aim to clarify whether the balance between Tfr and Tfh cells 
is affecting the process of B cell differentiation and formation of anti-donor antibodies and 
if this Tfr:Tfh balance can be shifted by blocking IL-21R signaling.
The formation of Tfh cells is highly dependent on nuclear factor of activated T-cells (NFAT) 
signaling (28, 29). Activated calcineurin promotes NFAT dephosphorylation followed 
by translocation of NFAT to the nucleus (30). The use of CNI-based treatment during 
transplantation inhibits the calcineurin-dependent activation of NFAT and thus in theory 
the formation of Tfh cells as well. In contrast, previous studies describe that high levels of 
IL-2, of which the expression is dependent on NFAT signaling, limit the differentiation of Tfh 
cells (31-33). A recent study by Wallin et al. shows that tacrolimus specifically inhibits lymph 
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node and circulating Tfh cells (34). The production of IL-2 promotes Blimp-1 expression, 
which subsequently prevents upregulation of the Tfh master transcription factor Bcl6. 
IL-2 production and Blimp-1 expression are inhibited during CNI treatment, followed by 
enhanced expression of Bcl6, which is in favor of Tfh cell development. These contradicting 
theories on the effect of CNI-based treatment on Tfh differentiation urge to further study 
this phenomenon to be able to better manipulate the formation of donor-specific Tfh cells, 
ultimately leading to a decrease in DSA formation.
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Figure 1. Tfr:Tfh ratio in PBMCs is significantly reduced in patients at six months after 
transplantation.
PBMCs of healthy controls (HC), patients prior to kidney transplantation (pre Tx), and patients six months post 
kidney transplantation (post Tx) were isolated and directly stained with CD4, CXCR5 and Foxp3. The ratio of CD4+ 
CXCR5+ Foxp3+ T follicular regulatory (Tfr) cells to CD4+ CXCR5+ T follicular helper (Tfh) cells was determined. 
Tfr:Tfh ratios are presented as individual ratios with medians. n=10 for each group; *p<0.05.
Optimizing current immunosuppressive treatment: a role for IL-21R blockade?
The pleiotropic cytokine IL-21 orchestrates the differentiation of multiple CD4+ and CD8+ 
T cell subsets (35). In this thesis we studied the role of IL-21R signaling in both in vitro 
and in vivo transplantation models. As described above, in Chapter 3 we found a non-
redundant role for IL-21 in Tfh-dependent differentiation of alloantigen activated B cells 
towards immunoglobulin producing plasmablasts. However, this in vitro model is designed 
to study the Tfh-B cell interaction after an alloantigen response. The effects of IL-21R 
blockade are complex and may depend on the experimental system used (35). Therefore, 
we set up a humanized mouse skin transplantation model with both human T and B cell 
reconstitution to explore the effect of IL-21R signaling blockade in an in vivo transplantation 
setting (Chapter 4). This humanized mouse model forms a valuable preclinical tool to study 
human-specific reagents. We demonstrated that blockade of IL-21R signaling inhibits the 
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alloimmune response and inflammation of the human skin transplant, but also influences 
T and B cell engraftment in the Balb/c IL2rγ-/- Rag2-/- mice. From these data, it is evident that 
IL-21R signaling is involved in the homeostatic proliferation of T and B cells, consistent with 
previous studies that implicated IL-21 in homeostatic T and B cell proliferation, especially 
of the CD8+ T cell subset (36, 37). And thus, this in vivo study provides evidence that IL-21 
exerts effects on both the cellular and humoral arm of the immune system. A technical 
obstacle of the humanized skin transplant mouse model is the long engraftment time of 
B cells, which can last five to six months from the moment of cellular infusion (38). This 
long B cell maturation time is not feasible in this model since after three months the risk 
of graft-versus-host disease caused by the human T cells that recognize mouse antigen is 
rapidly increasing (39). An alternative in vivo transplant model that bypasses the human 
lymphocyte engraftment might be skin transplantation on CD19-hBtk mice. These 
transgenic mice have increased expression of Bruton’s tyrosine kinase (Btk) within the B cell 
compartment, resulting in spontaneous germinal center formation and elevated levels of 
Tfh cells (40). Since IL-21R displays a high degree of homology compared to mouse IL-21R, 
transplantation of skin derived from C57BL/6 wild type mouse on CD19-hBtk mice in the 
presence and absence of the anti-IL-21R (αIL-21R) compound is specifically of interest to 
study the effect of IL-21R signaling within the Tfh-B cell interaction in an in vivo allogeneic 
setting (41). Overall, additional in vivo transplant studies are needed that shed light on 
the exact mechanisms by which IL-21 is contributing to the process of the alloimmune 
response, preferably in vivo models with a constituted immune system.
IL-21 plays a role in the communication between T and B cells in the allograft during 
rejection, as we found that IL-21+ T cells were present in organized T- and B-cell aggregates, 
also known as ectopic lymphoid structures (ELSs). We predominantly detected ELSs in 
biopsies diagnosed with aTCMRI, in contrast to aTCMRII and a/aABMR rejection biopsies 
(Chapter 5). In these ELSs, both IL-21 single positive and IL-21 Bcl6 double positive cells 
were detected. The presence of IL-21+Bcl6+ cells in combination with Ki67+ cells implies the 
presence of activated Tfh cells that promote a germinal center-like response. However, all 
aTCMRI cases were negative for C4d and DSA, which suggests a role for IL-21 in the IFNγ 
dependent cytotoxic activity of CD8+ effector T cells (42). Indeed, other studies present 
a role for IL-21 in sustaining CD8+ T cell responses during chronic infection, which may 
also occur in the graft at the time of an ongoing alloimmune response. In these studies, 
IL-21 directly interacts with CD8+ T cells to maintain the cytotoxic response and to limit 
exhaustion of the cells during chronic LCMV infection (43, 44). The IL-21 positive cells that 
we detected in the ELSs may also resemble Th17 cells, which are known to secrete IL-21 and 
to be involved in the formation of these lymphoid structures (45, 46).
7149
Summary and general discussion
As described above, IL-21 is taking a center stage during various effector immune processes 
after organ transplantation. In addition, our work shows that this broad role of IL-21 is exerted 
by peripheral T cells, as well as T cells that infiltrated the renal allograft. So far, only a phase 
I trial in healthy volunteers was conducted to assess the safety of the same IL-21-receptor 
antagonist (αIL-21R) as was used in our study. However, 76% of the healthy volunteers that 
received the αIL-21R compound developed anti-drug antibodies, which resulted in rapid 
clearance and thus a low bioavailability of the compound (47, 48). In the autoimmune 
field, phase I and II trials have been performed to study the role of IL-21-specific antibodies 
in rheumatoid arthritis, Crohn’s disease and systemic lupus erythematosus. However, the 
results of these trials have not been published so far. Clearly, further studies are necessary 
to identify an IL-21R antagonist or an anti-IL-21 antibody with high efficacy and safety. 
Ultimately, because IL-21R blockade affects the functions of various T and B cell populations 
this intervention might be of specific interest as a form of induction therapy. Especially for 
sensitized patients, induction therapy with an IL-21R antagonist may hamper the formation 
of donor-specific Tfh cells that are contributing to the formation of de novo DSA.
Lymphocytes infiltrating the renal allograft: friends or foes?
When studying T cell communication with other cell types in transplantation it is of high 
importance to consider the context. Peripheral T cells mainly bear a resting naïve or 
memory phenotype, in contrast to the cells that migrate to the lymphoid tissues where 
activation of the T cells takes place. In addition, inflammatory mediators produced by local 
stromal cells are able to control recruitment, activation and survival of lymphocytes locally 
in primary tissues (49). Despite the use of immunosuppressive therapies, T and B cells are 
able to infiltrate the kidney allograft. Moreover, organized lymphocyte structures have been 
detected within rejection biopsies of kidney allografts (50). Remarkably, we predominantly 
detected ELSs with an activated phenotype in rejection biopsies diagnosed with aTCMRI, 
while more diffuse T- and B-cell structures were detected in most of the aTCMRII and a/
aABMR biopsies, with no FDC networks, IgD and IL-21+Bcl6+ cells. This indicates that there 
may be more cells involved during an aTCMRI rejection on top of the infiltration of classical 
CD8+ T cells. The findings in Chapter 5 argue that ELSs are present in acute responses in 
which T cells are dominating. However, the function of the ELSs in the aTCMRI rejection 
biopsies is not fully elucidated, with contradicting evidence in literature that these structures 
have both protective and destructive immune properties (51-53). For this reason, it would 
be of high interest to study the inflammatory patterns of the ELSs which we detected in 
the aTCMRI rejection biopsies in more depth. The nCounter Analysis System (NanoString 
Technologies, Seattle, WA) platform for multiplex analysis of RNA expression on formalin-
fixed paraffin-embedded (FFPE) tissue might be an interesting approach to further study 
the ELSs in aTCMRI. The advantage of this technique is the direct and sensitive measurement 
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of mRNA expression in the absence of enzymatic or signal amplification (54). This technique 
has been applied to identify gene expression heterogeneity in different rejection types in a 
recent publication by Smith et al. (55). Overall, we plea that TCMR is ultimately leading to a 
chronic antibody-mediated rejection, which is also described by Loupy et al. and Halloran 
et al. (12, 13).
One particular subset of T cells infiltrating the non-lymphoid tissues has been acknowledged 
over the past decade: the tissue-resident memory T (T
RM
) cells. This subset of T cells rapidly 
responds to local antigens and forms a first line of defense against re-circulating pathogens 
(56). In this thesis, we identified T
RM
 cells with an effector phenotype in transplant 
nephrectomies (Chapter 6). When we stimulated the total population of renal lymphocytes 
with corresponding donor cells, these cells were able to mount an alloreactive response. 
We also found that donor-derived T cells are replaced by recipient-derived T cells in the 
first months after kidney transplantation. The retention of donor-derived cells might have a 
protective role in the renal allograft, as observed in other studies (57, 58). Moreover, in visceral 
transplants, donor-derived T cells with graft-specific TCR clones are thought to decrease the 
constant threat of recipient-derived T cells, thus slowing down the in situ development of 
rejection (59). It is of high interest to study the exact function of the donor- and recipient-
derived T
RM
 cells in the renal allograft. When we identify the balance between protective and 
destructive T
RM
 cells we will be able to better tailor immunosuppressive strategies. Assuming 
that recipient-derived T
RM
 cells contribute to the alloimmune response, strategies to diminish 
lymphocyte repopulation within the renal allograft are of interest. The immunomodulating 
drug FTY720 is an antagonist for the sphingosine-1-phosphate receptor (S1PR) and able to 
block T cell homing to the tissue. In this respect the results of phase I and II trials in multiple 
sclerosis patients are promising, however, after renal transplantation FTY720 has limited 
effects on migration profiles of T cells and subsequently did not decrease acute rejection 
incidence in combination with conventional immunosuppressants (60-62). A recent study 
by Tian et al. showed that IL-21R-/- mice had lower levels of T
RM
 cells in the small intestine. The 
remaining CD8+ T cells in these IL-21R-/- mice still expressed the typical CD69+CD103+ T
RM
 
cell phenotype but the levels of granzyme B produced by these cells are lower compared to 
the IL-21R+/+ mice (36). Overall, future studies need to clarify via which mechanisms we will 
be able to tailor the migration of T
RM
 cells in favor of the donor organ.
T cell communication in organ transplantation: what do we have to take 
into account?
The findings described in this thesis provide new perspectives in the mechanisms by which 
Tfh cells and T
RM
 cells modulate an alloimmune response after kidney transplantation as 
summarized in Table 1. Both cell types have an effector memory phenotype and are able 
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to mount an alloreactive response in which the function of IL-21 is involved. Moreover, 
these IL-21 driven T cells are active in the kidney allograft where they directly contribute 
to the process of rejection via the communication to CD8+ cytotoxic T cells and B cells. 
Furthermore, we found a broad effect of IL-21R blockade in our in vitro and in vivo transplant 
models all pointing to the same direction. Namely, blockade of IL-21R signaling has 
inhibiting effects on both the humoral and cellular arm of the alloimmune response. A 
next step is to translate the knowledge obtained in this thesis to the clinical setting. To 
this end, a randomized controlled trial with IL-21R antagonistic antibodies is needed that 
ultimately leads to new strategies to improve short- and long-term outcomes after kidney 
transplantation. This randomized controlled trial should be designed to treat an ongoing 
rejection episode or prevent the rejection by induction therapy to hamper the function of 
IL-21 responsive T and B cells. Moreover, the presence of potentially harmful Tfh cells and 
T
RM
 cells during a rejection episode might be an indication to use an IL-21R antagonistic 
antibody to reduce the activity of these cells. Another interesting future approach is to 
measure the pre-transplantation IL-21-producing memory T cells with specificity for the 
donor that might form a predictive marker to identify patients at risk for rejection. Currently, 
no routine tests are performed to measure pre-transplant-donor-specific T cells. It is 
tempting to speculate that patients with high numbers of IL-21+ T cells directed toward 
donor antigens should receive IL-21R antagonistic antibodies as a desensitization therapy. 
The findings described in this thesis might be used to also move away from a ‘one size fits 
all’ approach for the use of immunosuppressive treatment and care of patients after kidney 
transplantation. The outstanding questions for future research are summarized in Table 2.
Overall, in this thesis we functionally characterized Tfh cells and T
RM
 cells to gain knowledge 
about their role in alloreactivity after organ transplantation in patients. Our studies show 
that these T cell subsets communicate to other immune competent cells to enhance the 
alloimmune response via the formation of DSA, pro-inflammatory cytokines, and cytotoxins 
such as granzyme B and perforin. Modeling cell-to-cell communication networks of the T 
cells might help us to improve immunosuppressive treatment strategies, ultimately leading 
to enhanced kidney transplant outcomes. 
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Table 2.
Outstanding questions for future research
Fundamental questions:
•	 What is the balance between Tfh cells and Tfr cells during an allogeneic response and are we able to 
modify this balance via the use of immunosuppressive drugs?
•	 What are the exact mechanisms by which current maintenance immunosuppressive drugs alter the 
function of Tfh cells? 
•	 What is the number of alloantigen-specific T
RM
 cells in the renal allograft after transplantation compared 
to the number of T
RM
 cells with antigen specificity for viral and bacterial pathogens in a resting state and 
during a rejection episode?
•	 Are the donor-derived T
RM
 cells within the renal allograft slowing down the threat of recipient-derived T
RM
 
cells that are involved in the process of rejection?
New experimental approaches:
•	 Is the CD19-hBtk skin transplant mouse model a suitable in vivo model to study the impact of IL-21 
signaling on the T-B cell interaction during an allogeneic response?
•	 Can we identify the functional characteristics of ELSs in the aTCMRI biopsies by NanoString RNA expression 
analysis on FFPE tissue?
New treatment strategies:
•	 Are we able to specifically target the donor specific T
RM
 cells  and spare the recipient-derived T
RM
 cells that 
are specific for viral or bacterial pathogens?
Tfh cell = T follicular helper cell; Tfr cell = T follicular regulatory cell; TRM cell = tissue-resident memory T cell; ELSs 
= ectopic lymphoid structures; aTCMRI = acute T-cell mediated rejection grade I; FFPE = formalin-fixed paraffin-
embedded
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Het immuunsysteem beschermt het lichaam tegen het binnendringen van ziekteverwekkers 
zoals bacteriën en virussen. Het is continu actief om deze ziektekiemen te herkennen 
en uit te schakelen. De T en B lymfocyten vormen hierbij belangrijke spelers binnen het 
immuunsysteem. Er bestaan verschillende subtypen T cellen, die via de T-cel receptor 
(TCR) op hun celoppervlak lichaamsvreemde eiwitten (antigenen) zeer specifiek kunnen 
herkennen. De belangrijkste typen zijn de CD4+ T helper cellen en de CD8+ cytotoxische T 
cellen. De CD4+ T helper cellen worden gekenmerkt door hun ‘helper’ activiteit waarmee 
ze cytotoxische CD8+ T cellen en B cellen kunnen activeren. De B cellen kunnen ook 
specifiek antigenen herkennen en na activatie zich ontwikkelen tot plasmacellen, die 
verantwoordelijk zijn voor de productie van antistoffen (immuunglobulines). In deze 
activatie processen is - naast de specifieke antigen binding via de TCR - ook ligand binding 
van een co-receptor (co-stimulatie) en de uitscheiding van signaalstoffen (cytokines) van 
essentieel belang. CD8+ cytotoxische T cellen produceren naast cytokines ook toxische 
moleculen zoals granzyme B en perforine die met ziektekiemen besmette cellen kunnen 
uitschakelen. De T folliculaire helper (Tfh) cellen zijn een subtype CD4+ T cellen die specifiek 
betrokken zijn bij het activeren van B cellen in de lymfeklieren. Door middel van verschillende 
signalen, waaronder cel-cel contact (via CD40 ligand op de T cel en CD40 op de B cel) en 
uitscheiding van het cytokine IL-21, stimuleren de Tfh cellen de B cel differentiatie naar 
antilichaam-producerende plasmacellen. Het cytokine IL-21 is daarnaast ook betrokken 
bij de ontwikkeling van CD8+ cytotoxische T cellen. De T en B cellen bevinden zich in de 
bloedbaan en de lymfeklieren en migreren na activatie naar organen zoals de darmen, 
longen, en nieren. Een recent ontdekt type T cellen dat zich nestelt in organen zijn de 
zogenoemde tissue-resident memory T (T
RM
) cellen, die niet zozeer circuleren maar zich in 
de weefsels vestigen. Deze T
RM
 cellen kunnen een snelle respons genereren nadat ze lokaal 
in contact komen met ziektekiemen.
Zoals hierboven beschreven vormt het immuunsysteem de essentiële verdedigingslinie 
tegen ziekteverwekkers. Echter, het immuunsysteem zal ook worden geactiveerd als het 
na  orgaantransplantatie het donororgaan herkent als lichaamsvreemd. Indien de donor 
niet genetisch identiek is aan de ontvanger, zal dit in principe leiden tot afstoting van het 
donororgaan. Dit wordt ook wel een allogene respons genoemd.
Een niertransplantatie levert de beste uitkomst voor patiënten met eindstadium nierfalen. 
Na de niertransplantatie zijn patiënten niet meer afhankelijk van dialyse waardoor 
hun kwaliteit van leven en de levensverwachting sterk verbetert. Ondanks het gebruik 
van immuunonderdrukkende medicatie kan afstoting van de donornier optreden. Dit 
afstotingsproces kent verschillende vormen. Kort na transplantatie is het meest voorkomende 
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type afstoting de T-cel gemedieerde afstoting (TCMR) waarbij voornamelijk CD8+ 
cytotoxische T cellen de donornier aanvallen. De activatie van T cellen na niertransplantatie 
zorgt er ook voor dat B cellen geactiveerd worden. Activatie van de B cel vindt plaats door 
antigeen herkenning via de B-cel receptor, waardoor een cyclus van B-T cel interacties 
ontstaat. De geactiveerde B cellen differentiëren vervolgens naar plasmacellen die donor-
specifieke antilichamen produceren, hetgeen leidt tot een antilichaam gemedieerde 
afstoting (ABMR). Om het aantal afstotingen na niertransplantatie te verminderen is het 
essentieel om de huidige immuunonderdrukkende medicatie te verbeteren. Wanneer we 
de processen van de T cellen en B cellen die betrokken zijn bij het afstotingsproces beter 
begrijpen, zullen we in staat zijn therapieën te ontwikkelen die het immuunsysteem op 
een efficiëntere manier onderdrukken en tevens een lager bijwerkingen profiel hebben. 
Tezamen geeft dit een langere halfwaardetijd van het getransplanteerde orgaan en een 
langere overleving met een betere kwaliteit van leven voor de patiënt.
Het doel van dit proefschrift is om de functie van twee recent ontdekte subtypen T 
cellen - de Tfh cel en de T
RM 
cel - in het proces van een donor-specifieke immuunrespons 
beter te begrijpen. Een verbeterd inzicht in de werking van deze twee typen T cellen in 
het proces van donororgaan afstoting zal bijdragen aan een verbeterde afstemming van 
immuunonderdrukkende geneesmiddelen en het ontwikkelen van geneesmiddelen met 
minder bijwerkingen en een efficiëntere werking. Dit proefschrift bestaat uit twee delen. 
In Deel I wordt de rol van de IL-21 producerende Tfh cellen beschreven aan de hand van 
studies in verschillende allogene modellen. Deel II richt zich op de werking van ectopische 
lymfoïde structuren en T
RM
 cellen die zich in de donornier bevinden.
In hoofdstuk 2 wordt de huidige kennis van immuunonderdrukkende medicatie op de 
ontwikkeling en werking van Tfh cellen uiteengezet. Op basis van deze kennis bespreken 
we mogelijke nieuwe strategieën waarbij de functie van Tfh cellen beïnvloed kan 
worden. Deze strategieën dragen bij aan de ontwikkeling van betere en meer specifieke 
immuunonderdrukkende geneesmiddelen. De activiteit van Tfh cellen kan op verschillende 
punten beïnvloed worden, zoals door het blokkeren van co-stimulatie signalen, cytokine 
signalen, of signalen die de migratie van de Tfh cellen naar de lymfeklieren beïnvloeden. 
Daarnaast hebben we op basis van de bestaande literatuur de mogelijkheden in kaart 
gebracht om de Tfh cel te gebruiken als biomarker om een immuunrespons tegen het 
donororgaan  te voorspellen.
In hoofdstuk 3 wordt de rol van het cytokine IL-21 binnen de interactie tussen Tfh cellen 
en B cellen bestudeerd in een allogeen kweekmodel. Hierbij hebben we gebruik gemaakt 
van geïsoleerde Tfh cellen en B cellen van niertransplantatie patiënten. Deze Tfh cellen en 
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B cellen zijn gestimuleerd met de cellen van de donor zowel in de aan- als afwezigheid 
van een antagonistisch antilichaam dat de IL-21 receptor blokkeert. Hieruit bleek dat Tfh 
cellen in combinatie met de allogene stimulus de B cellen konden laten differentiëren 
naar immunoglobuline producerende plasmablasten. In de aanwezigheid van het anti-
IL-21 receptor antilichaam werden de plasmablastformatie en immunoglobulineformatie 
significant geremd. Het remmen van de IL-21 receptor signalering had geen effect op de 
activatiestatus van de Tfh cellen. We kunnen hieruit concluderen dat het blokkeren van 
IL-21 signalering een potentiële manier is om na transplantatie de formatie van donor-
specifieke antilichamen te remmen.
Om de rol van het cytokine IL-21 binnen de alloimmuunrespons verder te bestuderen 
wordt in hoofdstuk 4 gebruik gemaakt van een gehumaniseerd transplantatiemodel. In 
dit model zijn immuundeficiëntie muizen getransplanteerd met een stukje menselijke 
huid. Vervolgens zijn deze muizen geïnjecteerd met lymfocyten van een ander individu. 
De muis is in dit model dus de drager van een humane anti-donor immuunrespons. De 
controle dieren werden behandeld met fysiologisch zout terwijl bij de behandelde groep 
een blokkerend anti-IL-21 receptor antilichaam werd toegediend. In de controle dieren was 
de humane huid sterk verdikt en was er infiltratie van T en B cellen in de huid zichtbaar. Ook 
was de huid van de controle dieren ontstoken en konden we aantonen dat de expressie 
van de ontstekingsmarkers keratine 17 en Ki67 verhoogd was. Daarentegen bleek dat in de 
behandelde dieren de humane huid niet verdikt was, er nauwelijks T en B cellen geïnfiltreerd 
waren in de humane huid, en de ontstekingsmarkers keratine 17 en Ki67 nauwelijks tot 
expressie kwamen. Deze verminderde ontsteking van de huid in de behandelde dieren kan 
deels verklaard worden doordat het nestelen van de humane lymfocyten in de muis ook 
verstoord werd door de aanwezigheid van het blokkerende anti-IL-21 receptor antilichaam.
Deel II van het proefschrift richt zich op de werking van ectopische lymfoïde structuren 
(ELS) en T
RM
 cellen die zich in de donornier bevinden. ELS worden gedefinieerd als 
georganiseerde structuren van immuuncellen, die veel overeenkomsten vertonen met 
lymfeklieren, maar die zich in weefsels bevinden waar zich een immuunreactie afspeelt. Na 
een niertransplantatie wordt het lichaam van de ontvanger continu blootgesteld aan de 
lichaamsvreemde donornier. Ondanks het gebruik van immuunonderdrukkende medicatie 
zijn de lymfocyten van de ontvanger in staat om naar de donornier te migreren waar ze 
zich nestelen en organiseren tot ELS. De rol van ELS formatie in de donornier is niet geheel 
bekend.
In hoofdstuk 5 wordt de aanwezigheid en activatie status van ELS in nierbiopten van drie 
verschillende typen acute afstoting onderzocht. Hierbij hebben we gebruik gemaakt van 
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paraffine coupes van acute/actieve antilichaam-gemedieerde rejectie (a/aABMR), acute 
T-cel gemedieerde rejectie type I (aTCMRI) en acute T-cel gemedieerde rejectie type II 
(aTCMRII). Deze weefselcoupes van nierbiopten zijn gekleurd voor verschillende markers 
gerelateerd aan ELS formatie. Hieruit bleek dat voornamelijk in de aTCMRI biopten cel 
aggregaten aanwezig waren bestaande uit B cellen omringd door T cellen. Deze T-B cel 
aggregaten waren ook positief voor verschillende ELS markers. In tegenstelling hiermee 
werd in de a/aABMR en aTCMRII biopten een diffuser beeld gedetecteerd van geïnfiltreerde 
T en B cellen, in de afwezigheid van ELS formatie. We speculeren dat T cellen in ELS de 
aanwezige B cellen kunnen stimuleren tijdens een acute T-cel gemedieerde rejectie. Dit 
proces van T-B cel interactie kan op lange termijn leiden tot een chronische antilichaam 
gemedieerde afstoting tegen de donornier.
In Hoofdstuk 6 wordt de lokale rol van T
RM
 cellen in de donornier onderzocht. De T
RM
 
cellen nestelen zich in de organen waar ze vanwege hun memory status lokaal een snelle 
immuunrespons kunnen genereren. Voor deze studie is gebruik gemaakt van donornieren 
die vanwege eindstadium afstoting verwijderd zijn, ook wel explantaatnieren genoemd. In 
alle explantaatnieren waren T cellen aanwezig met het T
RM
 fenotype en genexpressie profiel, 
met de hoogste frequentie T
RM
 cellen binnen het CD8+ T cel compartiment. Deze CD8+ T
RM
 
cellen hadden de capaciteit om de pro-inflammatoire cytokines IFNγ en TNFα te produceren, 
waren positief voor granzyme B en zwak positief voor perforine. De aanwezige T cellen in de 
explantaatnieren kunnen in principe zowel van de donor als van de ontvanger afkomstig 
zijn. Indien zowel donor als ontvanger cellen aanwezig zijn spreekt men van chimerisme. 
Op basis van analyse van de explantaatnieren in deze studie kan geconcludeerd worden 
dat in de donornier binnen de eerste vijf maanden na transplantatie de T cellen afkomstig 
van de donor worden vervangen door T cellen afkomstig van de ontvanger. Dit chimerisme 
is dus van korte duur. Een interessante bevinding was dat de T
RM
 cellen afkomstig van de 
donor in vergelijking met de overige donor-T cellen langer in het donororgaan konden 
verblijven.
Concluderend, in dit proefschrift worden verschillende nieuwe manieren beschreven 
waarop Tfh cellen en T
RM
 cellen een bijdrage leveren aan de anti-donor respons na 
niertransplantatie. Beide typen T cellen hebben een effector memory fenotype en zijn in 
staat om een alloimmuunrespons te initiëren. Ook wordt beschreven dat IL-21 gestuurde 
T cellen lokaal actief zijn in de donornier, waar ze direct bijdragen aan het afstotingsproces 
door te communiceren met CD8+ cytotoxische T cellen en met B cellen. Met een blokkerend 
anti-IL-21R antilichaam werd bevestigd dat de functie van allogeen geactiveerde T en B 
cellen onderdrukt werd in de afwezigheid van IL-21R signalering. Een volgende stap is om 
de uitkomsten beschreven in dit proefschrift te vertalen naar een klinische setting. Een 
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klinische trial waarbij de effectiviteit van een anti-IL-21R antilichaam wordt onderzocht 
zou hierbij een goed vervolg kunnen zijn. Deze zou uiteindelijk een belangrijke bijdrage 
kunnen leveren aan nieuwe therapieën om de korte en lange termijn uitkomsten na 
niertransplantatie te verbeteren. Patiënten waarbij voorafgaande aan de transplantatie hoge 
waarden IL-21 positieve donor-specifieke T cellen circuleren zouden als inductie therapie 
behandeld kunnen worden met een anti-IL-21R antilichaam. Ook patiënten die ten tijde 
van afstoting hoge Tfh cel aantallen hebben zouden baat kunnen hebben bij een IL-21R 
blokkerende therapie die de activiteit van deze agressieve cellen vermindert. Samenvattend 
zouden de bevindingen uit dit proefschrift gebruikt kunnen worden om in de toekomst 
patiënten op een meer persoonsgerichte manier te behandelen die past bij het specifieke 
type afstoting dat zij ondergaan. Hierbij is het in kaart brengen van cel-cel communicatie 
tussen verschillende type T cellen en andere immuuncellen van groot belang om nieuwe 
geneesmiddelen te ontwikkelen die uiteindelijk zullen leiden tot verbeterde uitkomsten na 
niertransplantatie. 
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voor klassieke muziek. Hopelijk komen we elkaar nog vaak tegen bij mooie concerten.  
Prof. dr. van der Laan, beste Luc, sinds het tweede jaar ben jij betrokken geweest bij mijn 
promotietraject. Bedankt dat je tijd wist vrij te maken om mijn project te begeleiden en op 
de juiste momenten kritische vragen wist te stellen. Heel veel succes als jonge professor!
Dr. Dor, beste Frank, jij stond aan het prille begin van mijn promotietraject. Ik vind het 
bijzonder dat we, ondanks jouw vertrek naar Londen, het project ook samen afronden. Jouw 
enthousiasme voor wetenschappelijk onderzoek in combinatie met jouw toegankelijkheid 
zijn unieke eigenschappen. Hartelijk dank voor alle support.
 
Dr. Clahsen-van Groningen, beste Marian, wanneer ik de pathologie afdeling verliet deed 
ik dit altijd met een grote glimlach. Je was immer bereid om coupes te bekijken of materiaal 
voor de GIL-studie te verwerken (“alles voor de wetenschap!”). Ik bewonder jouw drive voor 
het uitvoeren van onderzoek naast jouw klinische taken. Dank voor alle hulp.
 
Dr. Hesselink, beste Dennis, jouw gedrevenheid ten aanzien van wetenschappelijk 
(lab)onderzoek naast de patiëntenzorg is bijzonder. Bedankt voor het meedenken met 
verschillende projecten en je oog voor precisie bij het lezen van mijn manuscripten.  
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Ook alle andere leden van de kleine en grote commissie bedank ik voor de tijd en bereidheid 
om mijn proefschrift te beoordelen.
Lieve paranimfen, Lilian en Marjolein, vanaf het begin van mijn promotie tot de 
feestelijkheden rond de afronding hebben jullie mij enorm geholpen en gemotiveerd. 
Ook wanneer het tegen zat, stimuleerden jullie mij om door te zetten. Met als resultaat dit 
boekje. Dank dat jullie op deze bijzondere dag naast mij staan! Lilian, als klein meisje vond 
ik het al heel erg interessant dat jij als mijn tante in een laboratorium in een groot ziekenhuis 
in Rotterdam werkte. Wie had ooit gedacht dat we jaren later beiden in datzelfde ziekenhuis 
zouden werken? De lunchafspraakjes met jou waren gezellig en zeer waardevol. Ze gaven 
vaak precies het steuntje in de rug dat ik nodig had. De vele activiteiten ‘buiten de stad’ 
waren altijd fijn en ik hoop dat we in de toekomst nog veel mooie tripjes gaan maken. 
Marjolein, jouw bijdrage aan dit proefschrift was onmisbaar! Van lange sort-experimenten 
tot prak-festijnen en ingewikkelde FACS kleuringen. Jij deinsde nergens voor terug. Naast al 
deze ingewikkelde experimenten hebben we ook ontzettend veel gelachen op het lab en 
daarbuiten. Als derde Bela-AIO van jou vlieg ik nu uit. Heel veel dank voor alle steun en hulp 
bij mijn project en vooral de fijne vriendschap. 
Team Bela, het dreamteam waar ik altijd op terug kon vallen tijdens dagen met onmogelijke 
experimenten, deadlines, een tekort aan suiker/koffie en andere lab struggles. Gretchen, 
nooit had ik verwacht dat ik op mijn eerste werkdag zo warm ontvangen zou worden in ons 
kantoor gevuld met Hello-Kitty gadgets. De eerste periode van mijn PhD heb je mij enorm 
geholpen om mijn weg binnen het transplantatielab te vinden. Dit heeft geresulteerd in een 
heleboel flawless data ;) Al onze congressen en andere uitjes, met als hoogtepunt Chicago, 
zal ik niet snel vergeten. Dank voor al je humor, gezelligheid en steun. Nynke, als Bela-
zusjes konden we altijd veel met elkaar delen en zeker in de laatste fase van mijn PhD kon ik 
altijd bij je aankloppen voor advies. Ook was het een hele eer om jouw paranimf te mogen 
zijn. Het was fijn om met jou samen te werken en ik hoop dat we elkaar nog vaak blijven 
zien. Rens, naast het handschoenen schieten en stoelen sjoelen waren er ook de eindeloze 
discussies over hoe die Tfh cel en B cel precies samenwerken. Jouw nieuwsgierigheid en 
enthousiasme voor de wetenschap (en Game of Thrones!) zijn aanstekelijk. Dank voor alle 
goede grappen en voor al je hulp bij mijn onderzoek. Marieke, als overburen hadden we 
al snel een klik. Het bespreken en verwezenlijken van onze carrièredromen, het delen van 
lekkere recepten, fantaseren over mooie vakantiebestemmingen maar ook uitwisseling van 
klinische en lab-gerelateerde zaken. Jouw hulp en fijne gesprekken hielpen mij altijd in de 
goede richting. Gaan we deze zomer nog een keertje racefietsen?
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All the other PhD’s, thank you for making my PhD time an inspiring and great time! Burç, 
buur! Wat heb ik ontzettend genoten van jouw droge humor in ons kantoor. We hebben 
heel wat afgelachen, maar daarnaast kon ik bij jou ook altijd terecht met serieuze vragen. 
Ik weet zeker dat jij een super huisarts gaat worden! Samantha, Sam, jouw open en lieve 
houding zorgden ervoor dat ik mij al snel thuis voelde op het lab. Dankjewel voor alle 
hulp en support bij mijn experimenten en vooral dat je daarbij de knisper-sokken wilde 
trotseren. Ook dank voor alle glitters, snoepjes, (brandweerman)posters en andere grapjes 
die mijn PhD zoveel leuker hebben gemaakt. Heel veel succes met de opleiding tot klinisch 
embryoloog. Franka, Fluk, mijn partner in crime bij het skin-transplant project. Wat hebben 
we veel getrotseerd, van een bezoekje aan de slager om onze dermatoom-skills te oefenen 
tot aan de eindeloze experiment-sessies in de stal. Jij laat je niet snel uit het veld slaan en blijft 
altijd positief. Dankjewel dat je altijd voor mij klaar staat! Ling, you always made me smile. 
Our late afternoon conversations in the office were always stimulating and inspiring for me. 
Thank you for being my happy friend and colleague and I hope we will meet again in China 
or in the Netherlands in the future. Lin, writing the review with you was a great experience! 
Every week you came up with new ideas that resulted in a really nice publication. I would 
like to wish you all the best with your career and life in Chengdu. Fleur, onze PhD’s gingen 
vrijwel gelijk op waardoor we veel konden delen. Daarnaast zaten we samen in het Young 
Professionals bestuur. Als pionier op het gebied van het epigenetica onderzoek binnen 
het transplantatieveld hield jij je staande als een gedreven onderzoekster. Gaaf dat je nu 
in jouw eigen Amsterdam aan de slag bent gegaan als Postdoc. Dankjewel voor alle leuke 
momenten en succes met jouw wetenschappelijke carrière. Thierry, jij stond altijd voor 
mij klaar om in vliegende vaart coupes te kleuren en mij de fijne kneepjes van de confocal 
microscopie te leren. Daarnaast zal ik onze congres week in Chicago niet snel vergeten. 
Veel succes met jouw werkzaamheden bij de Pathologie. Jesus, our Spanish beard man! 
Thank you for all the funny moments in and outside the lab. Especially during several 
conferences we spend together (Spain!). The cold beers alongside the pool after a long 
conference day were always good. Anusha, jij draait je hand niet om voor een ingewikkeld 
organoïd project. Ook bood je altijd een luisterend oor, zeker als we samen op kantoor 
waren en te lang bleven hangen ;) Heel veel succes met jouw promotietraject! Jeroen, 
koning van de graslelies! Als een lichtelijk chaotische wervelwind kwam jij bij ons op het 
lab. Met jouw doorzettingsvermogen en enthousiasme weet ik zeker dat je het ver gaat 
schoppen. Dankjewel voor alle fijne en grappige momenten en alle mooie posters (Ryan!) 
in ons kantoor. Wouter, niet alleen bracht jij veel reuring op het lab, je bent ook creatief. 
Deze creatieve en nieuwsgierige blik op wetenschap is inspirerend! Daarnaast delen we 
ook de liefde voor muziek en lekkere biertjes. Dank voor de goede tijd en succes met jouw 
PhD. Aleixandra, altijd vrolijk en in voor een koffiemoment beneden onder het mom van 
een Tfh/IL-21 werkoverleg. Rustig en gericht ga jij op je doel af. Veel plezier en succes de 
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komende jaren op het Tx lab! Steven, although we only worked together for a short period 
you were always interested in my work. Good luck with your PhD and enjoy your time in 
the Netherlands!
 
Alle Postdocs wil ik bedanken voor de input op mijn werk en uiteraard voor alle leuke 
momenten. Karin, jouw scherpe en doortastende blik heeft een belangrijke bijdrage 
geleverd aan mijn proefschrift. Onze sessies in het lab/microscoophok zal ik niet snel 
vergeten. Dankjewel voor al je support de afgelopen jaren en de fijne vriendschap. 
Martin, voor elk probleem had jij een ingenieuze oplossing. Onze samenwerking heeft 
geresulteerd in een mooie publicatie over het skin-transplant muismodel. Bedankt voor 
jouw geduld en hulp gedurende mijn PhD. Nicolle, er was altijd ruimte om een ingewikkeld 
experiment met jou door te nemen of gewoon even te kletsen. Dank daarvoor! Ik vind 
het leuk dat we elkaar als ‘bijna buren’ af en toe nog zien. Nicole, altijd geïnteresseerd in 
het reilen en zeilen van de verschillende projecten. Heel veel succes met jouw ELISPOT 
studies. Ana, me flipa como eres!! Your happy and crazy character always made me laugh. 
But also your enormous lab-knowledge and critical questions were valuable. Thank you 
for inviting us to your home in Cordóba, an experience I will never forget. Fabiany, it was 
a big surprise to welcome you again to the Tx lab as a Postdoc and a pleasure to spend 
some weeks together. I wish you all the best with your career and life in Rotterdam.     
De Analisten, ook wel de mecaniciens van het laboratorium. Zonder jullie waren mijn 
experimenten in het lab simpelweg niet mogelijk geweest. Annemiek, dankjewel voor 
je hulp bij de RT-qPCR experimenten en voor onze fijne gesprekken. Derek, altijd in voor 
nieuwe avonturen op het lab en tripjes naar de Efteling of het foute feest. Dank voor 
jouw hulp bij de muizenexperimenten. Ronella, praten over Lowlands, motorrijden of 
andere stoere dingen, de tijd vloog voorbij als ik naast je in de kweek zat. Dank voor je 
support! Wenda, heldin van de FACS sorts en vele andere praktische lab-zaken. Bedankt 
voor al je hulp en gezelligheid de afgelopen jaren. Mariska, wanneer het einde van de 
week naderde was jij vaak weer achter de FACS te vinden, een vertrouwd moment om 
even bij te praten. Dank daarvoor! Sander, jouw droog-ijs kunsten op het lab waren altijd 
een welkome afleiding. Dank voor alle leuke momenten. Jeroen, naast een harde werker 
op het lab ook altijd in voor een gezellig avondje (met speciaal biertjes). Dank voor alle 
grappige momenten en de inspirerende verhalen over de mooie reizen die je maakt.    
 
Alle andere oud-collega’s van het transplantatielab bedank ik voor de betrokkenheid bij 
mijn promotietraject: Joke, Marcel.la, Ruud, Yongkang Wu, Rocio, Tanja, Bastiaan, Elly, 
Ruben, Frieda, Thea.
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Ook mijn nieuwe collega’s van het Franciscus Gasthuis en Vlietland wil ik bedanken voor 
de fijne werksfeer en support tijdens de start van mijn opleiding en de laatste fase van mijn 
promotietraject. 
Jaarclub Femidabel, lieve Fiore, Tessa, Marjoleine, Sophia, Merel, Marlotte, Charlie, 
Machteld, Lorena en Elbrich. Van etentjes in onze kleine studentenkamers tot het 
daadwerkelijk realiseren van onze dromen. We hebben elkaar zien groeien en ontwikkelen. 
Dank jullie wel voor de nodige afleiding de afgelopen jaren en de hechte vriendschap.  
 
Jasmijn, Esther en Nienke, wat een cursus ‘career guidance’ allemaal teweeg kan 
brengen! De ontmoetingen met jullie zijn altijd een verrijking en bovenal ontspannend.  
  
Inez en Elisah, immer in voor avontuur en op zoek naar nieuwe uitdagingen. Wat ben ik 
dankbaar dat we elkaar na het NESKO project beter hebben leren kennen. Jullie zien mij zoals 
ik ben en dat waardeer ik enorm. Anouk en Marianne, Alle mooie tournees die we hebben 
meegemaakt en georganiseerd, de gekke schnabbels en de recente start van onze oranjebitter 
distributie. Niets is te gek! Het feit dat jullie altijd voor mij klaarstaan koester ik. Maaike, de 
studie en orkest zijn twee gemeenschappelijke delers. Het uitwisselen van ervaringen tijdens 
eindeloze koffie afspraakjes is iets waar ik altijd van geniet. Liesbeth, mijn aller-langste orkest 
vriendinnetje. Ondanks dat jij nu in Singapore woont blijven we elkaar op de hoogte houden 
van onze bezigheden, dat vind ik waardevol. Pieter, lieve Dini, op het moment van schrijven 
schiet ik al in de lach. Het contrast tussen onze diepgaande en wat minder diepgaande 
gesprekken is enorm. Je daagt me uit om verder te kijken dan de oppervlakte, een gave 
die niet veel mensen hebben. Dank voor jouw interesse en onze mooie vriendschap.  
 
Sytha en Jos, al snel voelde ik mij thuis tussen de Vinken. Naast lachen over wat we allemaal 
meemaken zijn jullie ook erg geïnteresseerd in mijn onderzoek maar ook in alles wat ik 
daarbuiten beleef. Heel veel dank daarvoor! Marlou, Jasper en Thomas, het is iedere keer 
weer een feest om naar jullie mooie stukje boerengrond aan de Lekdijk toe te komen. Dank 
voor alle lachstuipen en ontspanning de afgelopen jaren!
 
Piet, als oom en tevens mede-levensgenieter ben je altijd geïnteresseerd in waar ik allemaal 
mee bezig ben. Dankjewel voor al je interesse en de fijne familie etentjes. Lieve Oma 
van Capelle, een gedeelte van mijn PhD tijd heb jij nog meegemaakt. Jij hebt mij altijd 
gestimuleerd om verder te leren maar bovenal ook plezier te maken en te lachen. Wat ben 
ik dankbaar voor alle mooie herinneringen die we hebben.   
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Mam en Pap, zonder jullie onvoorwaardelijke liefde en steun was dit boekje er niet geweest. 
Jullie hebben mij altijd gestimuleerd om datgene te doen waar ik gelukkig van word. Fietsen 
door de duinen, gek doen in Miggelenberg en naar mooie concerten of musea gaan. We 
delen veel met elkaar, en dat is van onschatbare waarde voor mij.
Floris, lieve Flo, wat ben ik gek op jou! Snel nadat ik naar Rotterdam verhuisde begon ons 
grote avontuur. Jij maakt mij aan het lachen wanneer ik verdrietig ben en zet mij met twee 
benen op de grond wanneer ik ergens niet uit kom. En bovenal, je ziet mij zoals ik ben. Bij 
jou ben ik gelukkig!
